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certain high DR15-affinity DA peptides, and could be a factor in corresponding
autoreactive T cells escaping self-tolerance.
This work has provided strong evidence supporting the hypothesis that destructive
processing may account for the survival of self reactive T cells in the mature peripheral
repertoire. It has, in addition, provided a powerful tool in which to dissect the influences of
processing on the generation or destruction of a3(IV)NC1 peptides recognised by
patients' T cells and may be used to examine other factors postulated to influence antigen
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Autoimmune diseases are characterised by immune responses that cause self-injury that
are, to varying degrees, targeted at self antigen. More specifically, disease may be
caused by the activation of T cells, B cells or both in the absence of ongoing infection.
With the exception of Rheumatoid arthritis and autoimmune thyroiditis, most autoimmune
diseases are individually rare however together they affect greater than 5% of the
Western population (Sinha, 1990, Jacobson, 1997).
The immune system has developed complex ways of maintaining tolerance
(immunological unresponsiveness to self antigen) to combat a vast diversity of foreign
proteins whilst avoiding damaging self and causing autoimmune disease. For many years
immunologists believed the principal mechanism of tolerance was the clonal deletion of
autoreactive cells leaving a repertoire of B and T cells that recognise foreign antigen
alone. More recent work acknowledges that a low level of autoreactivity is physiologic
(Dighiero, 1999) and in fact crucial to normal immune function. Autoantigen helps to form
the repertoire of mature lymphocytes and the survival of naive T and B cells in the
periphery requires continuous low level exposure to autoantigens.
Some autoimmune diseases have been linked to altered peptide selection and
presentation suggesting that deviations from normal antigen processing pathways may
be sufficient to trigger pathologic situations (Manoury, 2002).
As there is no fundamental difference between the structure of self and foreign antigen it
is now thought that lymphocytes have evolved not to distinguish self from foreign but to
respond to antigen only in certain microenviroments, generally in the presence of certain
inflammatory cytokines. Therefore if autoreactivity is in fact physiologic, the challenge is
therefore to understand how it becomes a pathologic process and how T and B cells
contribute to injury.
T cells recognise peptides that are associated with major histocompatability complex
(MHC) on the surface of antigen presenting cells. Antigen recognition by T cells is the
initiating stimulus for their activation. The process by which peptides from internalised
exogenous antigen are processed within the antigen presenting cell (APC) and
subsequently presented to T cells is central in immunity. Immune responses that protect
us from infectious disease as well as those causing transplant rejection and autoimmune
disease are all driven by lymphocytes that recognise components of protein derived from
micro-organisms, foreign tissue such as in transplants or self antigen, (for example joint
tissue) to identify targets for immune attack.
The nature of these targets is clearly of immense importance in manipulating the immune
response (making new vaccines) and understanding what goes wrong in autoimmune
disease.
My work sought to unravel the process by which targets (usually peptides) are generated
or destroyed from intact antigen using a well characterised antigen that is attacked in an
autoimmune kidney disease as a model. In doing this I hoped to account for how this
process may lead to the survival of self-reactive T cells into the peripheral T cell repertoire
as a possible mechanism of tolerance breakdown and the development of autoimmune
disease.
In the following sections I will introduce the basic concept of tolerance and discuss the
possible mechanisms leading to the breakdown of tolerance and development of
autoimmunity. Key to my work is the understanding of how antigen is processed and
recognised by T cells. This will be covered in detail before considering how alterations in
the processing pathway may lead to deviations in the immune response to self. The
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second section of this chapter will deal with the model of autoimmune kidney disease
used for my research, Goodpasture's disease. I hope to highlight its strengths as a model
of autoimmunity and cover in some detail what is already known about the immuno-
pathogenesis of the disease including previous research within our own group. I will
conclude with how this work lead on to my own research, detailing the aims of the study
including an outline of the research approach used.
1.1.2 Mechanisms of tolerance
Immunological self-tolerance consists of all mechanisms which prevent the immune
system reacting to self, in other words, it denotes the absence of autoimmunity. This state
may be achieved passively (by the absence of activation of auto-reactive lymphocytes) or
actively (via mechanisms that eliminate or inactivate self-reactive lymphocytes).
The induction and maintenance of self-tolerance in the developing and mature T cell
repertoire is mediated by several mechanisms and controlled at numerous levels. Crucial
to self-tolerance is the interaction between APC and lymphocytes and occurs in both the
thymus (important in central tolerance) and peripheral lymphoid tissue (important in
peripheral tolerance) (Sprent, 1995, Schwartz, 1993).
1.1.3 Central tolerance
T cells first encounter the potential for self-reactivity as soon as they express their
antigen-specific receptor during intra-thymic development. If they recognise self-antigen
with high avidity at this stage, apoptotic cell death follows, a process defined as negative
selection (Sprent 1995, Schwartz, 1993).
Thymic selection had long been considered an effective tolerogenic mechanism only for
widely expressed self-molecules. This assumption was based on the belief that proteins
with tissue-restricted expression would not be available for presentation in the thymus
and that tolerance to these proteins could only be achieved through mechanisms of
peripheral tolerance. Recent evidence demonstrates, however, that numerous otherwise
tissue-restricted antigens are expressed in the thymus (Klein, 2000, Pugliese, 2002,
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Hanahan, 1998). This discovery along with studies demonstrating expression of self-
molecules in peripheral lymphoid tissues elevates the importance of the role of self-
antigen presentation in determining tolerance.
T cells recognise proteolytically cleaved peptide fragments (peptide epitopes) bound to
major histocompatability complex (MHC) rather than intact protein. The efficiency of
antigen processing and presentation is now known to be a major limiting factor in the
generation of self-epitope/MHC ligands on thymic APC with implications in turn for the
survival or deletion of potentially auto-reactive T lymphocytes.
1.1.4 Peripheral tolerance
For reasons described above, many tissue specific proteins are not expressed at
sufficient levels to induce deletion of auto-reactive T cells in the thymus. Several mutually
non-exclusive mechanisms under the heading of peripheral tolerance provide a
complimentary safety net whereby potentially autoreactive T cells that have survived into
the periphery are kept in check.
Deletion
In analogy to negative selection in the thymus, auto reactive T lymphocytes may be
eliminated on encounter of self-antigen in the periphery. Whether deletion in the periphery
represents a distinct tolerance mechanism involving a specialised type of APC for
instance, or merely reflects depletion due to chronic stimulation of T cells after
differentiation into effectors in the lymph node without causing tissue damage, is not
known. This "exhaustive" stimulation has been observed in the late stages of chronic
infections (Moskophidis, 1993).
Anerqy
The two-signal model of T cell activation suggests that in addition to the TCR signal
(signal 1) a second signal is required to fully activate the naive T cell. The CD28 receptor
and its ligand B7 have been identified as the first set of molecules capable of delivering
signal 2 although other pairs have been described (Mueller, 2000). Tolerance may be
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induced if the APC presenting self antigen bears insufficient co-stimulatory signals.
Triggering TCR in the absence of co-stimulation (signal 2) results in functional inactivation
of T cells a condition termed "T cell anergy" (Schwartz, 1990). This term refers to a T cell
state of inactivity but retaining the potential to become active.
Ignorance
This refers to the "harmless" co-existence of naive autoreactive T cells and their
respective target peptide antigen on peripheral tissues (Miller, 1993). Ignorance can be
described, in contrast to the above mechanisms, as a passive phenomenon. Ignorant
cells are readily activated on encounter with antigen in appropriate conditions such as
immunisation or viral infection but otherwise exist in the naive pool without contacting
their cognate antigens due to spatial separation (Ohashi, 1991, Barker, 1994)
Regulatory T cells
The "suppressor" T cell was the subject of heated debate for many years and for some
time fell into disrepute. This concept has been, however, resurrected with the unequivocal
demonstration of thymus-dependant T cells capable of modulating the function of
"conventional" T cells in vitro and to control immunopathogenesis in vivo (Saoudi, 1996,
Modigliani, 1996, Seddon, 1996 & 2000, Thornton, 1998, Mason, 1998, Itoh, 1999). The
molecular and cellular mechanisms involved in the thymic generation and selection of
these regulatory T cells remains poorly understood as does their mode of action which
depends on cell to cell contact rather than soluble factors. In addition to the thymus-
dependant regulatory T cells, T cells with similar functional characteristics have been
generated in the periphery using various experimental procedures including intranasal or
oral antigen administration. The regulatory effect of these T cells seems to be at least in
part related to the secretion of "anti-inflammatory" cytokine transforming growth factor p






































Figure 1.1 Central and peripheral tolerance
1.1.5 Breakdown of tolerance with development of autoimmunity
Altered signaling and APC maturation state
For decades it has been known that an adjuvant is required to induce an effective
immune response and that pathogens can break tolerance and induce autoimmunity
(Dresser, 1961, Brooke, 1965, Chiller, 1973, Ohashi, 1991, Rocken, 1992). Current data
is generally consistent with a model whereby T cell interaction with immature APC lead to
induction of tolerogenic mechanisms and T cell interaction with pathogens stimulate
mature APC leading to efficient activation of the immune response. For example, work by
Nussenzweig et al compared T cell response to antigen presented by un-stimulated and
stimulated APC (Hawiger, 2001). Antigen was targeted to dendritic cells (DCs) in vivo
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leading to tolerance via abortive expansion, deletion and anergy of antigen specific T
cells. If antigen was targeted to DCs with anti-CD40 antibody which promotes APC
maturation, a prolonged immune response was seen. Interactions with other members of
the TNF receptor family have been demonstrated to influence tolerance versus immunity.
(Bansal-Pakala, 2001).
In general, the majority of the literature is consistent with a model whereby factors that
promote APC maturation such as adjuvents and pathogens are crucial for converting
tolerogenic signals to activating signals and therefore have the potential to break
tolerance and cause an immune response to self.
There have been a number of recent studies uncovering the multiple molecular pathways
that must be triggered to induce APC maturation and optimal immune response and they
have in turn shed light on how pathogens may break tolerance. APC such as DCs and
macrophages are equipped with various receptors that are able to detect the presence of
different components of pathogens connecting the innate immune recognition to the
adaptive immune response. Pattern recognition receptors (PRRs) such as Toll-like
receptors (TLR) are an example. Direct recognition of pathogens by TLRs and other
immune receptors is an important mechanism where TLR signaling induces DC
maturation promoting activation of T cells and potential breakdown of tolerance.
Danger: molecules and receptors guiding APC function
Whereas direct recognition of pathogens by TLRs and other innate immune receptors is
an important mechanism whereby APC are stimulated to promote activation of T cells,
other situations such as organ transplantation and tumours may trigger the immune
response. Injuries damaging epithelial layer are often associated with infection and so the
innate immune system may have evolved to recognise molecular events associated with
trauma as danger signals promoting activation of the adaptive immune response.
Research revealed the immune system is programmed to sense this danger via TLRs.
One possible source of 'danger' is heat shock proteins (HSPs) which are released from
dying cells. These are abundant intracellular proteins which make up to 15% of total
protein after cells have been exposed to certain stress such as toxins, infection or heat.
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Studies suggest that necrotic cells may release HSPs inducing an inflammatory response
initiating DC maturation and immunity (Gallucci, 1999, Sauter, 2000, Somersan, 2001,
Kuppner, 2001, Breloer, 2001)
Altered presentation
The induction of peripheral T cell tolerance is also influenced by the concentration of self
antigen. If antigen is expressed at low levels, minimal presentation occurs and the self-
reactive T cells remain tolerised. Events modulating self antigen expression such as
tissue necrosis or tumour development alter the level of presentation. Increased
presentation of self antigen may allow ignorant autoreactive T cells to detect the self
antigen. The fate of the T cell will then be coupled with the events that lead to APC
maturation. If increased levels of antigen occur in the absence of signals promoting
maturation then tolerance will occur. If however self-antigen is detected in the presence of
pro-inflammatory signals that promote APC maturation, then tolerance will be broken and
autoimmunity will arise. Therefore events which lead to a sudden release of self-antigen if
coupled with signals that induce maturation of APC may break tolerance by activating
ignorant T cells (Ohashi, 2002).
Molecular mimicry
Cross reactivity between microbial and self-determinants recognised by the adaptive
immune system as a means of breaking tolerance and inducing autoimmune disease is
an intriguing hypothesis. Definite proof is however difficult to achieve and evidence has
often been circumstantial. Complex series of DNA rearrangement and other genetic
modifications generate a large diversity of TCR. Therefore the repertoire of the immune
system appears large enough to adapt to every possible antigen component in the realm
of foreign and self. However, there is much degeneracy. It is well known that these cross-
reactive receptors have the potential to interact with several ligands that share a certain
degree of similarity. The concept of molecular mimicry is based on this finding and
requires that two or more components (foreign or self) are structurally so similar, the T
cells cannot distinguish between them.
8
In recent years, cross-reactive T cells or antibodies have been found in situations where
association between an infectious agent and autoimmune disease have been known. For
example, a large number of patients with myasthenia gravis carry antibody to the acetyl
choline receptor which shares a cross reactive epitope to herpes simplex virus (HSV)
glycoprotein D (Schwimmbeck, 1989). Type I diabetes has been associated with a
number of viruses including coxsackie B (Gamble, 1980, Notkins and Yoon 1984, Yoon,
1979).
However, despite all the indications for molecular mimicry as a mechanism involved in the
aetiology of autoimmune disease, no direct evidence for molecular mimicry as an initiator
or accelerator of autoimmunity in humans could be demonstrated to date. Some propose
that molecular mimicry more likely impacts on an already existing autoimmune process
rather than precipitating de novo disease. (Christen, 2004).
1.1.6 Altered antigen processing as means of tolerance breakdown
Both central and peripheral tolerance mechanisms are influenced by constitutively
expressed self-proteins. As detailed, auto reactive T cells capable of recognising epitopes
from self peptide that are not presented in sufficient amounts to stimulate T cell deletion
("cryptic epitopes") must clearly be restrained from driving a deleterious autoimmune
response by peripheral tolerance (Elson, 1995, Gammon, 1989). There are now a
number of animal models of autoimmunity where pathogenic T cells have been
demonstrated to recognise cryptic self-epitopes (Moudgil, 2000, Sercaz, 2002, Watts,
2003).
Constitutive expression of self antigen was previously thought most strongly influenced by
affinity for HLA class II. However, the discovery of self-reactive T cells specific for high
affinity peptides in the peripheral repertoire in both animal models of autoimmunity and
human disease, has led to an interest in alternative mechanisms which may influence
presentation of self-peptides.
One such mechanism is destructive processing (Watts et al 2003, Trombetta, 2005)
whereby processing occurs such that specific epitopes are consistently destroyed and
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therefore, despite high affinity for HLA molecules, never presented to T cells. These
autoreactive T cells then escape irreversible self-tolerance and persist into the peripheral
repertoire with the potential to drive autoimmune disease in the appropriate environment.
1.2 Antigen processing and presentation
1.2.1 Introduction
Section 1 has already demonstrated that T cells play a critical role in the adaptive
immune response to both foreign and self protein antigens. The physical form of antigen
that is recognised by T cells differs however from those recognised by B cells. T cells
recognise peptide fragments derived from protein antigen bound directly to cell surface
proteins encoded by genes of the major histocompatability complex (MHC). MHC
molecules thus serve to display or present peptides to T cells. T cells in turn recognise
antigens through their clonotypic immunoglobulin-like T cell receptor which engages the
peptide/MHC complex. This resultant tri-molecular complex is the basis of antigen-
specific T cell responses (Figure 1.2) Usually peptides derived from cytosolic proteins
bind to class I MHC molecules and are recognised by CD8 T cells (including cytolytic T
cells). In contrast peptides derived from extracellular proteins that are endocytosed by
specialist antigen presenting cells (APC) bind to class II MHC molecules and are
recognised by CD4+ T cells which include T helper cells. These cells are often required
for the induction of humoral and cell mediated responses which are most efficient in










The tri- molecular complex
Figure 1.2 Antigen presentation to CD4+ T cells. The boxed figure represents the tri-molecular
complex: MHC class II molecule, bound peptide and T cell receptor. This complex forms the basis
of CD4 T cell recognition of antigen. However, many other cell surface and soluble signals may
participate and influence the type of T cell response generated following recognition of antigen.
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In this next section, I will review how complex protein antigens are internalised into APC
and processed into peptide fragments and how these fragments in turn are exposed to
and incorporated into the peptide binding groove allowing MHC/peptide complexes to be
displayed forT cell recognition.
1.2.2 Uptake of extracellular proteins into vesicular compartments of APC
Antigen uptake is a crucial initial first step in the processing and presentation of antigens
in the class II processing pathway with the possible exception of some peptide antigens.
Different APC utilise different mechanisms of uptake with varying degrees of specificity
and efficiency (Lanzavecchia, 1996). The rate at which antigen is internalised can be a
determinant in the efficiency of antigen presentation. (Lanzavecchia, 1990). All APC are
capable of endocytosis of extracellular fluid and plasma membrane. Endocytosis is the
process whereby invaginations of the cell membrane develop and pinch off as pre-
endosomal vesicles which in turn fuse with early endosomes. A number of alternative
mechanisms of uptake also exist. Macrophages internalise many different proteins with
limited or no specificity to surface molecules and internalise them by the process of
ligand-induced endocytosis or phagocytosis. Macropinocytosis is a distinct mechanism in
dendritic cells which internalises large amounts of extracellular fluid.
Special cases of more specific binding by well characterised surface molecules on the
APC can mediate binding and internalisation of antigen via receptor-mediated
endocytosis in clathrin-coated vesicles (van Deurs, 1989, Watts, 1992). Clathrin is
capable of binding a range of membrane proteins by interactions with their cytoplasmic
domains. Proteins that bind, are concentrated at sites of pit formation and subsequently
internalised into pre-endosomal vacuoles. Examples of this process include the specific
receptors for the Fc portions of immunoglobulin and receptors for the complement protein
C3b, both of which are present on the surface of macrophages. These receptors can bind
opsonised antigens and enhance their internalisation. Other receptors internalised by
clathrin-dependant endocytosis include the transferrin and LDL receptor. Endocytosis
may also occur via clathrin-independant mechanisms. Both clathrin-dependant and
independent mechanisms have been demonstrated to deliver pre-endosomal vacuoles to
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the early endosomes. (Hansen, 1993, Tran, 1987). Receptor mediated endocytosis is the
most efficient uptake mechanism for low abundancy extracellular antigens but is only
possible for antigens that can be captured via cell surface receptors so is relatively
specific.
Phagocytosis is a ligand-induced form of endocytosis where cell surface receptors bind
ligands such as immunoglobulin Fc, resulting in cytoskeleton rearrangements and
envacuolation of the ligand-coated antigen into phagosomes. The fate of these
phagosomes has been demonstrated to be determined by the receptors involved
(Falkow, 1992). Usually phagosomes fuse with lysososmes which leads to proteolysis
and peptide generation which are in turn efficiently loaded onto class II molecules.
Macropinocytosis is a distinct mechanism used by dendritic cells. Soluble protein antigen
is internalised into APC without actually binding to the cell surface by marked membrane
ruffling followed by envacuolation of the extracellular fluid within large vesicles. Dendritic
cells can use macropinocytosis to internalise large volumes of extracellular fluid (Sallusto,
1995). This leads to highly efficient presentation of fluid phase antigens. Macropinosomes
however do not exchange contents with early endosomes which suggests a distinct and
alternative pathway for antigen presentation (Hewlett, 1994).
1.2.3 Efficiency of antigen uptake
The efficiency by which antigen is internalised into APC varies considerably depending on
the mechanism of uptake and the abundance of antigen available. The most efficient
mechanism for low abundance extracellular antigen is that of receptor-mediated
endocytosis. This pathway is however specific and selects antigens that are captured by
cell surface receptors. The specificity of these receptors can vary from high specificity
such as the B cell mlg which allows a higher efficiency of uptake for a limited range of
antigens to a range of receptors which although allow uptake of a wider range of ligand-
associated antigens (Chu, 1993) e.g. dendritic cells internalise a wide range of mannose-
associated bacterial proteins using a mannose-fucosyl C-type lectin receptor (Sallusto,
1995).
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The efficiency of receptor mediated endocytosis is influenced also by the fate of the
internalised antigen-receptor mediated complexes. The mlg receptor and Fey receptor
are proteolytically degraded with antigen and internalisation can be limited in some cases
by available receptor. Mannose receptor, in contrast, recycles to the cell surface for re¬
use after it has released bound antigen, (Sallusto, 1995).
Fluid phase antigens which do not bind to surface receptors are internalised by
pinocytosis as described. Most cell types including B cell types internalise fluid by
micropinocytosis at 25-250 fl/cell/hr (Selby, 1995, Steinman, 1972). The efficiency of
antigen uptake therefore is dependant on the concentration of antigen in the extracellular
fluid. Only antigens at higher concentrations such as 10~6-10~8M are presented at levels
that induce a T cell response. Dendritic cells are capable of internalising fluid at much
higher rates, 1000-2,400 fl/hr (Sallusto, 1995) allowing much more efficient presentation
of low abundancy fluid phase antigens.
1.2.4 Antigen uptake and immunogenicity
The enhancement of antigen uptake which in turn influences the efficiency of antigen
presentation, has a marked effect on immune response in vitro and in vivo. This has been
demonstrated by conjugating antigens that are usually internalised by fluid phase
micropinocytosis to ligands for cell surface receptors. T cell responses can be induced at
500-1000 fold lower antigen concentrations if antigen is conjugated and targeted to
surface immunoglobulin (Barnes, 1995, Lakey, 1988, Snider, 1989). Enhancement can
also be demonstrated for conjugates targeting other cell surface receptors such as the
transferrin receptor, Fey receptors and mannose receptor. The increased immunogenicity
of cationised antigens has also been demonstrated to be a result of enhanced antigen
uptake (Faergeman, 1982).
1.2.5 Antigen processing
Different techniques have been utilised to study the pathway followed by internalised
antigen. Antigen has been radiolabeled and SDS PAGE lysates made of APC pulsed
with labelled antigen. Other techniques include the labelling of antigen with gold and
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tracking with electron microscopy. C13 labelling allows detection of peptide fragments
from labelled antigen using mass spectrometry.
Label has been detected within early endosomes within 5 minutes of exposure to antigen
and at later timepoints in late endosomes and lysosomes (Rabinovitz, 1992). SDS PAGE
of lysates made of APC incubated with labelled antigen demonstrate that antigen
fragmentation is occurring within 30 minutes of antigen exposure as a result of proteolysis
in early and late endosomes (Watts, 1989, West, 1994).
The environment in which protein antigen migrates within structures of the endocytic path
becomes increasingly acidic and reducing from early endosomes to lysosomes. These
conditions unfold and denature protein antigens allowing access of endosomal proteases
(Jensen, 1995) and in the later compartments, for binding to class II molecules.
Clearly APC exhibit a well developed capacity for lysosomal proteolysis. However it is
acknowledged that different APC may utilise distinct strategies for processing upon
antigen encounter. Macrophages contain high levels of lysosomal proteases and degrade
internalised protein antigen rapidly. Dendritic cells and B cells in contrast are protease
poor and have a limited capacity for lysosomal degradation.
1.3 Class II processing
1.3.1 Overview
Although perhaps an oversimplification, antigen processing and presentation can be
divided into two separate pathways which involve the two major classes of MHC; class I
and class II. This in turn leads to presentation to 2 distinct subsets of T cells (Germain,
1993).
Class II molecules, in contrast to Class I molecules which are expressed on all cells, are
only expressed by professional antigen presenting cells (APC) such as thymic epithelial
cells, dendritic cells, macrophages and B cells as well as certain other activated cell
types. The molecules present peptides of variable length (12-30 residues) to CD4+ T
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cells. Class II molecules are capable of binding peptides at several different locations
within the endosomal system and indeed on the surface of APC (reviewed by Robinson,
2002). Therefore most class II peptides are derived from self proteins present at high
concentration within endosomes although a proportion are derived from extracellular
proteins internalised into the endocytic system.
There is evidence that a degree of overlap can occur between the two pathways (e.g. in
some circumstances extracellular antigen is effectively presented to class I molecules).
1.3.2 Class II processing pathway
In almost 3 decades of research it has been established that T cell antigen receptors
recognise fragments of antigens or peptides bound to antigen presenting molecules
encoded mainly by genes of the major histocompatability complex or Human Leukocyte
Antigen (HLA).
Extensive literature has established that the majority of peptides recognised by CD4 T
cells are presented by a common pathway which is used by both professional and non¬
professional APC.
The peptide epitopes recognised by CD4 T cells are mainly derived from exogenous
proteins that require some form of processing before they are accessible to bind to MHC
class II molecules.
In addition this pathway is dependant upon a type II membrane protein, the invariant
chain, li which engages class II a and p-chains and serves as both targeting subunit and
a means of stabilising the class II peptide binding site.
1.3.3 Structure and function of MHC class II molecules
All class II molecules are composed of 2 non-covalently associated polypeptide chains
(figure 1.3). Typically the two class II chains are similar to each other in terms of structure
however the a-chain is slightly larger (32-34kD) than the p-chain (29-32kD) due to more
extensive glycosylation. In class II molecules both polypeptide chains contain N-linked
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oligosaccharide groups, both have extracellular amino termini and intracellular carboxy
termini and over two thirds of each chain is located in the extracellular space. The two
chains are encoded by different MHC genes that are usually polymorphic.
Peptide binding^-#^ - r






Figure 1.3 Schematic diagram of MHC of a class II MHC complex molecule. NH2 and COOH
represent the amino and carboxy termini of the polypeptide chains respectively. The red lines
represent disulphide bonds and CHO, carbohydrate.
The three-dimensional structure of class II molecules has been solved by x-ray
crystallography (Stern, 1994) and has demonstrated a similar structure to Class I MHC.
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Similarities are most striking in the peptide binding cleft (Figure 1.4) (Madden, 1995). Both
have an antigen binding groove with a beta pleated sheet floor bordered on 2 sides by
alpha helices allowing the secure binding of peptides and the concomitant exposure to T
cells. It is useful to divide class II molecules into a peptide binding domain, an Ig-like
domain, a transmembrane domain and a cytoplasmic domain (Figure 1.3).
In class II, the extracellular portions of both a and (B chains are subdivided into two
segments of around 90 amino acid residues called a1 and a2 or (31 and (32 respectively.
The peptide binding region of class II is formed by an interaction of both chains involving
the a1 and (31 segments. This differs from class I where only the a chain is involved in
forming the peptide binding cleft. Class II a1 and (31 fold to form an eight stranded,
antiparallel p-pleated sheet platform supporting two a helices fours strands of the p-
pleated sheet and one a helix formed by a1 and pi equally.
Both the a2 and 32 segments of class molecules contain internal disulfide bonds and
belong to the Ig superfamily. These segments like class I a3 and 32 microglobulin are
folded into Ig domains within the native MHC molecule. Class II a2 and 32 segments are
essentially nonpolymorphic among various alleles of particular class II genes but some
show differences in different class II loci.
The correlation of CD4 expression on T cells with specificity for class II MFIC molecules
arises from the binding of CD4 with a projecting loop of the Ig-like non-polymorphic 32
domain of the class II molecule similar to the interaction of CD8 with the a3 of the class I
heavy chain (see Figure 1.2)
The Ig-like regions of class II are probably important for non-covalent interactions
between the two chains although other portions of the polypeptide chains are likely to
contribute.
The carboxy terminal ends of the a2 and 32 segments continue into short connecting
regions followed by approximately 25 amino acid stretches of hydrophobic residues that
span the membrane. In both class I and II the hydrophobic transmembrane region ends
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with a cluster of basic amino acid residues which are followed by the carboxy terminal
ends of the polypeptides forming short hydrophilic cytoplasmic tails.
A Structure of class II molecule. Ribbon
diagram of MHC class II. Class II peptides are
not bound at termini and therefore are free to
extend beyond the groove. The length of the
peptide is usually 13-17 amino acids long. The
ends of the peptide are not constrained, the
protrusion of the side chains into small cavities
along the peptide binding hold the peptide in the
groove. These cavities are known as pockets
and may be deep or shallow.
Figure 1.4 Structural basis of peptide binding to MHC molecules
B Pockets in peptide binding groove of an
MHC class II molecule. A core region of nine
amino acids are known to be essential for
binding. The pockets that interact with the
residue at positions 1, 4, 6 and 9 in the peptide
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Before considering the structural features of the binding of peptides to class II MHC, there
are a number of properties of this interaction which have been deduced from biochemical
studies.
The association of antigenic peptides and MHC molecules is a saturable low affinity
interaction (Kd ranging from 1CT5to 10"8M) with a slow "on rate" that is regulated by DM
and a often a very slow "off rate" (although this may as fast as 60 minutes for low affinity
peptides). The affinity of peptide-MHC interaction is much lower than that of antigen-
antibody binding (Kd of 10~7 to 10"11M) (Abbas, 1991). Once bound peptides may stay
associated for hours to weeks.
X-ray crystallography has demonstrated that each class II molecule binds only one
peptide at a time. Functional assays and direct binding studies have provided definitive
evidence however that multiple different peptides are capable of binding to the same
MHC molecule (Reviewed by Madden, 1995). There are structural constraints that
prohibit peptides from binding. This together with the limited number of MHC alleles
expressed in individuals supports the hypothesis that MHC molecules have a broad
specificity for peptide binding but the fine specificity of antigen recognition is determined
the antigen receptors of T lymphocytes.
There are distinct differences in the nature of peptides binding to class I and II most
importantly peptides eluted from class I molecules are 9-11 amino acid residues in length
whereas peptides eluted from class II can range from 10-30 residues or more (Figure
1.4A).
In contrast to class I which has a tight limitation on the length of peptide capable of
binding to the groove, the a helical sides of the cleft in class II MHC molecules do not
converge allowing bound peptides to extend outwards from the ends of the cleft. This
ensures that there is no maximum length of peptide allowed to bind to class II. (Madden,
1995)
Most peptides binding to a particular allelic form of an MHC molecule demonstrate certain
common features. Examples of shared features are a hydrophobic residue at position 2
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or a positively charged residue at position 7. Mutagenesis studies have confirmed that
motifs like these can be crucial for peptide binding to particular allelic forms of MHC
molecules.
In class II peptides bind with 12-13 resides held in the peptide binding groove with longer
peptides protruding at either end. This bound segment is often termed the core binding
sequence and lies in the groove in an extended conformation with a type II polyproline
twist which causes about every 2 in 3 of the peptide side chain residues to be directed
into the walls and floor of the peptide binding groove and every 1 in 3 of the side chains to
be directed upwards where they contribute to the surface of the class II peptide complex
seen by the T cell receptor. Thus amino acid side chains from both peptide and MHC
molecules contribute to T cell recognition.
The interactions most involved in stabilising binding between peptide and class II occur
between backbone atoms and conserved residues/main chain atoms in the areas of class
II molecules flanking the peptide binding groove (Stern, 1994). Therefore binding is
stabilised mainly by interactions independent of the bound peptide's sequence.
The characteristically conserved features of peptides binding to MHC class II are
complemented by specific structural features of MHC such as the presence of pockets in
the floor of the cleft. These pockets are spaces between the peptide backbones of the (3-
pleated strands and are numbered according to the peptide side chain residue they
accommodate (figure 1,4B) These pockets determine the nature of the peptide side chain
that can fit into the pocket (e.g. hydrophobic, charged etc) and in some cases are critical
for attaching peptide the peptide to the MHC molecule ("anchor residues").
1.3.4 Synthesis, trafficking and loading
MHC class I la and (3 chains are synthesized de novo in the endoplasmic reticulum (ER)
where they are assembled and transported to the golgi under the regulation of
chaperones including the invariant chain (li). li acts as both targeting subunit and
guardian of the peptide binding groove. Trimerisation of li brings in three MHC class II
molecules to form a nonameric complex (liaP)3 which are then sorted to endosomes
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including multilamellar and multi-vesicular compartments (Neefjes,1999, Pond, 1999,
Geuze,1998) or to phagosomes (Ramachandra, 2000). li as well as the MHC class II- like
chaperones DM and DO regulate the peptide loading of MHC class II molecules
(Nordeng, 1998 Busch, 2000, Vogt, 1999, Alfonzo,1999). The li-derived class II invariant
chain peptide CLIP remains associated with the MHC class II peptide binding cleft until
DM catalyses the dissociation of CLIP and binding of processed antigen peptides which
is performed optimally at low pH (Kropshofer,1999). DO regulate DM activity probably by
enhancing the association of DM with MHC class II. MHC class II molecules bind the
peptides generated in endosomes and the complexes are then transported to the cell
surface for presentation to the CD4 T cells. Endogenous proteins and peptides may also
bind to MHC class II molecules following transport into the endosomal pathway. (Harding,
1997 Lechler, 1996). Cytosol to endosome transport may lead to the processing of
proteins translocated into the host cytosol by intracellular pathogens such as Listeria
monocytogenes.
Antigen processing occurs in roughly the same compartments as li processing (Watts,
1997) but the late endosomes are thought to be the usual location where the antigenic
peptides and the MHC class II molecules are able to interact. There is accumulating
evidence however that peptide binding occurs in other cellular compartments (discussed
below). In addition MHC molecules display peptides of varying length (often including a
core sequence) which is variably extended in both N and C terminal directions
(Engelhard, 1994). Peptide-loaded MHC class II molecules travel to the cell surface after
li removal and peptide binding.
The majority of evidence indicates that MHC class ll-li complexes enter the early
endosomes, capture peptides at various points along the processing pathway and can
probably exit at any point (Hiltbold, 2002). Once the cell surface is reached, the existence
of the class ll-peptide complexes is generally long. Some T cell epitopes generated in
early endosomes can still engage "recycling" MHC class II molecules which have most
likely exchanged their peptide or possibly reached the cell surface. (Robinson, 2002).
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1.3.5 Invariant chain
The association of MHC class II with invariant chain has important influences on the
assembly, transport and function of class II molecules (Ceman, 1995, Cresswell, 1994,
Germain, 1995). Although the genes encoding li are non-polymorphic, the molecule
occurs in several forms as a result of splicing of one exon, p41). And the use of 2 different
start codons. The major forms are 33,35,41,and 43 kD (which includes 2 kD added
through glycosylation) and are termed, p33, p35, p41 and p43 respectively. All variants
perform 3 important functions; they contain a trimerisation domain and spontaneously
associate into trimers to provide a framework in which 3 class II a(3 heterodimers bind,
they have a class II binding domain which includes a sequence that binds to the class II
binding groove, the class ll-associated invariant chain peptide, CLIP. CLIP once in the
peptide binding groove stabilizes the a(3 heterodimer and prevents early binding of
peptide or denatured protein in the ER. Finally they have targeting motifs in their
cytoplasmic domain that directs (liap)3 which are exiting the trans-golgi network towards
cytoplasmic vesicles.
In macrophages, B cells and dendritic cells, newly synthesized a(3li enters the MHC class
II compartment, MIIC, which is quite distinct from the compartments of the classical
endocytic pathway. It has a density similar to late endosomes but has distinct
multivesicular morphology on EM and lacks late endosomal (mannose-6-phosphate
receptor) and early endosomal (transferrin receptor) markers. It contains molecules
important for the formation of class ll/peptide complexes which include leupeptin sensitive
proteases which cleave li in a staged manner as discussed below. MIIC also contains
HLA-DM which promotes the dissociation of CLIP (discussed below). Most nascent af3li
reaches endosomes without visiting the cell surface. The exact route is not certain
however some is detectable at the cell surface but is rapidly recycled into endosomes.
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1.3.6 li processing
Studies using chemical and genetic ablation of lysosomal proteases have demonstrated
that li processing is a staged process which moves in a C-terminal to N-terminal direction.
The cysteine protease inhibitor, leupeptin causes the accumulation of a 22kDa or 10kDa
li product in human or mouse cells respectively (Blum, 1988, Amigorena, 1995). The
leupeptin insensitive enzyme responsible for initiating li processing in these conditions is
Asparginyl endopeptidase (AEP) which targets asparginine residue 155 (Asn 155) and
probably Asn 132 on the outside of the trimerized C-terminal domain (Manoury, 2003).
Processing of the mouse li proceeds further because of an additional more N-terminally
located asparginine residue. However li processing can be initiated by proteases other
than AEP. Maehr et al have addressed li processing in AEP null mice and found the
absence of AEP had no effect on li processing at any stage suggesting li processing can
also be initiated by enzymes other than AEP (Maehr, 2005). This is not unexpected given
the importance of li removal. Although lack of AEP does not impair invariant chain
processing in the murine model, AEP inhibition has been shown to delay the initiation of li
cleavage in some human EBV transformed B cell lines and monocyte-derived dendritic
cells. The specific cleavage by AEP immediately C-terminal to asparginine residues (an
action which is insensitive to cysteine protease inhibitors, leupeptin and E-64) has been
implicated in li processing. In humans there are at least two subsequent steps in li
processing.
The use of specific inhibitors and the study of gene knockout mice have been utilised to
identify putative proteases involved in li and antigen processing. Blockade of the
progressive cleavage of li results in the accumulation of li intermediates and a decrease
in the surface expression of class II MHC products (Neefjes, 1992, Brachet 1997).
Experiments in human EBV B cells treated with a cathepsin S-specific inhibitor and
characterization of cathepsin S knock out mice have implicated cathepsin S in the
terminal cleavage to yield CLIP. (Busch, 2005) Further studies have demonstrated cell-
specific cleavage of p10 by cathepsin L (CatL) in thymic epithelial cells (Nakagawa, 1998)
and cathepsin F in macrophages (Shi, 2000) Inhibition of cathepsin S leads to the
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accumulation of a 10kDa processing intermediate, p10 (Riese, 1996). Processing of this
intermediate is less redundant and the terminal stages of li processing are cathepsin S-
dependant, at least in respect to some HLA haplotypes. In its absence or in the presence
of leupeptin, MHC class II l-Ab-p10 complexes accumulate, slowing but not completely
inhibiting transport to the cell surface. (Brachet, 1997, Driessen, 1997). Although
transport can still occur in the absence of cathepsin S, class II peptide loaded is
prevented.









Figure 1.5 Class II antigen processing and presentation This diagram demonstrates an APC
presenting peptides from extracellular antigen to a T cell. Sequential aspects of this pathway are
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represented. 1. Internalisation of protein by endocytosis into endosome 2. Proteolytic processing of
protein in endosome or lysosome generating peptides 3. Class II MHC polypeptide synthesis 4.
Fusion of endosomal derived CIIV/MIIC vesicle containing class II MHC 5a. Degradation of li and
DM mediated release of CLIP 5b. Binding of peptide antigen to class II MHC 6. Fusion of vesicle
with plasma membrane; expression of peptide-class II MHC complexes on cell surface 7.
Presentation of peptide-class II MHC complex to CD4 helper T cell.
1.4 Proteolytic enzymes and their importance in antigen
processing
1.4.1 Introduction
The capture of peptides by class II molecules is remarkable given the unfavourable
circumstances in which this occurs. Class II molecules and their li chaperone are
delivered to the endosome/lysosome system and exposed to an environment rich in
proteolytic enzymes. Despite this, processed peptides derived from protein antigens
which are usually present in very small amounts weather this aggressive proteolytic
environment and survive to bind to the peptide binding groove of newly synthesised and
(once the li is removed, potentially unstable) class II molecules. DM stabilises this
complex and assisted by DO in some cells, guides peptide loading in immunological
desirable directions.
1.4.2 Antigen processing and processing enzymes
The list of proteases found within the endosome/lysosomal compartment continues to
increase (reviewed by Watts, 2001, Chapman, 2006). There are at least a dozen
enzymes related to the cysteine protease, papain. Of these cathepsins
B,H,L,S,F,Z,V,0,C and possibly K are expressed in APC of different types. In addition,
APC contain other classes of proteolytic enzymes, including the aspartic proteases,
cathepsins D and E/G and asparginyl endopeptidase (AEP). Most of these proteases
operate in an acidic pH optima and exhibit rather broad substrate specificity. Cathepsin S
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is the exception to the former and AEP an exception to the latter. Other enzymes such as
cathepsins H,C,B and Z have structural features that limit access to the active site and
function as amino (cathepsins H and C) or carboxyl (cathepsins B and Z) exopeptidases
(Figure 1.1).
Reduction of disulphide bonds has been shown to be important for the presentation of
certain T cell epitopes and to depend on a reducing environment in endosomes and
lysosomes. GILT, is an IFN-y-inducible lysosomal thiol reductase identified in endosomes
that were positive for class II MHC. GILT reduces protein disulphide bonds at an acidic
pH optimum and is therefore be involved in the reduction and possibly the unfolding of
protein antigens. (Phan, 2000)
Exopeptidases are likely to partly account for the heterogeneous termini of naturally
processed T cell epitopes found bound to class II MHC. Many of these enzymes have
homologues in plants or simple animals. It would appear therefore that the mammalian
immune system has taken advantage of ancient proteolytic systems to perform essential
steps in antigen presentation. Expression in APC of the most useful enzymes and
regulation of the expression of some of these with cytokines such as IFN-y tailor the
processing machinery to the requirements of the APC.
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Protease Example Cleavage preferences
Initiating protease AEP, Cathepsin B, D, S
GILT
Preference for polar/charged
side chains. Relatively non-
redundant. Initiate processing
Secondary protease Cathepsin D, E, others?
Preference for cleavage at
hydrophobic sites. Some
redundancy. GILT/other
chaperones may aid with
disulphide bond cleavage &
unfolding
Exopeptidase Cathepsins H, C, Z, B Generate short but
heterogeneous peptides
Table 1.1 Proteases involved in endosomal processing (From Watts, 2001)
A number of studies have identified proteases that generate T cell epitopes from protein
antigens in vitro but it has been more difficult to establish which enzymes are responsible
in vivo (Watts, 1997). A number of approaches have been utilised in an attempt to shed
more light on which enzymes are involved in processing including the identification and
mutagenesis of processing sites in protein antigens, the use of specific inhibitors (Puri,
1988) and the use of protease-gene-targeted mice (Nakagawa, 1999, Shi, 1999).
Other factors apart from proteases are involved in the generation of suitable substrates
for loading onto class II molecules.
The open ends of the class II MHC peptide binding groove appears well suited to the
capture of unfolded and extended antigen domains. Indeed this feature could be essential
in avoiding over-digestion and potential destruction of T cell epitopes. Peptides eluted
from bulk class II MHC populations usually have a maximum size of around 25 residues
but a number of studies have suggested that longer processing products might be
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captured by class II MHC (Davidson, 1991, Lindner, 1996). A study performed on HEL-
pulsed splenocytes identified a class II MHC dimer made up of one l-Ek and one l-Ak
class II MHC molecule. This association was only seen in HEL-pulsed cells and appeared
to be due to a 7kDa processed fragment of HEL linking the two class II MHC molecules
(Castellino, 1998). Intermediates of this type are difficult to detect due to their transient
nature; the l-Ek-HEL-l-Ak complex was detected probably because of its unusual longevity
and stability. However, capture of unfolded, extended sequences by class II is probably
important for capture of vulnerable peptides in an aggressive proteolytic environment
because once bound they are protected.
After uptake, protein antigens undergo unfolding and disulphide reduction followed by
degradation by cysteinyl and aspartinyl proteinases with optimal activity in an acidic
enviroment. A number of recent studies have shown that epitopes within denatured intact
proteins can bind to MHC class II without any prior degradation (Germain, 1994)
1.4.3 Variability of antigen processing
Accessibility of antigen
How much processing is needed before binding to class II MHC occurs? As detailed
above, earlier studies have shown that class II MHC can bind long peptides and even
intact proteins (Germain, 1994). However it has been more difficult to determine whether
this actually happens during normal antigen processing. Both functional and biochemical
data now exist to support the notion that class II MHC can capture long peptides.
(Davidson, 1991, Lindner, 1996) Work from Moss et al indicates that in the case of the
tetanus toxin C fragment (TTCF) substrate, very limited processing by AEP is sufficient
for generation of a form of antigen that is able to bind to available class II molecules.
Capture by class II MHC in the early stages of the processing can involve long unfolded
stretches of antigen substrate. The open-ended peptide binding groove of the class II
molecule allows extended peptides to bind (Castellino, 1998) This may have evolved to
allow early capture of extended peptides thereby allowing protection from further
proteolysis. This has in turn led to a hypothesis by Watt to explain how the problem of
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epitope destruction can be solved in the class II MHC pathway. Here 3 different types of
proteases are described: (1) initiating or unlocking proteases; (2) endoproteases that
preferentially act on partially processed and unfolded antigen; and (3) exopeptidases that
trim long MHC-bound peptides to their normal size range (12-25 residues). (Watts, 2001)
(See Table 1.1)
Quaternary structure
Quaternary structure may affect presentation of exogenous oliguric protein by influencing
a) uptake of protein by APC b) the endocytic pathway c) proteolytic degradation into
peptides.
Several reports have demonstrated that conformation of protein antigen influences
processing in turn affecting antigenic potency (Vacchio, 1989, Del Val, 1991).GIimcher et
al described the tertiary conformation of the insulin molecule was important in the
formation of an antigenic determinant recognised by insulin-specific T cells (Glimcher,
1983). Atassi et al (Atassi, 1989) reported T cells specific for regions in the interface
between a and (3 subunits of HbA recognised isolated monomeric but not haemoglobin
tetramer. Rouas et al demonstrated that dimerisation of hCG subunits failed to stimulate
T cells generated against peptides derived from the a monomer subunit of hCG,
suggesting dimerization of subunits may affect the nature of processing (Rouas, 1993).
Janssen et al inserted a T cell epitope containing 72-85 of MBP (the critical T cell epitope
in experimental autoimmune encephalomyelitis in Lewis rats) in different sites of outer
membrane protein of PhOE of e.Coli and examined responses of MBP72-85- specific T
cells in denatured monomeric and native trimeric forms of chimeric PhOE constructs.
They found that monomeric but not native trimeric forms of PhoE constructs induced
proliferation of T cells. This discrepancy was independent of site of epitope insertion in
PhOE. Immunisation with monomeric form induced priming of MBP72-85 T cells but
trimeric forms were much less efficient in priming cells. Differences were more apparent




Several reports confirm the influence of antibody on antigen presentation in vitro for
model antigen such as HEL (Guermonprez, 1999) and for putative autoantigen such as
GAD 65 and thyroglobulin (Reijonen, 2000, Banga, 2004, Dai, 1999 & 2005) as well as
viral antigen (Fournier, 1996). In all cases the effectors of antigen could be attributed
similarly to enhanced FcR-mediated uptake but was more likely a combination of uptake
and antibody-modulated (autoantigen) processing. In vivo studies have demonstrated
enhancing and inhibitory effects on presentation depending on combination of antibody
and T cells specificity. Studies on processing of tetanus toxin (TT) processing in the
human system using tetanus toxin C fragment (TTCF) demonstrated a striking
enhancement of presentation of some but not all T cell epitopes from TTCF with antibody
(Antoniou, 2002).
Extracellular processing
There is abundant evidence that MHC class II molecules on the surface of fixed APC can
directly bind and present synthetic peptide epitopes although requiring higher
concentrations than fixed cells (Lindner, 1996, Aoi, 1997, Harris, 1996). Fixed APC have
also been shown to present denatured protein (Jensen, 1991, 1993, Carrasco-Marin,
1998). Therefore class II molecules on the surface of APC are capable of binding protein
or peptides denatured or degraded by the activity of extracellular enzymes in the
inflammatory exudate.
A number of proteins have been demonstrated to bypass intracellular processing and
influence presentation by surface MHC class II including MBP68-86 from guinea pig MBP
(Mannie, 1990). Cleavage by serum proteinases implicated in the serum-dependant
extracellular processing of soluble Hep 6 antigen (HDAg) leading to the presentation of
HDAg 106-122 at the surface of B cells (Accapezzato, 1998). Immature dendritic cells
(DC) have been shown to express ectoproteinases at the cell surface (Amoscato, 1998)
and secrete serine proteinases which cleave proteins into antigenic peptides
(Santambrogio, 1999).
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Peptide generated by extracellular processing may bind cell surface MHC class II
molecules under the control of DM expressed on the surface of professional APC such
as B cells or immature DC (as shown for MBP111-129 and MBP87-99 or type II collagen
COL259-276) (Arndt, 2000). It has been suggested that B cells and immature DC by
virtue of high DM expression on cell surface, facilitate loading of peptides at sites of
inflammation, rescuing peptides that are easily degraded which are processed by
endosomal proteases.
1.4.4 How may diversity in antigen processing influence the immune
response to self?
T cells are implicated in the pathogenesis of organ-specific and systemic autoimmunity,
leading to the identification of candidate autoantigens and mechanisms precipitating
diseases. An altered array of peptides to which the T-cell repertoire has not been
exposed by whatever mechanism, could potentially break self tolerance. Possible
mechanisms by which processing might give variable results include:
1.4.5 Non-professional APC
It has been hypothesised that self-tolerance could be broken if an altered array of self
peptides to which the T cell repertoire has not been previously exposed, is presented on
the cell surface in association with MHC class II in the absence of li and DM regulation
therefore potentially breaking self tolerance (Lechler, 1996). The loading of MHC class II
molecules in early endosomes is less strictly regulated by li or DM which permits
association between MHC class II molecules and unfolded endogenous proteins. In this
way self-epitopes may be generated in some non-professional APC, which lack li chain
expression. Therefore it is possible that cellular compartments such as early endosomes
that permit li chain and DM-independent loading of MHC class II molecules, play an
important role in the generation of autoepitopes implicated in the pathogenesis of
autoimmune diseases. The hypothesis is supported by studies of myelin basic protein
(MBP) a major autoantigen implicated in the pathogenesis of multiple sclerosis (MS)
(Stinissen, 1998).
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It has been shown that APC from li chain-deficient MBP84-105 TG mice could present
additional self-epitopes from the MBP fragment compared to T cells from li-chain
sufficient MBP84-105 TG mice. (Bodmer, 1994) MBP 84-105 has been shown to load
surface and recycling MHC class II molecules independent of DM (Pinet, 1995,
Vergelli,1997). Two human DR4-restricted immunodominant MBP autoepitopes MBP
111-129 and MBP 87-99 involved in MS (Zamvil,1988) were also shown to be presented
on MHC class II molecules in a DM-independent pathway in immature DC and B cells
(Arndt, 2000). DM was found to inhibit presentation of an immunodominant autoepitope
from type II collagen COL259-273 implicated in RA (Arndt, 2000).
Therefore considerable interest should be focused on antigen processing itself and in
particular, factors that could account for certain autoantigen-derived peptides being
constitutively presented at low abundance despite good affinity for MHC class II.
1.4.6 Aberrant processing
Several other autoantigens have been described as being processed independently of
newly synthesized MHC class II molecules and endosomal acidification. The presentation
of the retinal S-antigen, involved in the pathogenesis of endogenous posterior
uveoretinitis was resistant to cyclohexamide and chloroquine. In addition processing of S
antigen was not influenced by inhibitors of cysteine proteinases and other lysosomal
enzymes except the serine proteinase plasmin. These observations suggest that S-
antigen is not processed for binding to newly synthesized MHC class II in late
endosomes. It has been speculated that since 2 out of the 3 conserved putative
uvitiogenic epitopes include a cathepsin B cleavage site, these epitopes are likely to be
forwarded for destructive processing in the late endosomes unless rescued by MHC class
II molecules recycling from the cell surface. (Liversidge, 1992)
1.4.7 Creative and destructive processing
In the MHC class I processing pathway the proteolytic machinery that generates peptides
primarily in the proteosome is separated from the machinery that catalyzes the loading of
peptides onto nascent class I molecules. The key events of peptide generation and
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peptide loading are separated by the membrane of the ER. The situation is quite different
from that which occurs in the MHC class II processing pathway where the entire process
of antigen processing and peptide capture by class II MHC takes place within the same
compartmental system. (Watts, 2003) In addition many of the enzymes present within the
endosomes and lysosomes of APC are rather non-specific in terms of their cleavage
specificity. The question arises then how can T cell epitopes survive and be loaded onto
MHC class II in such an aggressive proteolytic environment? Are specific enzymes
required for optimal processing and loading of T cell epitopes-/'e how redundant is antigen
processing in the class II pathway?
Possibly professional APC such as dendritic cells (DC) have specialised mechanisms to
overcome this difficulty. DC function is carefully regulated by a process of terminal
differentiation called "maturity". DCs can alter their ability to form and accumulate peptide-
MHC complexes depending on their maturity (Mellman, 1998). Trombetta et al
demonstrated that a key mechanism responsible for this alteration was the generalised
activation of lysosomal function where immature DC slowly and inefficiently degraded
internalised antigen. In contrast, maturation-induced activation of the vacuolar proton
pump that enhanced lysosomal acidification and antigen proteolysis, facilitated the
efficient formation of peptide-MHC complexes (Trombetta, 2003).
Some potential T cell epitopes will contain protease cleavage sites and will be destroyed
during antigen processing. The immunological consequences of this have not yet been
established. In the case of self-proteins this destructive processing may have serious
consequences and proteolytic enzymes in turn may have a profound influence on the
establishment and potential breakdown of tolerance.
Proteases perform 2 key roles in the MHC class II processing pathway. They initiate
removal of invariant chain chaperone for MHC class II and also generate peptides from
foreign and self proteins for capture and display to T cells. It is however difficult to
understand how a balance is achieved between generation of peptides and their
destruction in such an aggressive proteolytic environment. Nor is it known in most cases
which proteases are involved in antigen processing.
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Moreover little is known about the processing of putative human autoantigens and why
tolerance is achieved to some T cell epitopes and not others.
Recent work by Watts et al studied the processing of the candidate human autoantigen in
multiple sclerosis, myelin basic protein (MBP) which can also induce the MS-like disease,
experimental allergic encephalomyelitis (EAE) in susceptible strains of mice and rats.
They demonstrated that a principal human HLA-DR2-restricted epitope-amino acids 85-
99 of MBP 'MBP(85-99)' contained a processing site for the cysteine protease aspargine
endopeptidease (AEP) after Asn 94. Presentation of this epitope by human antigen
presenting cells is inversely proportional to the amount of cellular AEP activity where
inhibition of AEP in living cells greatly enhanced presentation of the MBP(85-99) protein
whereas over expression of AEP diminished presentation. The results indicated that
central tolerance to the encephalitogenic MBP epitope may not be established because
destructive processing limits its display in the thymus (Manoury, 2002). Supporting this
hypothesis, they also demonstrated that AEP is expressed abundantly in thymic antigen
presenting cells.
How this epitope, rendered "cryptic" through destructive processing is in turn presented
as a target for autoreactive T cells, is not yet known. It may be related to the levels of the
enzyme responsible for destruction (AEP expression in the central nervous system, for
example in the case of MBP, where MBP 85-99 reactive T cells are thought to be
responsible for the immunopathology)
1.5 Goodpasture's disease as a model of autoimmunity
1.5.1 Introduction
Autoimmunity is thought to be important in the pathogenesis of most forms of
glomerulonephritis which together account for approximately 25% of patients with end
stage renal failure. Although rare, Goodpasture's disease provides a unique opportunity
for the study of renal autoimmunity as it is the only glomerulonephritis in which the target
of autoimmunity has been characterised.
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Anti-glomerular basement membrane (anti-GBM) disease or Goodpasture's disease is
the best defined renal organ-specific autoimmune disease. The disease is tightly
associated with autoantibody formation to a specific target found in the glomerular and
alveolar basement membranes and is characterised by a rapidly progressive
glomerulonephritis which is often associated with pulmonary haemorrhage though either
may occur alone.
In 1919 Ernest Goodpasture first described a patient with pulmonary hemorrhage
associated with glomerulonephritis in an 18 year old man during the 1918 influenza
pandemic (Goodpasture, 1919). Stanton and Tange described in 1958 a group of 9
patients with similar findings and gave Goodpasture's name to the syndrome (Stanton,
1958).
There are multiple causes of the association between glomerulonephritis and pulmonary
haemorrhage. The term Goodpasture's disease is reserved for individuals who have
disease in association with antibodies to the glomerular basement membrane (GBM)
either bound directly to the target organ or in the circulation. In early series mortality was
very high and irreversible renal failure a common outcome. The introduction of
cyclophosphamide and plasma exchange however transformed therapy, and this became
the first unequivocally effective therapy for inflammatory renal disease (Lockwood, 1976).
1.5.2 Epidemiology
Goodpasture's syndrome is uncommon with an incidence of up to 1 case per million
population per annum in the UK based on the identification of anti-GBM antibodies by
immunoassay and biopsy specimens. It has been reported to account for up to 5% of
cases of glomerulonephritis (Wilson and Dixon, 1973; New Zealand GN Study group,
1989) but 10-20% of crescentic glomerulonephritis (Couser, 1988, Andrassy 1991).
The distribution by gender is approximately equal with a slight preponderance of males to
females. The age at presentation can vary from first to ninth decade. There is however a
bimodal distribution with a greater number of individuals presenting around 30 years and
a second peak at around 60 (Savage, 1986). The youngest case presented at 11 months
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old and several patients in their 9th decade have been described although presentations
at such extremes are very rare. This age and gender distribution is somewhat dissimilar
to those of other organ-specific autoimmune disorders.
The disease is more common in white and certain other racial groups including the
indigenous population of New Zealand (Teague, 1978). It seems to be rare in South
Asian and Black races but cases have been reported in Japan and China.
Pulmonary haemorrhage appears more common in the young and in males and
glomerulonephritis alone is more common in older patients and in women. The disease
can present at any time but its incidence appears to increase in the spring and early
summer.
Clustering of cases has been described in 3 reports (Simpson, 1982, Perez 1974,
Williams, 1988) and many anecdotes. For example, within our own unit in Edinburgh, 2
cases presenting within a few months of each other were unrelated individuals who were
in fact next door neighbours. Such reports lend support to the hypothesis that exposure to
an infective or other exogenous agent is involved in the pathogenesis (see later). To date,
no such pathogen has been identified. One of the greatest difficulties in analyzing
potential exogenous agents is the likelihood that any infective agent may exacerbate pre¬
existing inflammation leading to its clinical presentation without necessarily causing it.
Disease associations may give some clues to etiology. Several are disorders in which
there may be increased production or destruction of the target antigen in GBM (Table
1.3). Associations with other autoimmune disorders are uncommon unlike other AID
such as SLE and autoimmune thyroiditis, suggesting a general breakdown of tolerance is
not the underlying pathogenic mechanism of this particular disease.
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Disease Number of reports (approx)






Lithotripsy to intrarenal stones
3
(Alport's syndrome following renal
transplantation) (tens)
Table 1.2 Disease associations Diseases recurrently associated with Goodpasture's disease.
Alport's syndrome following transplantation is bracketed as it has a distinct aetiology and is not
'true' Goodpasture's disease
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A strong class II MHC association has been described, with over 80% of patients carrying
HLA-DR15 (Phelps, 2000). A negative association exists with DR7 and possibly DR1
(Phelps, 2000). Class II MHC associations are found to varying degrees in almost all
autoimmune diseases and this is discussed further below.
1.5.3 Aetiology
The clinical outline presented above gives some clues that are helpful in approaching the
pathogenesis of disease. It illustrates that
• Breaking of tolerance is rare
• Association with other autoimmune diseases is rare
• Increased turnover or destruction of basement membrane may be implicated in disease
initiation suggesting a possible change in presentation due to increased turnover a factor
in immunopathogenesis
• Clustering of cases suggests a potential role for exogenous infection/toxin in breaking
tolerance
• Antibody formation is a consistent finding and likely to be a central part of the
pathogenesis of the disease
• HLA is a strongly predisposing factor in disease susceptibility
The clinical syndromes of autoimmune disease caused by activation of T cells, B cells or
both in the absence of infection is the consequence of the failure of a number of safety
mechanisms established under the heading of tolerance.
The challenge then is to understand how this physiological process becomes
pathological. More is known about Goodpasture's disease than any other autoimmune
renal disorder. Some information comes from animal studies, but in this disease there are
also invaluable clinical studies and results from laboratory investigations of the human
antigen, antibodies and lymphocytes.
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1.5.4 Antigen
Basement membranes are specialized and complex structures found usually at the
boundary between cells and connective tissue stroma. The membranes themselves can
influence the fate of cells, the polarization of subcellular constituents and the location of
cell receptors and transporters.
The majority of the components of the basement membrane are ubiquitous to all
basement membranes but others have a more restricted distribution probably related to
more specific function within the respective basement membrane (Miner, 1999). Within
the kidney the GBM is a key component of the ultrafiltration barrier. It is assembled
through interweaving of IV collagen with laminins, nidogen and sulphated proteoglycans.
Collagen IV (Figures 1.6 and 1.7) was first isolated by Kefalides from GBM in 1966. It
belongs to a family of collagenous proteins with at least 25 members. Six genes encode
collagen IV chains: a1(IV)-a6(IV), COL4A1 to COL4A6. Collagen IV is composed of triple
helical (protomers), a1a1a2, a3a4a5 and a5a5a6 which are selectively expressed in
different membranes at different stages of embryonic development. These protomers
create fishnet-like collagenous networks by covalent associations as dimers head-to-
head and tetramers tail-to-tail. The a1a1a2 network is present in almost all basement
membranes while the other networks have a much more tissue-specific distribution with
that of a3a4a5 being particularly limited. It is found especially in basement membranes
formed by fusion of epithelial and endothelial cell basement membranes or those involved
in gas or fluid exchange or transfer. These networks occur in the GBM and some tubular
basement membrane; the kidneys, lungs testis, cochlea and eye (Cashman, 1988).
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Figure 1.6 Type IV collagen is the major protein of basement membranes. Its triple helical
protomers have multiple non-collagenous interruptions that make the fibres non-linear, with kinks
and tertiary coils and the head-to-head and tail-to-tail interactions form an open meshwork. The




NC1 Hexamer NC1 Dimers, monomers
Collagenase SDS-PAGE
Figure 1.7 The NC1 domains of adjacent a3a4a5 protomers are tightly associated as
hexamers. Digestion with enzymes that break down collagens releases hexamers intact and this
process is likely to be part of normal basement membrane turnover and of destructive proteolysis
during inflammation. Dissociation of NC1 hexamers (e.g. for SDS-PAGE chromatography or by low
pH) releases dimers and monomers of the constituent alpha chain NC1 domains and exposes
further antibody-binding epitopes. Persisting dimers are composed of monomers covalently linked
by disulfide and other covalent linkages.
Hudson and co-workers identified that most of the circulating antibodies in patients with
anti-GBM disease were directed against a non-collagenous (NC1) domain of a new type
IV collagen chain that they termed a3 (Wieslander, 1984, Saus, 1988). This was
confirmed by cDNA cloning, which showed that the 230 amino acid carboxy terminal
domain a3(IV)NC1 was the consistent target of autoantibodies in all patients with anti-
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GBM disease (Turner, 1992). Glomerular epithelial cells seem to be responsible for the
synthesis of a3a4a5 collagens in the formation of GBM.
1.5.5 Antibodies and B cell epitopes
In detailed studies with recombinant proteins some patients show additional, usually
minor reactivity to other NC1 domains but reactivity with a3(IV)NC1 is consistent and
specific. Much of the reactivity of any one patient's autoantibodies can be blocked by
other patients' sera or even by single monoclonal antibodies (Hellmark, 1994) suggesting
consistent specificity between patients. Most patients' anti-a3(IV)NC1 antibodies include
a high proportion specific for epitopes involving residues 17-31 (EA) towards the N-
terminal end of the NC1 domain close to the triple helical region, and a smaller population
specific for EB in the second hemi domain at 127-141 (Ryan, 1998; Netzer, 1999;
Hellmark, 1999, Borza, 2000, David, 2001). The epitope is highly conformational,
rendering early studies using synthetic peptides or bacterially produced antigen
unreliable. There is a degree of concealment or crypticity of the B cell epitope in the fully
folded hexamer, which can be purified from GBM as a hexamer containing the NC1
domains of two adjacent a3a4a5 protomers (Borza, 2000, Wieslander, 1985) (Figure
1.7). However circulating antibodies bind to the normal GBM of experimental animals
including primates in vivo, and the apparently normal GBM of humans in vivo. Detailed
studies suggest that subtle differences in the covalent bonding between monomers of
adjacent fibrils may influence the accessibility of the epitope, with many more sites
becoming available when the molecule is dissociated (Borza, 2005).
1.5.6 Regulatory and effector T cell epitopes and their generation
Tolerance to self antigens is maintained by regulatory T cells as well as by deletion of
cells with a high affinity for presented peptides of self antigens. The a3 chain of type IV
collagen has been demonstrated to be 'promiscuously' expressed in the thymus, in
common with many other known autoantigens (Salama, 2001, Wong, 2001). Although the
percentage of T cells capable of recognising the alpha chain that are deleted in the
thymus is not clear, it is known that a small percentage do survive into the periphery.
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Peripheral blood T lymphocytes in both healthy individuals and patients with disease are
capable of proliferating to a3(IV)NC1 in vitro (Derry, 1995, Salama, 2001). T cells that
proliferate in healthy individuals are much less abundant than in those with active disease
or those in the recovery stage of disease (Salama, 2001). Cairns et al demonstrated that
patients' T cells consistently recognised certain epitopes in a3(IV)NC1 with greater
abundance in comparison with healthy controls and this is discussed further below. The
relative proportions of anergic and regulatory cells are not yet known (Cairns, 2003).
1.5.7 Initiation of the autoimmune response
In experimental animals, initiating an autoimmune response requires several actions, and
these are highly informative when considering how autoimmune diseases may be
initiated in man:
• Choose a susceptible strain - where genetic susceptibility has been mapped, multiple
loci are usually involved, for example in the Wistar-Kyoto rat which is particularly
susceptible to crescentic nephritis and vasculitis (Reynolds, 2002). It is clear that this is
also true in human autoimmune diseases.
The only well established genetic association in Goodpasture's disease so far is HLA
linkage. There are reports of discordance in monozygotic twins, and this is generally true
for autoimmune diseases, showing that at least second if not third hit is required on a
background of genetic susceptibility. Reports of clusters of cases mentioned above
provide strong circumstantial evidence for an exogenous factor - but no factor has been
identified in any of these clusters.
• Immunize with a slightly modified antigen - to induce an immune response that is to a
slightly different molecule that can cross-react with a self protein. The most common
strategy is to use antigen prepared from another species so that there are some
sequence differences, but post-translational or chemical or structural alterations may also
suffice. B lymphocytes may often be important in generating this type of cross-reactivity.
It is frequently hypothesized, though rarely proven, that molecular mimicry by
microorganisms might be an important initiating element in autoimmune diseases
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(reviewed by Wucherpfennig 2001). Looking for linear sequence similarities is probably
an oversimplification as T cells see shapes, not sequences, and T cell clones may be
stimulated by peptides of quite different sequence (Wucherpfennig, 1995).
• Use an adjuvant - without an adjuvant, immune responses in animals are frequently
absent or benign. The stimulation of toll-like receptors and possibly other pathways can
critically influence the outcome of the interaction between an antigen presenting cell and
interacting lymphocytes, to shift the response from the default response of tolerance to
one of active immunity - the 'danger hypothesis' (Gallucci and Matzinger, 2001). If the
mimicry hypothesis is favoured, the same microorganism might provide the adjuvant
stimulus too. However there is no demonstrable consistent relationship between specific
infections and most autoimmune diseases.
The outcome of interactions is likely to be highly contingent on quantitative aspects of
each of these three factors.
The associations of Goodpasture's disease with small vessel vasculitis, lithotripsy, and to
a lesser extent membranous nephropathy and possibly diabetes support the idea that a
quantitative or qualitative change in antigen presentation may be important. Lithotripsy is
known to cause renal trauma; as the kidney moves with respiration it is almost impossible
to prevent some exposure to shock waves and potential tissue damage when
fragmenting intrarenal stones (Evan, 1991, Jaeger, 1995). In diabetes and membranous
nephropathy the thickened and abnormal GBM contains an increased amount of
Goodpasture antigen. As discussed above, there is good reason to suspect that a change
in antigen presentation must occur in disease initiation, to permit generation of disease-
associated peptides which are not normally presented, and to which there is therefore no
(or less) tolerance.
1.5.8 Mechanisms of Injury
Though opinion on the predominant mechanism of injury has swung forward and back, it
is now widely accepted that both cell-mediated and antibody mechanisms are integral to
the damage seen in anti-GBM disease.
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1.5.9 Injury caused by antibodies
In 1967, Lerner, Glassock and Dixon demonstrated that anti-GBM antibodies were
nephrotoxic. Nephritic kidneys from patients with anti-GBM disease were acid-eluted and
antibody purified in order to obtain purified antibody. The antibody was then injected into
the unilaterally nephrectomised squirrel monkeys which then went on to demonstrate
non-crescentic glomerulonephritis and renal failure. In humans, pathogenicity of
circulating anti-GBM antibodies was suggested by the close association of circulating
antibodies and disease as well as the titre of antibody and severity and subsequent
resolution of disease (Simpson, 1982, Savage, 1986, Herody, 1993).
In genetically engineered mice that produce human IgG antibodies, immunization with
a3(IV) NC1 domains results in the production of human anti-GBM antibodies and a
proliferative glomerulonephritis (Meyers, 2002). It should be noted that in this model the
changes produced by antibodies alone were not of a crescentic nephritis. In the WKY rat,
transfer of antibodies has been demonstrated to transfer disease (discussed further
below).
Human anti-GBM antibodies usually of the IgG-complement-fixing class or rarely IgA are
of particularly high affinity and remain attached to the GBM for prolonged periods
(Rutgers, 2000) (Figure 1.8).
When anti-GBM antibodies bind GBM they activate complement leading to cell injury and
inflammation. The cleavage of C3 leads to C3 fragments and ultimately to the formation
of the membrane attack complex (C5b-9) which inserts into cell membranes where it can
kill cells or activate them to secrete cytokines: recruitment of cellular effectors is critical to
further damage
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Figure 1.8 Immunofluoresence image of linear deposition of IgG on glomerular basement
membrane.
1.5.10 Injury caused by T lymphocytes
The strong evidence to suggest that cell mediated immunity has an important role to play
in aggressive glomerulonephritis has been summarised by Bolton (Bolton 2002).
Lymphocytes can be seen in biopsies, and the IgG subclass distribution of autoantibodies
IgG 1 and lgG4 suggest a T cell dependent process. The strong association of disease
with HLA Class II alleles, in vitro evidence of cell mediated immunity and the observation
that effective treatments also act on cell mediated immunity provide additional support.
In animal models of injury caused by anti-GBM disease CD4+ and CD8+ T cells and
intrinsic renal epithelium induce the migration of macrophages and neutrophils into the
kidney (Tipping, 1997, Wu 2002, Timoshanko, 2001). IL-12 and IFN-y mediate crescent
formation. (Timoshanko, 2001, 2002). The initial inflammatory reaction in the glomerulus
produces proteinuria and the attendant downstream consequences for tubular epithelium
the development of interstitial nephritis and the subsequent appearance of fibrosis
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(Abbate, 1998).
Studies of murine models show the importance of inducing a Th1 response if pathology is
to develop and suggests T cells may be important not only in providing help for
autoantibody production but in driving glomerular inflammation (Huang, 1997). In
particular disease could only be passively transferred with anti-a3(IV)NC1 antibody from
nephritogenic strains to syngeneic recipients but not to TCR deficient mice suggesting
crescentic nephritis requires cell mediated immunity. (Tipping, 2006)
In the last few years, a model of experimental allergic glomerulonephritis (EAG) in the rat
has allowed a greater understanding of the potential role for T cells in the
immunopathogenesis in disease. The Wistar Kyoto (WKY) rat model of experimental
allergic glomerulonephritis (EAG) originally described by Sado (Sado, 1998)
demonstrates that EAG can be generated in animals without antibody production, that
disease can be transferred by T cells alone, and that disease can be induced by peptide
immunization where antibodies are undetectable on the GBM (Robertson, 2005).
Interestingly, transfer of antibodies can transfer disease in the WKY rat perhaps through
altered antigen presentation leading to generation of new aggressive T cells in the
recipient animal - though antibody independent disease can also be shown in this model.
The T cell epitope responsible for EAG in WKY rats is in the amino-terminal third of
a3(IV)NC1 where the human antibody epitope is to be found (Bolton, 2005), but it is
distinct from the T cell epitopes identified in patients (Cairns, 2003). Remarkably,
immunization with a minimal peptide can induce disease in which antibodies are formed
as a secondary phenomenon, or without antibody generation at all. The length of the
peptide influences the formation of anti-GBM antibody and the presence of certain amino
acid residues at position 19 appears to be critical for disease induction (Bolton, 2005).
The potential for immunotherapy directed at T cells is highlighted by the success of
tolerogenic intervention by oral a3(IV)NC1 administration in attenuating nephritis and the
associated Th1 response in disease susceptible rats (Reynolds, 2005).
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1.5.11 Factors modulating injury
Intercurrent infection has long been known to increase the intensity of the inflammatory
response and end organ damage (Rees, 1978). These clinical observations are
supported by experimental evidence (e.g. Karkarand Rees, 1997).
1.5.12 Genetic influences
Epidemiological studies have demonstrated that genetic factors are crucial determinants
of susceptibility to autoimmune disease. Most autoimmune diseases are multigenic with
multiple susceptibility genes working to create susceptibility. On their own these
polymorphisms or mutations are usually subclinical. Only when present with other
susceptibility genes do they contribute to autoimmunity, and even then, some kind of
'second hit' is required to intiate the disease process.
In common with other human autoimmune diseases, Goodpasture's has been associated
with inheritance of specific class II HLA alleles (Phelps, 2000) HLA class II molecules
consist of an alpha and beta chain with the greatest variability in the beta chain. They are
encoded at the DR, DP and DQ loci on chromosome 6. DR specificities are determined
exclusively by differences in the 3 chain encoded by the DRB1 locus. DR2 requires
DRB1*15 or DRB1*16 at the B1 locus, the former of which accounts for >80% of the DR
specificity in the northern European caucasoids that are most commonly affected by this
disease.
Meta-analysis has confirmed that anti-GBM disease is strongly associated with
DRB1*1501 and has clarified weaker associations with alleles DRB1*04 and DRB1*03.
Indeed weaker negative associations are also seen with DRB1*07 and DRB1*01 (Phelps,
1999).
Susceptibility to Goodpasture disease is shown to be influenced by a combination of
DRB1 alleles inherited on maternal and paternal chromosomes. Gene dosage does not
affect susceptibility as it is similarly increased in homozygous or heterozygous individuals
for DRB1*1501. The effect also includes neutralization of the susceptibility enhancing
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effect of DRB1*1501 by co-inherited DRB1*07. Thus DRB1 and 7 confer dominant
protection against anti-GBM disease. This strongly suggests an interaction most likely
occurring between the class II molecules they encode. The obvious assumption is that
there might be competition for the disease-causing peptide. However the explanation
could also lie in the opposite interpretation, that a tolerance-inducing (or regulatory cell-
stimulating) peptide is particularly well presented by the protective alleles and poorly
presented by DR15.
1.6 Processing of the Goodpasture autoantigen
Work within my supervisors' group has focused on Goodpasture's disease as a model for
autoimmunity for a number of reasons;
• the target of autoimmunity has been characterised and is known to reside in the 230aa
COOH-terminal of the non-collagenous domain of the a3 chain of type IV collagen
(a3(IV)NC1), a constituent of the GBM (Turner, 1992, Saus, 1988, Hellmark, 1999,
Leinonen, 1999, Ryan, 1998).
• This can be produced in a number of recombinant forms, some with conformations
similar or even identical to that of the native antigen, as detected by binding of
conformation-sensitive antibodies.
• As with the majority of autoimmune diseases and as detailed above, it has a strong
HLA association with a positive association with HLA DRB*1501 and a negative
association with HLA DRB1*0701, which is dominant in the presence of DRB1*1501
(Phelps, 1999)
Extensive work in our laboratory has used biochemical approaches to identify the major
peptides that are bound to HLA-DR15 on the surface of B cells that have processed
recombinant Goodpasture antigen (a3(IV)NC1). This avoids the confounding effects of
tolerance in using conventional lymphocyte responsiveness assays to define peptides
presented. This work has lead to a number of key observations:
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• The major naturally processed peptides are three nested sets of peptides, each centred
on core sequences of 9 amino acid long MHC-binding motifs. The peptides have only
intermediate affinity for the presenting HLA-DR15 molecules, confirming that antigen
processing pathways exert a strong influence the peptides presented (Phelps, 1996 &
1998).
• Importantly, data investigating what a3(IV)NC1-derived peptides are recognised by T
cells from patients with active Goodpasture's disease found that autoreactive T cells in
6/6 patients with active disease recognised two a3(IV)NC1 derived peptides, dap79-91
(VNDVCNFASRNDYSYWLSTPA) and dap131-150 (IPPCPHGWISLWKGFSFIMF)
(Cairns, 2003), which were not efficiently presented, as detected using biochemical
studies despite a much higher affinity for DR15 than detected peptides (Phelps, 1998).
• Recent observations suggest that the disease-associated peptides might be impeded
from tolerising self-reactive T cells because in normal antigen processing they are
destroyed very early in an obligatory first 'unlocking' step in proteolysis by Cathepsin D/E
(Zou, 2007). This dependence on a specific unlocking step has been described for other
globular proteins including another potential autoantigen, myelin basic protein (Manoury,
2002), but with dependence on a different proteolytic enzyme, asparginyl endopeptidase,
AEP). The dependence of processing on a specific and consistent unlocking step could
be immunologically important, as it should help antigen presenting cells to generate a
predictable rather than random set of peptides in early antigen processing.
1.7 Purpose and design of study
These observations raised the question I set out to study. My question was:
Could low presentation of disease associated peptides (dap) in Goodpasture's disease
such as dap79-91 and dap131-150, despite high affinity for FtLA DR15, be a
consequence of processing factors and of so, how can processing be perturbed so that
disease associated peptides are presented at all?
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When I joined the lab, another worker was attempting to answer the question by adopting
a biochemical approach using techniques already described by Watts et al (Antoniou,
2000, Watts, 2005). This approach involved endolysosomal processing of recombinant
a3(IV)NC1 whereby antigen was incubated with either freshly disrupted lysosomes from
human EBV B cells or specific proteases. Degradation was then followed by SDS page
gel and mass spectrometric analysis. This first approach affords the potential to detect all
peptides generated as a result of processing but generates a complex array of peaks in
the mass spectrogram which in turn influences specificity.
As described above, 6/6 patients with disease have T cells with specificity for two
a3(IV)NC1 derived peptides peptides, dap79-91 and dap131-150, which are not
efficiently presented despite high DR15 affinity. Biochemical studies have shown both
these epitopes are exquisitely sensitive to endosomal proteases, but does this sensitivity
have any bearing on presentation to T cells by living APC?
Since it would be necessary to quantify low level presentation, I needed an alternative
approach to the biochemical studies which had already shown itself only able to detect
most abundant peptides. Cellular approaches have been used to determine the amount
of specific peptide complexes on APC, but have always involved the use human T cell
clones and this technique is limited by the difficulties in production and maintenance of
cell lines. I thought I might use T cell hybridomas, which have a number of advantages
over T cell clones in the study of APC function. They are reliable, reproducible and
convenient to use, they can also be grown to unlimited supply for large antigen
presentation experiments. In addition they function well with fixed APC allowing for
kinetics analysis and the use of inhibitors for antigen processing. Most importantly
however they have the advantage of detecting specific peptide-MHC complexes on the
surface of APC. An alternative approach is the use of transgenic mice with human MHC
genes to produce "humanised" murine T cells and subsequent T cell hybridomas that are
restricted by human HI_A alleles and therefore respond to peptide presented on human
APC.
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I chose to adopt a cellular approach, which would allow me to follow the consequences of
processing factors on specific a3(IV)NC1 peptides of interest. With this approach,
presentation of a3(IV)NC1 peptides by human APC was determined using a3(IV)NC1
peptide-specific DR15 restricted murine T cell hybridomas in mice engineered to express
HLA DR15 (donated by Professor Altmann, (Altmann, 1995) to study the influence and
consequences of processing.
On this background, I addressed my question by:
1. Developing murine DR15-restricted T cell hybridomas specific for the two major
epitopes in a3(IV)NC1 that are recognised by patients with Goodpasture's disease.
2. By pulsing recombinant a3(IV)NC1 into different DR15 expressing human antigen
presenting cells, I proposed to examine whether propensity of lysosomal aspartate
protease activity to destroy a3(IV)NC1 T cell epitopes in vitro had discernible
consequences in live APC.
3. Using these hybridomas as peptide detectors, I aimed to probe the effects of various
factors, in particular focussing on the influence of aspartate proteases (with the use of
specific protease inhibitors), on the processing and presentation of peptides dap79-91
and dap131-150. This would in turn allow me to address the specific hypotheses that
the disease-associated peptides in Goodpasture's disease are particularly susceptible
to proteolytic destruction in APC.
If I was successful in generating DR15-restricted and peptide specific T cell
hybridomas, I would have a powerful tool with which to examine what other factors
thought to alter the processing of a3(IV)NC1 so as to influence its presentation.
Specifically, I hoped to investigate the effect of dominant protection observed with the
co-expression of HLA DRB1*0701 and HLA DRB1*1501 on the presentation of the
same disease associated peptides shown to be destroyed in early processing.
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The first and most straightforward approach would utilise EBV transformed B cells from
patients known to express either DR15,7 or DR15,15 and compare ability to present
either dap79-91 and dap131-150 to the DR15-restricted T cell hybridomas already
generated. Differences in presentation could also potentially be compared with other







All materials, unless otherwise mentioned, were obtained from either Sigma-Aldrich
Company Limited, UK; Fisher Scientific, UK; BDH Laboratory Supplies (VWR
International); or Scientific Laboratory Supplies Ltd, UK.
b) Molecular biology stock solutions
The following stock solutions were formed and stored at -20°C
Ampicillin 50mg/ml in dH20
Carbenicillin (CN Bioscience) 50mg/ml in dH20
Chloramphenicol (Transgenomic Limited) 34mg/ml in 100% ethanol
IPTG (Transgenomic Limited) 1M in dH20)
c) Plastics / Glassware
All materials, unless otherwise mentioned, were obtained from either Nalge Nunc
International (Denmark), Sarstedt Inc. (USA), orTechne (Cambridge) Ltd (UK).
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d) Cell Lines
All cell lines, unless otherwise mentioned, were obtained from either Invitrogen Life
Technologies (Holland)
e) Media
All media, unless otherwise mentioned, were obtained from either Invitrogen Life
Technologies (Holland) or PAA Laboratories (UK).
2.1.2 Solutions
a) Agarose mini gels
All solutions were produced following the methods laid out in Sambrook et al
(Sambrook, 1989).
b) SDS-PAGE gels
All solutions were produced following the methods laid out in Sambrook et al
(Sambrook, 1989 ).
c) Triton wash solution
0.5% Triton X-100
1 mM EDTA
The solution was made up to 1 litre and stored at room temperature





The solution was made up in dH20
e) Nickel chelation chromatography
All solutions were passed through a 0.45pm filter (PAL Gelman Corporation) prior to
use
f) Column stripping solution
100mm EDTA
1M NaCI
The solution was made up in dH20, adjusted to pH 8.0 using NaOH to dissolve EDTA
g) Column metal loading solution
100mM NiCI2
10mM sodium acetate
The solution was made up in dH20, adjusted to pH 4.5 using 1M HCI and stored at room
temperature.




Solution made up to 250mls in distilled H20 at pH 7.5
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Solution made up to 250mls in distilled H20 adjusted to pH 7.5
j) 12-5% acrylamide/Bis gel
4.2mls Acrylamide/Bis 30%
3.2mls dH20
2.5mls 1.5M pH 8.7
100pl 10% SDS
40pl 10% Ammonium persulphate
7pl TEMED
k) Running buffer x5
93.75g Glycine
15.1 g Tris Base
50mls 10% SDS




830|j| Tris pH6.8 (1.5M)
0.3ml Bromophenol blue (0.2%)
10g Sucrose
Solution diluted to 50mls dH20
m) Agar plates
SOB/LB agar plates were prepared by adding 1.5% agar (7.5g) to 500mls dH20. The
bacretial growth medium was autoclaved in a microwave before pouring onto 90mm
plates (Bibby Sterilin). If adding antibiotics, the solution was left to cool to approximately
55°C before adding the antibiotic and then pored as before. The solution was then left to
cool and set before drying overnight at 37°C.
2.1.3 Bacterial protein production methods
Production of recombinant a3(IV)NC1
a) Transforming BL21(DE3) Cells
BL21(DE3) (CN Bioscience) cells were transformed using the constructs for a3PHisBirA
ligated into pET25b (CN Bioscience) as previously described (Phelps, 1996). These
transformed cells were stored as glycerol stock and used for future protein production.
Transformed bacteria were plated onto LB agar plates containing 100pg/ml carbenicillin
by streaking the plate with the still frozen glycerol stock of pET25ba3PHisBirA using a
sterile applicator (Nalge Nunc Ltd.) The plate was incubated overnight at 37°C.
b) Small scale production and analysis
At least 5 isolated colonies were then selected for inoculation into 5-10mls LB broth
containing carbenicillin 200pg/ml. Inoculations were grown at 37°C in an orbital shaker
at 250rpm until starter cultures had an OD of approximately 0.6 then stored overnight at
4°C.
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1 ml of each starter culture was then inoculated into 15mls of LB broth containing
400pg/ml carbenicillin and grown at 37°C in an orbital shaker at 250rpm for approximately
3-4 hours.
The use of high concentrations of carbenicillin helps prevent the overgrowth of cells that
have lost the transformed plasmid which may otherwise occur due to bacterial p-
lactamase production.
The optical density at 600nm (OD600) was measured. Cultures were allowed to grow to an
OD of approximately 0.5-0.6. At this stage 1ml from each culture was then induced with
0.8mM IPTG for 4 hours at 37°C in an orbital shaker at 250rpm before storing overnight at
4°C. The following day, samples were spun alongside 5 x 1ml of non-induced cultures at
10,000rpm for 1 minute and supernatant removed. 100pl of ice cold PBS and 100pl 2x
SB was then added mixed and samples sonicated for approximately 15 seconds on ice at
duty cycle 30% (Ultrasonic Processor - Jenkons Scientific Ltd). At this stage a sample
from each suspension was analysed using an SDS PAGE gel and Coomassie Brilliant
Blue stain as described in section 2AVa. a3PHisBirA was identified by having the
molecular weight of 31 kD and could be present as either a dimer or monomer.
Colonies were selected for large scale protein production according to SDS PAGE
analysis where the colony with the greatest protein production was used.
c) Large scale production of recombinant protein
Once the colony with the highest protein yield had been selected from the small scale
preparation, a larger scale preparation was made. 500mls LB with 300ug/ml carbenicillin
was inoculated with 10mls of starter culture in a 2 litre baffled flask. The suspensions
were incubated at 37°C in an orbital shaker as before at 250rpm until the OD60o had
reached 0.5-0.6. Cell suspensions were induced with 0.8mM IPTG for 3 hours and
transferred to oakridge tubes. Suspensions were pelleted by spinning for 25 minutes at
5000rpm. Pellets were stored at -20°C until required.
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d) Bug busting and inclusion body preparation
Frozen pellets were defrosted and resuspended in 10mls ice cold PBS by sonicating on
ice at 30% duty cycle for 80 seconds. Following this, 0.2mg/ml Hen egg lysozyme (HEL)
was added and samples left on ice for 30 minutes before adding 0.1% deoxycholate,
2mM magnesium chloride (MgCI2) and DNase I to a final concentration of 2pg/ml. The
inclusion body preparation was left at room temperature for 15 minutes. Samples were
then sonicated on ice until liquid (60 seconds) and spun at 10000rpm for 7 minutes at
4°C. Supernatant was removed and spun again to collect any further pellet. Pellets were
then washed in 10mls PBS and 0.1% Triton and sonicated for another 80 seconds.
Samples were pelleted as before resuspended in 10mls PBS before sonicating and
spinning as before. Pellets were then resuspended in 2M urea Tris 50mM pH 7.5. This
solution was sonicated and spun and pellet resuspended in 6M GnHCI Tris 50mM pH 7.5.
The pellet was sonicated for approximately 160 seconds and left rolling at 4°C
e) His Tag purification of recombinant protein, a3HBirA
20ml columns were packed with approximately 4mls IAA beads. The column was
initially washed twice in 50mM Tris pH7.5 before running 5mls NiCI2 through the
column. This was repeated with 10 mis NiCI2 until the beads had turned blue
(approximately three times in total). Any unbound nickel was washed off by washing the
column twice with 50mM Tris pH 7.5 and a further three times with 6M GnHCI, 50mM
Tris pH7.5, 20mM imidazole. Sample solution was then added directly to the column
and the beads agitated gently. The column was clamped at the end and the solution
allowed to settle for a few minutes before being allowed to run through. This first
collection was labelled the post load). Three washes were carried out with wash
solution (GnHCI,Tris,imidazole) and bound a3HBirA then eluted by sequentially running
2mls GnHCL,Tris,imidazole,EDTA through the column three times, agitating the beads
as above before collecting the eluate. 10mls 100% EtOH was added to each 2ml
sample before storing at -20°C overnight. Samples were then washed twice in 70%
EtOH before resuspending the pellets in 6M urea, 50mM Tris pH 7.5.
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Representative samples (50-200pl) from pre and post load as well as all samples from
washes and eluates were precipitated in 4x EtOH, left overnight and washed on 70%
EtOH before being resuspended in 40pl SB (7-8M urea, 10mM DTT, 50mM Tris) and
analysed using SDS PAGE gel and Coomassie Brilliant blue stain.
f) Quantification of recombinant a3(IV)NC1
100pl of stock solution was diluted 1 in 5 in 6M urea/50mM Tris pH 7.5. Absorbance was
measured at 260nm and 280nm. Concentration was calculated using the equation (1.55 x
A280) ■ (0.76 x A260) x 5.
g) Testing of recombinant a3(IV)NC1
Prior to use in any experiments, purified recombinant a3(IV)NC1 was used to pulse
antigen presenting cells at 10, 50, 100 & 200 pg/ml as described in section 2.3.4.f
2.1.4 Protein identification methods
a) SDS-PAGE
All solutions were produced following the methods laid out in Sambrook et al
(Sambrook, 1989).
Once set, the gels were placed in an electrophoresis tank which was subsequently filled
with running buffer. Samples were mixed 50:50 with SDS sample buffer and the protein
allowed to run at 120V,20mA (per gel) for approximately 1.5 hours (consort E834). 10ul of
perfect protein™ marker (CN Bioscience) was loaded in the first well as a means of
identifying protein by molecular weight.
b) Coomassie Brillaint Blue
To identify proteins, gels were stained overnight using GelCode® Blue Stain Reagent
(.Perbio Science) and washed thereafter in distilled water.
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c) Drying SDS-Page gels
Gels were washed in dH20 as above and carefully sandwiched between two sheets of
gel drying film that had been soaked in a solution of 40% methanol, 10% glycerol and
7.5% acetic acid. The films were stretched and clamped between two drying frames




All synthetic peptides were 20mers generated using standard F-moc chemistry by G.
Bloomberg (University of Bristol U.K.). The composition and purity of these peptides had
been confirmed by mass spectrometry.
DerP1 was used as a negative control in peptide recognition assays. It is a major mite
faecal antigen belonging to the peptidase C1 family with a molecular weight of
approximately 36kD
All peptides were dissolved in DMSO (Sigma) at 20mg/ml and further diluted to 0.5mg/ml
















Table 2.1 Sequence of peptides
b) Bacterial protein production of recombinant a3(lV)NC1
See section 2.1.3.1
c) Mice
These mice were originally a kind gift from Professor D.M. Altmann, Imperial College,
London as described previously, (Altmann, 1993)
d) Enzymes and inhibitors
Cathepsin D
The recombinant antigen was digested with Cathepsin D purified from human liver and
was obtained from Athen Research & Technology. Cathepsin D was in phosphate buffer




Pepstatin A is a highly selective inhibitor of aspartate proteases (see Chapter 6).
Preparation of this inhibitor was initially problematic due to problems with solubility which
is in turn related to preparation purity. It is only sparingly soluble in water but can be
dissolved in 10% v/v acetic acid in methanol (9:1 methanol: acetic acid). The later is not
desirable due to unknown and potentially toxic effects on cells. Attempts to dissolve the
inhibitor in ethanol were also abandoned. Heat is often required for complete solution and
temperatures of up to 60°C can be used without any decomposition of the peptide but in
my hands the peptide did not dissolve.
Initial samples of pepstatin A were obtained from Sigma but subsequent samples were
obtained from Calbiochem which was > 95% pure by HPLC and reported to be soluble at
5mg/ml in DMSO. This allowed easier and more reliable means of preparation. Stock was
therefore made in DMSO at 5mg/ml. Samples were further diluted 1 in 10 in R10 to 0.5
mg/ml and aliquoted and stored at -20°C
Chloroquine
This is a member of the quinolone family with a number of applications. It was used in
processing experiments to assess the influence of increasing pH. Stock solution was
dissolved in water at a concentration of 10mM and stored at -20°C prior to use.
2.2.2 Solutions
a) media
All media and solutions unless otherwise stated were from Gibco or Sigma-aldrich.
Solutions were prepared under sterile conditions in a laminar flow Hood and stored at
4°C.




10% heat inactivated fetal bovine or fetal calf serum
L-glutamine 2mM
Penicillin 10,000U/ml /streptomycin 10mg/ml
5x10"5 M p2-mercaptoethanol
B cell media (EBV transformed B cells)
RPMI





10% heat inactivated fetal bovine or fetal calf serum
L-glutamine 2mM
Penicillin 100U/streptomycin 0.1 mg
HAT (50x) reconstituted in 10ml sterile R10 and added to 500ml RPMI. Working solution




10% heat inactivated fetal bovine or fetal calf serum
L-glutamine 2mM
Penicillin 100U/streptomycin 0.1mg
HT (50x) Reconstituted as with HAT
b) Solutions for tissue culture
RBC lysis solution
Solution A HN4CI 8.26g/100ml
Solution B KHCO31g/100ml







Heat inactivated Fetal calf serum (9 mis)
Sterile DMSO (1 ml)
Stored at -20°C
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c) Solutions for FACS
FACS buffer
PBS







d) Solutions and reagents for ELISA









Solution was filtered through 0.2pm filter












The above solution were made up to 500mls in Tris-buffered Saline and pH adjusted to








1.0ml of streptavidin conjugated to horse-radish peroxidase was stored at
-4°C. Samples were diluted to a working concentration in Reagent Diluent.
Substrate Solution





180pg/ml of rat-anti mouse IL-2 was reconstituted in 1.0ml PBS. Samples were aliquoted
and stored at -20°C. Samples were diluted to a working concentration of 1 pg/ml in PBS,
without carrier protein.
Detection antibody
72pg/ml of biotinylated goat anti-mouse IL-2 was generated when reconstituted in 1.0ml
Reagent Diluent. Samples were aliquoted and stored at -20°C after reconstitution. These
samples were diluted to a working concentration of 400ng/ml in Reagent Diluent.
Standards
65ng/ml of recombinant mouse IL-2 was reconstituted in 0.5ml of Reagent Diluent.
Standards were allowed to sit for a minimum of 15 minutes with gentle agitation prior to
making the dilutions. The reconstituted standard was aliquoted and stored at -20°C. A
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seven point standard curve using 2-fold serial dilutions in Reagent Diluent was made with
a high standard of 1000pg/ml.
2.3 Tissue culture materials and methods
2.3.1 General methods
a) Thawing cell lines
Cells were thawed rapidly at 37°C and added drop wise to 9mls pre-warmed R10 in a
15ml falcon tube. This was spun 1200rpm for 5 minutes, supernatant removed and the
pellet resuspended in 1ml R10. This was transferred to a medium (6-10ml) or small (3-
5ml) flask and incubated at 37°C 5%C02. Cells were examined using light microscopy
initially to assess general health and viability was formally assessed by staining 1:1 with
trypan blue and counting using a Neubauer haemocytometer.
b) Freezing cell lines
Approximately 1x106 cells were pelleted and re-suspended in 0.5ml R10 and added to
0.5ml freeze brew before transferring to NUNC cryotubes and freezing at -80°C for
24hours. Cells were thereafter transferred to liquid nitrogen
c) Maintenance of long term cell lines
Passage of cells varied depending on cell lines as described below. In general lines
underwent no more than 20 passages.
2.3.2 Methods specific to cell lines
a) EBV transformed B cells
Cells were grown in suspension (flasks) in B cell media and split ~2-3 times per week to a
cell count of 3 x105/ml
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b) THP-1 cells
THP-1 cells have monocyte characteristics and were derived from a 1 year old with acute
monocytic leukaemia (Auwerx, 1991) and express HLA A2, A9; B5; DRw1, DRw2 (DR1 &
DR15). They can be differentiated into a macrophage phenotype using a number of
stimulants such as PMA, DMSO, IFNy and vit D. In their monocyte phenotype, THP-1
cells have low constitutive expression of class II which can be induced by incubating with
IFN-y. After a number of optimisation experiments, THP-1 cells were routinely incubated
with 100U IFNy and 10ng/ml PMA for 24 hours before use in processing experiments.
Non-stimulated cells were grown in R10 and split 2-3 times a week to a cell count of
3x105/ml. Prior to use in antigen presentation experiments cells were stimulated with
PMA 10ng/ml and IFNy 100U/ml in 10mls R10 for 24 hours. Following stimulation,
adherent cells were detached by removing media from flask, washing cells gently with
10mls sterile pre-warmed PBS and adding 1ml trypsin/EDTA x1 and leaving for ~5
minutes until cells were seen to detach. 10mls R10 was added and the flask was tapped
firmly to encourage further detachment. Cells were then spun at 12000rpm for 6 minutes
and the pellet resuspended in R10.
c) BW5147 cells
BW5147 cells are an immortal T cell fusion partner derived from a myeloma (TcRa'P) cell
line (a gift from D. Anderton, King's buildings, Edinburgh). They are grown in 24 well
plates or small flask in R10 and are split 2-3 times a week. When using for fusion cells
were thawed and set up approximately one week before planned fusion and split at
different concentrations 48 hours pre-fusion to ensure cells were healthy and optimized
for fusion.
d) T cell hybridomas
Cells were grown in suspension (flask) in R10 and split 1 in 10 to 1 in 20 three times
weekly.
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2.3.3 Establishment and maintenance of T cell lines
a) Priming mice
Crude peptides were dissolved in DMSO then PBS as described above to a final
concentration of 0.5mg/ml. 50ug of peptide/mouse in 10Oul PBS was added to an equal
volume of complete freund's adjuvant (CFA) ensuring complete resuspension of CFA
first. The mixture was emulsified by repeatedly exchanging the solution between 2 glass
2.5ml syringes attached by means of a 3 way tap. The resultant emulsion was then
carefully transferred into a 1ml syringe ensuring no air bubbles were present.
50pg peptide was used to prime each mouse. 100pl of emulsion was injected
subcutaneously into the left and right inguinal region for subsequent retrieval of
splenocytes. Alternatively, 50pl was injected intradermal^ into the base of the tail and 50
pi subcutaneously into the scruff of the neck and left and right inguinal region for
subsequent retrieval of lymph nodes and splenocytes.
b) Setting up T cell lines
Spleens and lymph nodes were retrieved after 10-14 days or 7 days respectively
Spleen was injected with 5mls red cell lysis solution and passed through a filter using a
rubber plunger into 50mls R10. Cells were spun 1200rpm for 5 minutes and counted.
2x106 cells were aliquoted into 24 well plates and 20pg/ml peptide added into an end
volume of 2 mis. Lymph nodes were retrieved from the inguinal, para-aortic and axillary
regions). Nodes were emulsified using a rubber plunger through a sieve into 10mls R10
and spun and aliquoted as with spleocytes.
Cell lines from individual mice were cultures separately.
c) In vitro recall response
2x105 splenocytes were aliquoted into 96 well flat bottomed plate and 20pg/ml (7.5pM)
relevant or control peptide or 300pg/ml (9pM) r-a3(IV)NC1 added into an end volume of
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200pl R10. Samples were set up in triplicate. Plates were incubated at 37°C 5% C02 for
a total of 72 hours. Supernatant was removed at 24 and 72 hours (stored at -20°C for
later cytokine analysis using ELISA as described below). Cells were subsequently pulsed
with 0.5pCi 3H thymidine in 10pl R10 media. Following pulsation cells were incubated for
a further 18 hours and proliferation measured using a liquid scintillation p-counter.
d) Maintenance of T cell lines
Only cell lines derived from splenocytes and lymph nodes in mice shown to respond to
peptide were selected to continue T cell lines for potential fusion (Figure 3.9 Chapter 3).
After 3 days re-stimulation with peptide as described above, cells were retrieved and any
dead feeder cells removed by spinning the cells through histopaque at 2000rpm for 25
minutes. Resultant interface was removed and washed in 10mls R10, cells counted and
aliquoted at 2-4x105 in 2mls media containing 20U/ml rlL-2.
After 4 days expansion with 20U IL-2, 1ml of media was removed and replaced with 1ml
R10 + rlL-2 to give a final concentration of 1U/ml. Cells were then rested for 3 days
before replacing with a further 1ml of fresh R10 + rlL-2 1U/ml and incubated for a further
4 days (rested for a total of 7 days).
Cell lines could then be rested for a further 7 days or passed through another cycle of re-
stimulation, expansion and resting phases.
In further rounds of re-stimulation and in subsequent in vitro recall responses1", fresh
splenocytes from DR15+ transgenic mice pre-treated with mitomycin c were used as
feeder cells*.
tCell lines were checked for specificity prior to fusion and after each round of in-vitro re-
stimulation to ensure antigen specificity of the lines was maintained.
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2.3.4 Generation and selection of T cell hybridomas
a) Generation of T cell blasts
Only T cells from primed mice shown to have recognised peptide using in vitro re-call
assays were used to fuse with BW5147 cells.
Activated T cells were required for optimal fusion and were usually obtained at day 4
b) Fusion
2x106 T cell blasts and healthy BW5147 cells were washed separately 3 times in 10ml
pre-warmed HBSS in order to remove all the serum from the cells which may inhibit the
fusion process. Before the last wash cells were counted and mixed at a ratio of 1:1 using
2-3x10® of each. After the last wash all the HBSS was removed from the pellet using
suction and the pellet re suspended gently but thoroughly.
0.7ml PEG-1500 (pre-warmed to 37°C) was added gently to the pellet with constant
gentle agitation over 90 seconds to ensure all the pellet was disrupted. 5mls HBSS (pre-
warmed to 37°C) was added over 2 minutes and 15ml warmed HBSS then added over 3
minutes again with constant gentle agitation ensuring complete mixing.
The cells were then spun at 200g for 5 minutes and the pellet very gently resuspended in
an end volume of 30ml pre-warmed R10 over 3 minutes. Cells were then plated out in
10Opil volumes in 2x 96-well flat-bottomed plates. The remaining 10mls was diluted 1:3
and 1:9 respectively in R10.
A total therefore of 6 plates duplicated in top dilution, 1:3 and 1:9 dilutions were incubated
for 24 hours at 37°C 5% C02 before adding 100pl R10 with 2x HAT.
c) Isolation and cloning of Hybridomas
Hybridomas were generally found from day 5 or 6 after fusion and were identified by
examining the 96-well plate from underneath and confirming with an inverted microscope.
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Healthy clones were easily distinguished growing usually to one side of the well and
positive wells were marked. Individual colonies were selected for picking when seen to be
growing to about one third of the surface area of the well-if more than this the chance of
the colonies not being clonal increased.
As fusion frequency is in the order of 1 in104 the top dilution plate was often unusable.
The growing clones were transferred in 200pl to a 24 well plate and 800pl R10 1x HAT
added. Most clones adapted well to this. Transferring 250-500pl of well contents was then
used to further seed new wells.
Once the cells were growing well in 1x HAT seeding was then carried out into a well
containing only HT to wean them off aminopterin. Wells were then seeded into R10 only
and when growing well, the entire well contents transferred into a 25cm2 flask containing
5ml R10.
d) Screening and selection
Expression of CD4 and TcR
All potential T cell hybridomas were initially screened at the 24-well stage for the
expression of TcR and CD4 by FACS.
Briefly approximately 1x106 cells were taken from the contents of 1 well and resuspended
in 200pl R10/FACS buffer. 1pl PE-labelled anti-mouse TcR (B-chain and 1pl APC-labelled
anti-mouse CD4 (giving 1 in 200 dilution, Pharmingen). Cells were left at 4°C in dark for
30 minutes before washing x 2 in FACS buffer and resuspending in either 100pl FACS
buffer (if analysing within 24 hours) or FACS fix.
Only cell populations demonstrated to be clonal and expressing both surface antigens
were selected for further screening.
All subsequently selected T cell clones frozen at -80°C, were assessed for expression of
CD4 and TCR routinely after thaw as loss of expression of either surface marker can
occur at any point in the course of cell culture and storage.
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Peptide recognition
Resultant CD4+ TCR+ clonal populations after fusion were screened for peptide
specificity.
Initial screening of candidate T cell hybridomas was set up by pulsing 2x105 mitomycin C
treated splenocytes from DR15 transgenic mice and control IA-E+/DR15" mice with 1,
5,and 20pg/ml test or control peptide. After incubation with the candidate hybridoma for
24 hours, the supernatant was removed and frozen and later analysed for IL-2 production
determined by ELISA (Duoset-details) as described below. Control wells containing either
splenocytes or hybridoma in R10 or in the presence of peptide were also set up to ensure
any IL-2 detected was produced solely by hybridomas stimulated by peptide-MHC
complexes presented by APC.
DR15 restriction
As the initial mice used to generate T cell clones expressed both human and mouse class
II it was crucial to ensure any specific recognition of test peptide by hybridoma was
restricted to DR15. A number or different human DR15 expressing antigen presenting
cells (APC) were co-cultured potential T cell hybridomas and relevant or control peptide.
The method used was identical to that with DR15 splenocytes although the human cell
line were not pre-treated with mitomycin c prior to co-culture. Results are discussed in
more detail in chapter 3.
e) Peptide binding assays
In these experiments antigen presenting cells included various murine splenocytes, EBV
transformed B cells and IFNy/PMA stimulated THP-1 cells.
APC (0.5 -2 x105) were pulsed with 1,5 or 20pg/ml test or control peptide for 4-6 hours
before incubated with 0.25 - 1x105 hybridoma in an end volume of 200pl for 24 hours at
37°C 5%C02. The ratio of APC to hybridoma was regardless of actual numbers, always in
the ratio of 2.1 100pl of supernatant was then analysed in duplicate or triplicate for the
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presence of IL-2 or IFNy using an enzyme-linked immunosorbent assay kit (R&D/BD
biosciences) as described below. Analysis was performed using Stingray software and
results were presented as the mean concentration of duplicate wells.
f) Antigen processing assays
APC were pulsed (0.5 -2 x105)with 50, 100, 200 or 300 pg/ml recombinant a3(IV)NC1
(mention molarities here). a3(IV)NC1 was dissolved in 6M urea 50mM Tris pH7.5 as
described.. Stock solutions ranged from 5-16mg/ml depending on the production and
purification of protein antigen. Stock was dissolved directly into 100pl R10 media
(allowing for a further 1 in 2 dilution) before adding to a further 100pl R10 media
containing APC. Wells were set up in duplicate or triplicate. THP-1 cells that had been
pre-treated with PMA and IFNy were aliquoted at room temperature and antigen added
directly. EBV transformed B cells were aliquoted and left on ice for 30 minutes before
antigen was added, (discussed further in chapter 3). Murine splenocytes were pre-treated
with mitomycin c before pulsing with antigen. In preliminary experiments APC were left for
4-6 hours before adding hybridomas directly to the wells in an end volume of 10pl. (the
ratio of APC: hybridoma was 2:1 as in the peptide binding assays). The cells were sealed
and co-cultured for 24 hours at 37°C in 5% C02 before collecting and analysing the
supernatant as above.
Ideally supernatant would have been removed from individual wells and each test well in
turn set up in duplicate or triplicate in ELISA. Due to evaporation during the 24 hour
incubation, the media was usually reduced by 30-50pl per well making it impossible to set
each test well even in duplicate. Therefore supernatant from duplicate wells was pooled
and samples set out in duplicate for ELISA as described.
f) Cathepsin D inhibition
THP-1 cells or EBV transformed B cells were aliquoted as before in 100pl R10. Prior to
pulsing with peptide or antigen, Pepstatin A was added to the culture at concentrations of
0.1-100pM. Serial dilutions of pepstatin A were made fresh from stock in RPMI allowing
for a further 1 in 2 dilution on adding to APC. If B cells were used, pepstatin A was added
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to the cells and left on ice for 30 minutes. THP-1 cells were left at room temperature. All
cell lines were pretreated for 30 minutes before adding peptide or alpha 3 directly into
wells. As 96 well plates can only hold just over 200ul and any further significant volume
would alter dilutions, peptide and alpha 3 were added directly from stock. Cells were
incubated at 37°C 5% C02 for varying timepoints. There was considerable variation in
method of fixation or washing of APC before adding hybridoma. This is discussed in detail
in chapter 6. Essentailly however cells were fixed with FACS fix or washed at different
timepoints. Briefly at each timepoint the plate was spun at 1200rpm for 4 minutes,
supernatant removed and 200pl FACS Fix added (pre-warmed to 37°C). The plates were
left at room temperature for 30 minutes before washing the cells twice in RPMI. After
three washes 200pl RPMI was added containing hybridoma ha3p132.3. Plates were
incubated for another 24 hours at 37°C 5% C02 before analyzing supernatant for IL-2
production as before.
g) Chloroquine
Experiments were carried as described with pepstatin A. Pre-incubation time with
respective inhibitors varied however. APC were incubated with chloroquine for 15
minutes before washing or fixing.
2.4 FACS methods and analysis
a) Expression of HLA DR DP DQ on THP-1 cells
The expression of human class II molecules on THP-1 cells after stimulation was
determined using a FITC-conjugated mouse anti-human HLV\ DP DQ DR mAb. (Serotec).
The corresponding Isotype control was a FITC-conjugated mouse lgG2a.
b) Expression of CD4/TCR on T cell hybridomas
T cell hybridoma studies used a mouse APC-conjugated anti-mouse CD4 (mAb) and
mouse PE-conjugated anti-mouse TcRa(3. Isotype controls were APC-conjugated mouse
IgdK and mouse lgM« respectively. (PharMingen, San Diego,USA).
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All working dilutions of antibodies were 1 in 100.
Method
Cells were counted and aliquoted at 1x105 -1x106 in FACS buffer. Either test or isotype
antibody was added in an end volume of 10Oul in a non-sterile 96 well plate. For potential
T cell hybridomas cells were stained as follows:
Sample 1 APC conjugated lgG1«/ PE conjugated IgMx
Sample 2 APC conjugated CD4/ PE conjugated IgMx
Sample 3 PE-conjugated TcR/ APC conjugated IgdK
Sample 4 APC conjugated CD4/PE conjugated TcR .
The plate was left for 30 minutes at 4°C in the dark. Cells were then washed twice in PBS
supplemented with 1% FBS and 0.2% sodium azide (FACS Buffer). After a final wash
cells were resuspended in 100pl FACS fix and 150pl PBS and analysed either
immediately or stored in the dark at 4°C and analysed within 48 hours.
Analysis
Flow cytometry analysis was performed using FACsCaliburflow cytometer and CellQuest
software. Unstained populations were always run first to gate on the healthy cell
population first before analysis.
2.5 Phagocytosis by activated THP-1 cells
To demonstrate THP-1 cells ability to phagocytose following IFNy treatment, 10 pi
fluorescent paramagnetic particles (Polysciences Inc., Warrington, PA) were washed
three times in media before resuspending in an end volume of 100pl media. 5pl of this
suspension was added to 1x106 THP-1 cells pre-treated with PMA and/or IFNy as
described above in an end volume of 3 mis media. Cells were incubated for a further 24
hours with beads and adherent cells detached using Trypsin/EDTA and washed x 3 in
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Corning Costar 9018 high protein-binding capacity polystyrene 96-well ELISA plates were
prepared by aliquoting 100pl of capture antibody (diluted to a working concentration of
1pg/ml in PBS) to a 96 well ELISA plate. The plate was sealed and left overnight at room
temperature (-4°C). Each well was then aspirated and washed with wash buffer three
times by forcefully filling each well using a squirt bottle. Complete removal of liquid was
ensured at each stage by inverting the plate and blotting it against clean paper toweling.
The plates were blocked by adding 300pl of blocking buffer to each well and incubating at
room temperature for 1 hour. The aspiration and washing steps were repeated as before.
Serial dilutions of standards were carried out in polypropylene tubes. Samples were
vortexed between each dilution to ensure the samples were mixed properly. 100pl of
sample or standards was added in diluent to each well. The plate was then sealed with
an adhesive strip and left at room temperature for 2 hours. The aspiration and washing
step was repeated as before. 100pl of Streptavidin-HRP was diluted in reagent diluent
and added to each well. The plate was then sealed and incubated at room temperature
for 20 minutes avoiding direct sunlight. After further aspiration and washing, 100pl of
substrate solution was added to each well (50pl each of color reagent A and B) and
incubated for 20-30 minutes at room temperature avoiding direct light. 50pl of stop
solution was added to each well and tapped gently to ensure thorough mixing. The optical
density (O.D) of each well was determined within 30 minutes using a plate reader set to
test filter at wavelength 450nm and reference filter 560nm. To correct for optical
imperfections in the plates and allowing more accurate readings.
Analysis was automated using stingray software. This allowed various methods of curve
fitting to be assessed including linear, semi-log, log/log and 4 parameter logistic, to
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determine which curve best fitted the data. The results from experiments in this work
were determined using a semi-log sigmoid fitting curve with tails. Essentially the standard
curve was generated using computer software by plotting the mean absorbance (OD) for
each standard on the y-axis against the concentration (in pg) on the x-axis. The best fit
curve was generated through the points on the graph. Results were expressed as
concentration in pg/ml. If samples were diluted, the concentration read from the standard
curve was multiplied by the dilution factor. A standard curve was generated for each set
of samples assayed.
All standards and samples were plated out in duplicate and results expressed as the
mean of two wells.
2.7 Digestion of a3(IV)NC1
Digestion of a3(IV)NC1 used a zip tip method. This is a method by which the tip contains
hydrophobic beads which are dry. Organic solvents are better at wetting hydrophobic
beads therefore the tip is washed in 70% then 35% acetonitrile (+dH20) then H20. This
allows uptake of peptide and enzyme onto the tip and resultant peptide can be removed
by exposing to organic solvent.
Using the zip tip, 10ul 70% acetonitrile was taken and removed then the process was
repeated with 35% acetonitrile and dH20. Finally, after expelling the dH20, 10ul
peptide/buffer mix (2ul peptide in 30ul citrate buffer (10x)) was taken up and mixed into
the tip. The tip was washed in 10uL dH20x2 (if sample is in urea this is repeated again).
To remove the peptides , 70% ACN+matrix mix was taken up and pipetted severeal times
on the matrix plate to ensure all peptide was expelled then allowed to dry on the plate (TE
matrix was diluted 1:1 in 70% CAN as if use saturated TE matrix, crystals may form
resulting in decreased sensitivity).
1 ul of Cathepsin D was added to the remainder of the peptide/CB sample and left at 37°C
for 4 minutes before repeating the above process to elute resultant peptides. Remaining
sample was left in the hot plate for another 25 minutes allowing 2 Cathepsin D digestion
timepoints: 5 and 30 minutes.
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All samples were dried on the plate reader before analysing
2.8 Mass spectrometry
Peptides were sequenced by a number of mass spectrometric techniques including
MALDI TOF with MAC analysis (Zou, 2003) followed by data base and manual
interpretation of daughter ion spectra.
2.9 Cathepsin D assay
The assay used was innoZyme™ Cathepsin D Immunocapture Activity Assay Kit
(Calbiochem®). This assay is designed specifically to measure human cathepsin D in
tissue extracts and cell lysates as well as the screening of cathepsin D inhibitors.
All components were brought to room temperature prior to use.
The standards were made up by preparing serial dilutions of the standard (5pg/ml stock)
ranging from a concentration of 50ng/ml to 3.125ng/ml. 495pl of the sample buffer was
aliquoted into the first tube and 250pl into the remaining tubes. 5pl of the standard was
added to the first tube (50ng/ml), the sample vortexed and 250pl of this mixture
transferred to the second test tube (25ng/ml). This continued until tube 5. Tube 6
contained sample buffer only.
Due to the small cell numbers, samples were not diluted with sample buffer. Cell lysates
were prepared by washing cell pellets with ice-cold PBS. 500pl cell lysis buffer
(CytoBuster™ Protein Extraction Reagent) was added and cells incubated for 30-60
minutes. Samples were then vortexed and spun in the centrifuge at 14,000xg (should
have been a pre-cooled tabletop microcentrifuge). Sample supernatants were
immediately transferred into a new microcentrifuge tube and protein concentration
estimated via the BCA assay (see below).
100pl of standard or sample was added to each well. All samples were set up in
duplicate. The plate was closed with sealer and incubated for 30 minutes at room
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temperature with gentle shaking. The plate was then washed 4 times with 300pl wash
buffer and any liquid removed by tapping the plate gently on paper towels. 50pl assay
buffer was added to each well followed by 50pl substrate solution. The plate was sealed
tightly and incubated for one hour at 37°C.
Fluorescence was measured by on a fluorescence plate reader (FLUOstar OPTIMA) at
excitation wavelength 328nm emission wavelength 393nm.
2.10 BCA protein assay
50pl of each standard or protein sample was pipetted into a test tube. 1.0ml of BCA
working reagent (Novagen®) was added and the sample mixed with gentle vortexing.
Reactions were then incubated at 60°C for 15 minutes. Samples were allowed to cool to
room temperature before recording the absorbance.
1ml water was added to a clean cuvette and absorbance adjusted at 562nm to zero.
Each sample was transferred to a clean cuvette and absorbance (A562) of all reactions
read immediately. The correct absorbance was calculated by subtracting the absorbance
of the blank standard from the absorbance measurement of the standard and protein
samples. The corrected absorbance was then plotted against the known mass of the BSA
standards to generate a standard curve. This curve was then used to interpolate recorded
corrected absorbance for samples. The amount of protein present was calculated by
correcting for the dilution and sample volume.
2.11 Statistical analysis
ELISA test samples were run in duplicate or triplicate and results expressed as a mean of
all samples (SD included in graphs). Where comparisons between 2 variables (such as
the comparison of hybridoma reponse to peptide compared with media control), a student
unpaired t -test was undertaken. Where experiments were pooled together, either a 2
way ANOVA or Mann Whitney test was used to compare the two groups. In all analysis p
values of < 0.05 was taken to represent a significant difference between variables.
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Chapter 3
Generation of DR15-restricted murine T cell hybridomas
3.1 Introduction
The fine specificity and sensitivity of peptide detection offered by a cellular approach
justifies why I selected this method to study the effects of a3(IV)NC1 processing on the
presentation of peptides in Goodpasture's disease.
Previous cellular approaches used to determine the presence of specific peptide
complexes on APC have involved the use human T cell clones but their production and
maintenance is difficult. The generation of human T cell clones is a lengthy process
requiring the re-stimulation of cell lines every few weeks usually with autologous feeder
cells. The ethical issues which prevent the vaccination of humans with a potential
epitopes of interest preclude this approach as a potential avenue of investigation. In
addition, many human T cell clones eventually lose antigen specificity and sensitivity and
often do not respond to fixed human APC which are required for use with inhibitors of
antigen presentation. Experiments may also be limited by the number of cells from a T
cell clone that can be produced.
A different approach in the study of APC function is to use polyclonal T cell lines. These
however lack the same fine specificity. A technique that overcomes the challenging
culture requirements of lymphocyte clones is hybridoma formation.
Fusion of B cells with an immortal fusion partner was developed in the 1970s to generate
B-cell hybridomas and monoclonal antibodies (Kohler and Milstein 1975). Shortly
thereafter this same process was applied to produce T-cell hybridomas that secrete IL-2
after T-cell receptor (TCR) signaling (Kappler, 1981, Rock, 1990).
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T cell hybridomas have a number of advantages over T cell clones in the study of APC
function. They are more reliable, reproducible and convenient to use and they can often
be grown to an unlimited supply for large antigen presentation experiments. In addition,
they usually function well with fixed APC allowing for kinetics analysis and the use of
inhibitors for antigen processing. They are much less influenced by co-stimulation and so
can examine non-professional antigen presenting cells. Most importantly, however, they
have the advantage of still detecting specific peptide-MHC complexes on the surface of
APC.
There is a need for HLA-restricted T-cell hybridomas to study human APC but human
antigen-specific immortalised T cell lines have not been successfully generated.
An alternative approach, however, is the use of transgenic mice with human HLA genes
to produce human HLA-specific murine T cells and subsequent T cell hybridomas that are
restricted by human HLA alleles and therefore respond to peptide presented on human
APC.
Mice transgenic for HLA molecules have been produced for a number of HLA class I and
MHC class II alleles. HLA-A2 transgenic mice have been used by a number of groups to
study HLA-A2 epitopes in humans. There was a strong correlation between immune
responses in HLA-A2 transgenic mice and humans (Wentworth, 1996). HLA-DR1 and
HLA-DR4 mice have been studied as models of human autoimmune disease (Boyton,
2002). HLA-A2 transgenic mice used in the studies by Canaday et al have human a1 and
a2 chains in the peptide binding domain but a murine a3 chain in the CD8 docking region
of the MHC molecule (Le, 1989). This complex allows for a better T-cell response than in
mice which have a human a3 chain (Newberg, 1996). Some HLA-DR transgenic mice
similarly have a human a1 and pi chains in the peptide binding domain but murine a2
and P2 chains in the CD4 docking domains (Itoh, 1996)
Since the early reports, a number of technical advances have been applied to ease
production of T cell-hybridoma clones and maximise chances of successfully generating
an antigen specific hybridoma. The fusion partner is a T thymoma line, which cannot
survive in hypoxanthine/aminpoterin/thymidine (HAT) selection medium unless it is fused
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with a normal T cell (see Figure 3.8 in appendix). In addition, the fusion partner does not
express endogenous TcR a and 3 chains to combine with a normal T cell's TCR (Born,
1988).
When an HLA-DR4 transgenic mouse was initially described, T-cell hybridomas from this
mouse were found to recognise human peripheral blood mononuclear cells (Woods,
1994). This technique has been further characterised by only a handful of groups since
then (Backlund, 2002, Manoury, 2002). Canaday et al were the first to report the
systematic characterisation and validation of use of HLA-transgenic mice to make both
MHC-I and MHC-II restricted T cell hybridomas that respond to peptide-MHC complexes
on human APC (Canaday, 2003).
In this chapter I will describe the generation of DR15 restricted T cell hybridomas specific
for a3(IV)NC1 antigen derived peptides, their screening and selection and the initial
experiments that demonstrated that the hybridomas were capable of recognising the
disease associated peptides dap131-150 (ISLWKGFSFI) and dap71-90 (AS345) (Table
3.2) on the surface of human DR15 expressing APC pulsed with recombinant
a3(IV)NC1.
3.2 Results: Generation of T cell Hybridomas
3.2.1 Generation of T cell lines
I initially elected to generate T cell hybridomas capable of recognising the two a3(IV)NC1
peptides that were recognised by T cells from all patients in the study by Cairns et al
(Cairns, 2003). Mouse class ll/HLA-DR15+ transgenic mice were a gift from Professor
D.M. Altmann, Imperial College, London. These mice were used to generate T cell
hybridomas which were used in all subsequent experiments described.
3.2.2 Priming of transgenic mice and establishment of T cell lines
The priming of transgenic mice and subsequent establishment of T cell lines is described
in detail in chapter 2.
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3.2.3 Cell lines generated from HLA-DR15/IA-E transgenic mice demonstrate
an in vitro recall response to peptide
To ensure the primed mice had in fact responded to peptide, an in vitro recall assay was
set up and only cell lines from mice subsequently shown to respond to peptide were
propagated further as T cell lines (Figure 3.1).
□ media
30000 □ AS345 20ug/ml












Mouse 1 Mouse 2
Figure 3.1 Example of an in vitro re-call response by splenocytes retrieved from DR15
transgenic mice primed with AS345. 2x105 splenocytes were incubated with a3(IV)NC1,
relevant or control (DerP1) peptide added into an end volume of 200pl R10. Splenocytes contain a
combination of both feeder and T cells allowing for the presentation of peptide to potentially
peptide responsive T cells. Plates were incubated for 72 hours before pulsing with 0.5pCi 3H
thymidine and measuring proliferation at 18 hours with a beta-scintillation counter. Note that cells
from mouse 2 but not mouse 1 demonstrated a recall response. However, mouse 2 proliferated
only in response to AS345 and less strongly to recombinant antigen, a3(IV)NC1 but not to WISL or
control peptide, Derpl, confirming a specific response to the peptide originally used to prime the
mouse.
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3.2.4 Cell line maintenance
Cell lines shown to respond to peptide specifically were selected to create T cell lines for
potential fusion. Further details on cell line maintenance are described in Chapter 2 and
illustrated in Figure 3.2. Different approaches were used in the maintenance of cell lines
prior to fusion with the myeloma cell line BW5147. All were in an effort to achieve a T cell
line that was not only specific for the peptide of interest but in a healthy state and
adequate number in order to optimise the chances of a successful fusion. These
approaches differed mainly in the number of cycles of re-stimulation, expansion and
resting phases prior to fusion. One approach involved numerous cycles (>4) prior to
fusion. This had the disadvantage of large cell loss in the early stages of the cycle
process. Providing the line could be maintained after the 5th or 6th cycle, however, the cell
line would eventually expand and, in turn, contained a much higher proportion of peptide-
specific T cells. An alternative approach involved one cycle prior to fusion, which had the
advantage lessening the risk of complete loss of the cell line. The disadvantage was that
cells available for fusion included a much higher proportion of non-specific cells which led
to more labour intensive line maintenance and screening after fusion.
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Figure 3.2 Generation of T cell lines
3.2.5 Selection of T cell hybridomas as determined by surface expression of
CD4 and TCR
The selection media was controlled so as not to support the original T cell lines and the
myeloma fusion partner. All surviving cell lines were expected to be successfully fused
clonal hybridomas. However, a number of problems can arise at the stage of clone
selection. Firstly, clonal populations may not express both TCR and CD4 as hybrids
throw out chromosomes over time. Secondly, populations may not in fact be clonal
despite serial dilutions at the time of fusion (see chapter 2). Clones were selected by
visual examination of the bottom of 96 well plates and subsequent selection of wells
where isolated populations covered less that one third of the well surface area. To select
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out clones expressing both cell surface markers, TCR and CD4, cells were stained for
expression of TCR and CD4 using PE-labelled anti-CD4 and APC labelled anti-TCR and
analysed using FACS analysis as described in chapter 2.
Only cell populations expressing CD4 and TCR were selected for further analysis. (Figure
3.3) This was often carried out at the 24 well stage to avoid unnecessary and labour
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Quad Events % Gated % Total Quad Events % Gated % Total
UL 27 0.27 0.27 UL 1238 20.80 20.80
UR 9913 99.13 99.13 UR 4697 78.93 78.93
LL 5 0.05 0.05 LL 12 0.20 0.20
LFt 55 0.55 0.55 LR 4 0.07 0.07
Figure 3.3 Examples of clonal and non-clonal T cell populations Cells were stained with PE-
labelled anti-mouse TcR p-chain (FL2-Height channel) and APC-labelled anti-mouse CD4. A
shows a homogeneous population of cells likely to be of a single clone. B shows two populations
indicative of at least two clones. (All test samples were tested with isotype controls; APC-
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conjugated mouse IgdK and mouse IgMK respectively. In test samples represented above, gates
were placed according to isotype controls.)
3.2.6 T cell hybridomas recognise peptide presented on murine DR15
expressing splenocytes
CD4+TCR+ T cell hybridomas were screened for peptide specificity by measuring IL-2
production when incubated with same peptide used to prime the mouse from which the
clone had been derived. In these studies IL-2 concentration was determined by ELISA as
described in chapter 2. I considered assessing IL-2 concentration using a bioassay that
measures proliferation of the IL-2 dependent CTLL-2 line. CTLL-2 assays can be very
sensitive but are notoriously difficult to establish in inexperienced hands and for this
reason I selected the former method.
Initial screening of candidate T cell hybridomas was set up by pulsing mitomycin c-treated
splenocytes from DR15 transgenic mice with either ISLWKGFSFI, AS345 or control
peptide, DerP1 (Figure 3.4). After incubation with the candidate hybridoma for 24 hours,
the supernatant was removed and frozen and later analysed for IL-2 production using the
ELISA technique as described (see Chapter 2). Although not demonstrated in Figure 3.4,
control wells containing either splenocytes or hybridoma alone or in the presence of
peptide were also set up to ensure any IL-2 detected was produced solely by hybridomas
stimulated by peptide-MHC complexes presented by APC.
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Figure 3.4 T cell hybridoma IL-2 response to ISLWKGFSFI presentation on splenocytes
from DR15 expressing transgenic mice. Representative experiment examining 7 of the final 11
T cell hybridomas derived from ISLWKGFSFI primed DR15/mouse class II TG mice already
demonstrated to express CD4/TCR. Shaded bars represent production of IL-2 by respective
hybridomas in a 24 hour co-culture supernatant as determined by ELISA. All ELISA test wells were
set up in duplicate and results expressed as the mean of 2 wells. Error bars represent the standard
deviation of 2 wells. Statistical analysis of peptide response compared to medium is expressed for
each sample (unpaired t-test) The graph demonstrates that the T cell hybridomas make IL-2 in
response to ISLWKGFSFI using mitomycin treated DR15+ve splenocytes as APC. No response
was seen in the in absence of peptide or control peptide, DerP1. Response was dose dependant
at 5 and 20pg/ml.
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3.2.7 T cell hybridomas recognise specific peptide presented on human
DR15 expressing APC
As future experiments which would eventually involve manipulation of the class II
processing pathway, the use of splenocytes from a DR15 TG mouse would be difficult to
use for two reasons. Firstly, it is impossible to isolate splenocytes in similar states of
maturity from the spleen and these cells are a mixed population of dendritic cells,
macrophages and lymphocytes. Secondly, their short life span once stimulated and the
impossibility of ensuring consistency in the health and stage of maturation between
experiments. For this reason it was elected that human DR15 expressing APC were used
as well. Human cell lines have the advantage in being more representative of the human
system of class II processing and presentation of peptide as well as offering consistency
in phenotype, health and state of maturation.
Initially 2 DR15 expressing APC, DR2lum (HLA-DR15, DR1) and CRC036 (DR15.15), an
EBV transformed B cell line (kind donation from Professor Dorothy Crawford) were
selected as both expressed DR15. They were easily cultured and reliable cell lines. Either
DR2lum or CRC036 were pulsed with increasing concentrations of peptide as described
in chapter 2. Cells were then co-cultured with different clones already screened for dual
positivity for CD4 and TCR. Cells were co-cultured for 24 hours before supernatant
removed and analysed for expression of IL-2 as described. An example of one
experiment using either cell line CRC036 or DR2lum as APC is shown in Figure 3.5.
Controls (not demonstrated here) included APC or hybridoma cultured in isolation or in
the presence of peptide and APC and hybridoma co-cultured in the absence of peptide to
ensure IL-2 produced was as a result of peptide/DR15 recognition by the hybridoma. It
should be noted that at a later stage fixed APC pulsed with peptide were used to
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Figure 3.5 T cell hybridomas recognise specific peptide presented on human DR15
expressing APC Response of 11 different T cell hybridomas derived from T cell lines specific for
ISLWKGFSFI. DR15 expressing EBV transformed cell lines, CRC036 or DR2 lum were used as
antigen presenting cells and pulsed with 20pg/ml ISLWKGFSFI, 20pg/ml control peptide Der P1 or
media alone . Shaded bars represent production of IL-2 by hybridomas in a 24 hour co-culture
supernatant as determined by ELISA. Samples were set up in duplicate. Error bars represent the
standard deviation of the mean of the 2 samples. 8 of the 11 hybridomas demonstrated a response
by producing IL-2 when co-cultured with ISLWKGFSFI-pulsed CRC036 B cells. 7 of the 11
hybridomas produced IL-2 when co-cultured with ISLWKGFSFI-pulsed DR2 lum cells. 6 of the 11
responded to peptide expressed on either APC. 3 hybridomas, ha3p132.3, ha3p132.5 and
ha3p132.11 failed to demonstrate any response to either ISLWKGFSFI-pulsed APC. This may
reflect that these hybridomas were not DR15 restricted as earlier selection methods (represented
in Figure 3.4) could potentially have identified mouse class II responders by using murine
splenocytes from DR15/IA-E TG mice. When repeated, hybridoma ha3p132.3 subsequently
consistently demonstrated one of the strongest responses to ISLWKGFSFI.
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3.2.8 T cell hybridoma recognition of peptide is restricted to presentation by
DR15
As the transgenic mice used to make initial T cell hybridomas were HLA-DR157l-A/E+, it
was crucial to demonstrate that the hybridomas were not only peptide specific but that
recognition was restricted to presentation of peptide by DR15. A number of human EBV-
transformed B cells expressing either DR15 or DR7 were pulsed with either control
peptide DerP1 or ISLWKGFSFI and their ability to stimulate the T cell hybridomas








WISL 7.5pM j Der-P1 7.5pM WISL 7.5pM J Der-P1 7.5pM
CRC013 (DR15) CRC021(DR7)
Figure 3.6 Only APC expressing DR15 are capable of stimulating ISLWKGFSFI-specific
hybridomas The ISLWKGFSFI-specific hybridoma, ha3p132.3 was co-cultured with DR15 or DR7
expressing human EBV transformed B cell lines CRC103 and CRC021 respectively. B cells were
pulsed with either ISLWKGFSFI (denoted here as WISL) or control peptide, DerP1 at a
concentration of 20pg/ml (equivalent to 7.5pM). Stimulation of hybridoma was expressed as before
as the production of IL-2 in a 24 hour co-culture supernatant. This graph is representative of 3
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experiments where DR7 expressing APC pulsed with ISLWKGFSFI failed to stimulate ha3p132.3.
ISLWKGFSFI-pulsed DR15 expressing B cells however strongly stimulated ha3p132.3. No
response was seen in cells pulsed with control peptide, DerP1.








Table 3.1 Summary of characterisation of T cell hybridomas. 11 hybridomas were
generated from T cell lines in mice pulsed with ISLWKGFSFI and 4 hybridomas from mice
pulsed with P8 (AS345). Of the 11 hybridomas generated from mice pulsed with ISLWKGFSFI,
9 recognised ISLWKGFSFI presented by DR15+/I-A/E+ murine splenocytes but only 7 of these
recognised peptide expressed on human DR15-expressing EBV transformed B cells and were
therefore DR15 restricted. Only 1 of the 4 hybridomas generated from AS345 primed mice
recognised AS345 presented by DR15/I-A/E+murine splenocytes. However when tested against
DR15-expressing human B cells, this hybridoma did not recognise peptide and was assumed to
be restricted to mouse class II and not DR15.
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3.2.10 Similarity of fine specificity to patients' T cells
Hybridomas generated against the ISLWKGFSFI peptide were demonstrated to respond
to ISLWKGFSFI (dap131-150). I selected one hybridoma (ha3p132.3) to compare with
patients' T cells. It was demonstrated to have very similar fine specificity indistinguishable
(with 15mer peptides overlapping by 10) from patients' T cells (Figures 3.7). The common
sequence of the stimulatory peptides contains only 1 register with high capacity to bind
DR15 (Phelps, 1999) Therefore, this hybridoma (and probably the remaining hybridomas)
as well as patients' T cells, almost certainly recognise the peptide a3(IV)NC1139.148 with
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Figure 3.7 Responses of the T cell hybridoma (ha3p132.3) (panel A) and a patient's (panels
B and C) peripheral blood T cells to 5 overlapping peptides presented by DR15-
homozygous EBV transformed B cell lines. Ha3p132.3 and a major population of autoreactive
T cells in this representative patient most likely respond to ISLWKGFSF with side chains orientated
into pockets in the DR15 peptide-binding groove as shown in Table 3.2
















Table 3.2 Sequence of peptides
3.3 Discussion
In this chapter I successfully generated 7 DR15 restricted hybridomas specific for the
a3(IV)NC1-derived disease associated peptide, dap132-154 (ISLWKGFSFI). The
hybridomas were peptide specific and sensitive, maintaining their ability to recognise
peptide antigen on fixed APC (although sensitivity was less than in non-fixed APC). This
allowed the accurate detection of small amounts of DR15/ISLWKGFSFI complexes on
APC surface and in addition can respond to much smaller numbers of peptide pulsed
APC. Hybridomas responded in a consistent manner although it became clear at an early
stage that 2 of the 8 hybridomas, ha3p132.3 and ha3p132.15, responded consistently
well in terms of IL-2 production. They were also easily maintained and for this reason
were selected for use in most future experiments.
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The major advantage of generating this highly specific detector for one peptide, was the
potential to examine the influences of factors thought to be of importance in the
a3(IV)NC1 processing pathway, and in particular to focus on the generation or
destruction of one particular peptide. This specificity was in some ways limiting as I was
restricted to examining only one of many potential peptides. The difficulties I encountered
in generating T cell hybridomas specific for AS345 were a disappointment and efforts had
to be abandoned eventually due to time constraints. The first 4 hybridomas successfully
derived from AS345 immunised mice were specific for peptide but the mice used at this
early stage co-expressed mouse class II as well as DR15. These AS345-specific
hybridomas were not restricted to presentation on DR15 and could not be used.
A further 3 attempts to generate AS345-specific hybridomas were unsuccessful despite
the use mice that were now mouse class II KO. The first attempt related to the loss of the
T cell line after a 4th round of re-stimulation. An alternative approach was taken as
described in chapter 2 where the cell lines were fused after only 1 round of re-stimulation.
This carried the risk of generating a large number of T cell hybridomas, none of which
may be peptide-responsive as the AS345-specific T cell lines had not been selected out
prior to fusion. This unfortunately proved to be the case. In a final attempt, mice were
primed with the intention of retrieving lymph nodes as well as spleen. Lymph nodes offer
a greater yield of T lymphocytes if the mouse has responded. Only mice demonstrated to
have responded to AS345 in an in vitro recall response, were utilised. These lines
underwent 2 rounds of re-stimulation before fusion. Once again the hybridomas
generated were not specific for AS345. Although the problems encountered in generating
these AS345-specific T cell hybridomas were likely related to method initially, later
problems related to difficulties achieving an adequate and sustained response to peptide.
This may have been due to alterations in the conformation of peptide, AS345 and are
discussed further in Chapter 8.
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3.4 Appendix
De novo and salvage pathways
De novo pathway Salvage Pathways
Phosphoribosyl pyrophosphate Thymidine Hypoxanthine
Figure 3.8 The de novo and salvage pathways. The generation of hybridomas was a technique
developed originally for the production of monoclonal antibodies by immortalising B cells that
produce a specific antibody. It is based on the fact that each B cell produces antibody of single
specificity and T cells express a TCR of single specificity. Therefore each monoclonal tumour from
a T cell, known as a thymoma, expresses only one TCR. Unfortunately, most thymomas express
TCR of unknown specificity as the transformation process giving rise to the tumours affects T cells
and B cells randomly. As normal T lymphocytes are unable to grow indefinitely, the alternative
approach has been to immortalise T cells. The first and still generally used technique was
described by Kohler and Milstein in 1975. The method involved fusion or somatic cell hybridisation
between a normal T cell and a T cell myeloma line, and selection of fused cells that express TCR
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of the desired specificity derived from the normal T cell line. These fusion-derived immortalised
TCR expressing cell lines are known as hybridomas. The technique depends on the development
of cultured myeloma lines that would grow in normal culture medium but would be unable to grow
in defined "selection" medium as they lack functional gene(s) required for DNA synthesis in this
selection medium. Fusion of the normal T cell lines to the defective myeloma fusion partners would
provide the necessary gene(s) from the normal cells so that only somatic hybrids would survive in
selection media. In addition, genes from the myeloma fusion partner would make such hybrids
immortal. Cell lines used as fusion partners can be created by inducing defects in the nucleotide
synthesis pathway. Normal cells synthesise purine nucleotides and thymidylate de novo from
phosphoribosyl pyrophosphate and uridylate respectively in a number of steps one of which
involves the transfer of a methyl or formyl group from activated tetrahydrofolate. Anti-folate drugs
such as aminopterin block the reactivation of tetrahydrofolate inhibiting the synthesis of purine and
thymidylate. As they are necessary components of DNA, aminpoterin blocks DNA synthesis via the
de novo pathway. Aminopterin-treated cells can use the salvage pathway where purine is
synthesised from exogenously supplied hypoxanthine using the enzyme hypoxanthine-guanine
phosphoribosyltransferase (HGPRT) and thymidylate synthesised from thymidine using the
enzyme thymidine kinase (TK). Cells can grow normally in the presence of aminopterin if the
culture medium is also supplemented with hypoxanthine and thymidine (HAT medium). Cell lines
can be made defective in HGPRT and TK by mutagenesis. Such cells cannot use the salvage
pathway and therefore die in HAT medium. If normal cells are fused with HGPRT negative or TK
negative cells, the normal cells provide the necessary enzyme(s) so that hybrids synthesize DNA
and grow in HAT medium. The fused cells are diluted out such that each culture well is expected to
contain only one hybridoma cell.
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Figure 3.9 Generation of T cell hybridomas. Advances in the technique described in Figure 3.10
have used thymoma T cell lines that do not express their own TCR. I elected to use the mouse AKR
thymoma, BW5147 (kind gift from Professor J. Robinson, Newcastle & Dr S Anderton, Edinburgh).
BW5147 has rearranged both of its TCR beta-chain loci, using the same J beta region in each but
with different V beta segments. The 2 rearrangements are expressed equally in cytoplasmic RNA
but the principle of allelic exclusion ensures that only one rearrangement is in frame and therefore
capable of encoding a functional protein. In hybridomas made with BW5147, this protein may
combine with the alpha-chain protein derived from the normal cell to form new Ag/MHC specificities.
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Chapter 4
Response of ISLWKGFSFI-specific hybridomas to APC
pulsed with intact a3(IV)NC1
4.1 Introduction
A number of DR15 restricted hybridomas were successfully generated to recognise
ISLWKGFSFI presented on different DR15 expressing EBV transformed B cells as
described in Chapter 3. There are many reports of T cells expanded to peptide that do not
respond to intact antigen. To examine the influence of processing on the generation of
peptides from intact a3(IV)NC1, it was crucial to demonstrate that these hybridomas were
also capable of recognising DR15/ISLWKGFSFI expressed on APC pulsed with intact
a3(IV)NC1.
The objectives in this chapter were threefold.
1. To ascertain that the hybridomas generated to recognise ISLWKGFSFI peptide
were capable of recognising peptide bound to DR15 on the surface of APC pulsed
with intact a3(IV)NC1.
2. To determine if DR15/ISLWKGFSFI could be generated from a3(IV)NC1 pulsed
into different murine and human DR15 expressing APC
3. To examine the time course of uptake and presentation of a3(IV)NC1 in different
human APC.
The first and second objectives were addressed by pulsing intact recombinant a3(IV)NC1
into DR15 expressing APC and co-culturing with the ISLWKGFSFI-specific T cell
hybridoma ha3p132.3. In later experiments in this chapter, a3(IV)NC1 -pulsed APC were
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fixed prior to co-culture with hybridoma. Determination of the optimum time from pulsing
with intact a3(IV)NC1 to surface presentation of peptide/DR15 complexes on APC was
therefore vital. The third objective addressed this issue. Ultimately, this would allow me to
examine the processing influences of factors such as proteases and in particular,
cathepsin D on the presentation of ISLWKGFSFI.
The model also provided an ideal opportunity to examine the differences in the
processing of a3(IV)NC1 in both human B cells and macrophages and putatively examine
whether alternative pathways were involved in processing of a3(IV)NC1.
4.2 Results
4.2.1 ISLWKGFSFI-specific T cell hybridomas respond to DR15 expressing
murine splenocytes pulsed with intact a3(IV)NC1
I had generated 7 T cell hybridomas capable of recognising ISLWKGFSFI-peptide and
that recognition was not only specific but restricted to presentation on DR15 expressing
APC alone. I was now ready to utilise the model to examine what response (if any)
ISLWKGFSFI-specific T cell hybridomas made when co-cultured with APC pulsed with
recombinant antigen. I elected to utilise mitomycin c treated splenocytes from DR15
transgenic mice as APC for initial antigen pulsing experiments. Methods are described in
Chapter 2 and results demonstrated in Figure 4.1 below.
4.2.2 ISLWKGFSFI-specific T cell hybridomas respond to EBV transformed
B cells pulsed with intact a3(IV)NC1
Consistent T cell hybridoma response to the antigen pulsed EBV transformed B cell could
be obtained using the protocol described in Chapter 2. As with the murine splenocytes,
the human B cell line presented both ISLWKGFSFI and intact a3(IV)NC1 to hybridoma
ha3p132.3 (Figure 4.2). Presentation of intact a3(IV)NC1 but not ISLWKGFSFI peptide
was abrogated by fixation (Figure 4.3) and chloroquine (Figure 4.4), indicating that




















Figure 4.1 Representative graph of 1 of 2 experiments determining response of
ISLWKGFSFI-specific T cell hybridomas to DR15 splenocytes pulsed with intact a3(IV)NC1.
Murine splenocytes retrieved from DR15 transgenic mice were mitomycin c treated then pulsed
with either ISLWKGFSFI peptide (denoted in this graph as AS346) at 5 or 20 pg/ml (equates to
1.75 and 7.5pmol) or intact a3(IV)NC1 at 50, 100 or 200 pg/ml (equates to 1.5, 3 and 6pmol). In
control wells, neither peptide nor antigen was added. Hybridoma response to ISLWKGFSFI/DR15
expression on splenocyes was read as production of IL-2 in a 24 hour co-culture supernatant. (IL-2
was measured as before using ELISA. All sample wells were in duplicate. Shaded bars represent
the mean of 2 samples, error bars represent the SD. Statistical analysis of peptide or antigen
response compared to medium is expressed for each sample (unpaired t-test). Both hybridomas
ha3p132.3 and ha3p132.15 recognized peptide and intact antigen in a dose responsive manner.
Response to cells pulsed with intact a3(IV)NC1 was less than seen with ISLWKGFSFI peptide. 5
other ISLWKGFSFI-specific hybridomas were tested but only 1 of these (ha2p132.2) demonstrated
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Figure 4.2 DR15 expressing EBV transformed B cells pulsed with intact a3(IV)NC1 or
ISLWKGFSFI-peptide are capable of stimulating ISLWKGFSFI-specific T cell hybridomas.
The DR15,15 expressing EBV transformed B cell CRC013 was pulsed with either 20pg/ml
(7.5pM), ISLWKGFSFI peptide or 100, 200 or 300 pg/ml (3, 6 or 9 pM) recombinant a3(IV)NC1. In
this experiment, cells were not fixed at any stage prior to co-culture with the ISLWKGFSFI-specific
T cell hybridoma, ha3p132.3. As before, hybridoma recognition of DR15/ISLWKGFSFI is
expressed as production of IL-2 in a 24 hour co-culture supernatant. This is a representative graph
demonstrating ha3p132.3 response to DR15/ISLWKGFSFI in EBV transformed B cells pulsed with





Figure 4.3 Processing is required before the epitope recognised by ha3p132.3 is generated
by human B ceil processing of intact a3(IV)NC1. This graph is representative of one of many
experiments where the DR15 expressing EBV transformed B cell, CRC013 was lightly fixed (as
described in Chapter 2) before pulsing with either peptide or intact antigen. Cells were washed
prior to co-culture with the ISLWKGFSFI-specific T cell hybridoma, ha3p132.3. Fixation has no
effect on response to cells pulsed with peptide but abrogated response to intact a3(IV)NC1
indicating that processing is clearly required as no response was observed when the APC was
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Figure 4.4 Processing is required before the epitope recognised by ha3p132.3 is presented
by human B cell incubated with a3(IV)NC1. B cells were pulsed with 9pM intact a3(IV)NC1
(dark shaded bars) or pre-treated with 0.1 pM chloroquine for 15 minutes prior to pulsing with intact
a3(IV)NC1 (light shaded bars). B cells were incubated for 4 or 18 hours prior to light fixation and
assessing DR15/ISLWKGFSFI presentation by determining IL-2 concentration in 24 hours co-
culture supernatant with ISLWKGFSFI-specific T cell hybridoma, ha3p132.3. IL-2 production
determined using ELISA. In the presence of chloroquine, presentation of DR15/ISLWKGFSFI was
reduced at 4 hours and completely abrogated at 18 hours whilst untreated B cells continued to
present DR15/ISLWKGFSFI.
4.2.3 ISLWKGFSFI-specific T cell hybridomas respond to THP-1 cells pulsed
with intact a3(IV)NC1
To determine if ISLWKGFSFI could be generated from intact antigen when pulsed into
different human DR15 expressing APC. I selected the monocyte cell line, THP-1 as it
expresses DR1,15 and can be induced to switch from a monocytic to macrophage
phenotype by treatment with PMA (Sakamoto, 1999). Class II expression is induced by












maintenance as a cell line, made the THP-1 cell line a suitable alternative human APC in
which to study processing of a3(IV)NC1.
Some time was taken optimising the method stimulating the maturation of THP-1 and is
described Chapter 2. In brief, THP-1 were pre-treated with 10ng PMA and 100U IFNy for
24 hours prior to all experiments. Mature cells were adherent and therefore were
detached and washed prior to use. Class II expression following culture with IFNy was
assessed as described using a FITC-labelled anti-HLA DR,DP,DQ monoclonal antibody
and FACS. Viability was checked as with all other cell lines prior to experiments.
As with the murine splenocytes and human B cells, THP-1 cells presented ISLWKGFSFI
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PMA 10ng/ml/IFNy 100U
Figure 4.5 ISLWKGFSFI-specific T cell hybridomas, ha3p132.3 and ha3p132.15 respond to
THP-1 cells pulsed with intact a3(IV)NC1 as well as ISLWKGFSFI peptide. THP-1 cells were
treated with PMA and IFNy as detailed before pulsing with 20 pg/ml ISLWKGFSFI, 100 or 200
pg/ml a3(IV)NC1. In this experiment cells were not fixed at any stage before co-culture with
hybridomas ha3p132.3 or ha3p132.15. Both hybridomas responded to THP-1 cells pulsed with
intact antigen and this was dose responsive. Response was reduced when compared to roughly
equimolar concentrations of peptide (20 pg/ml peptide ~ 7.5pM and 200 pg/ml a3(IV)NC1 ~ 6 pM)
Although not demonstrated here, if cells were lightly fixed before adding intact antigen, no
response was observed with either hybridoma.
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4.2.4 Response to protein antigen a3(IV)NC1 is specific and not due to
contamination
As a3(IV)NC1 had been produced in the bacterial vector, pET14b, I was conscious to
ensure IL-2 responses could not be due to LPS contamination which is notoriously
difficult to exclude from recombinant protein made in E.Coli. To address this concern,
50pg/ml LPS was added to control wells with THP-1 cells co-cultured hybridoma alone.
No IL-2 production was observed (Figure 4.6). APC were also pre-treated with polymixin
B, an antibiotic with bactericidal action which binds to the lipid A portion of LPS interfering
with the permeability of the cytoplasmic membrane. It is also used for the removal of
endotoxins from solutions. Results confirmed that polymyxin had no effect on IL-2
production. (Figure 4.7)
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media alpha3 alpha3 alpha3 LPS
(1ug/ml) (10ug/ml) (100ug/ml) (50ug/ml)
Figure 4.6 The presence of LPS in a co-culture of hybridoma ha3p132.3 and EBV





P14 10ug/ml a3 3pM P14 10ug/ml ' a3 3pM
100ug/ml
LCL061 THP-1
Figure 4.7 Polymyxin has no effect on the response of hybridoma ha3p132.3 to either EBV
transformed B cells (LCL061) or THP-1 cells pulsed with intact antigen. In the presence of
polymyxin B recognition of both peptide and a3(IV)NC1 was not significantly affected indicating
responses were specific to peptide and not due to LPS contamination.
4.2.5 Time course of uptake and processing a3(IV)NC1 in different DR15
expressing human APC
Current understanding of the class II processing pathway stems from studies using
soluble proteins and recombinant antigens expressed in various bacterial species
employing various expression vectors. Antigen uptake includes a number of pathways
including different cell surface receptors, endocytosis and F-actin microfilament and
115
microtubule cytoskeleton motility motors. Internalization of antigen is then thought to
trigger a number of intracellular events which lead to the production of peptide fragments
which are available for binding to MHC class II. Traditionally it was believed that the
peptide loading occurred predominantly in the more acidic environment of the late
endosome or MHC-II molecule-loading compartment(s) (MHCII) with subsequent binding
to newly synthesized class II. Alternative pathways have been investigated where antigen
may be targeted to early endosomal compartments and peptide fragments bound to class
II MHC recycled from the cell surface through an li-independent recycling MHC-II
pathway (reviewed by Robinson, 2002). Recent work therefore is proving this sequence
of events to be more complex than previously thought. It appears yet unclear what
determines the route a particular antigen may take following uptake and indeed whether
the type of antigen presenting cell involved will also influence peptide production.
Having established that the ISLWKGFSFI-specific hybridomas responded to both EBV
transformed B cells and THP-1 cells pulsed with intact antigen as well as peptide, I hoped
to use this system to examine the time course of uptake and presentation of a3(IV)NC1 in
different human APC.
Figure 4.8 shows a schematic diagram of the method employed initially in examining
processing of intact a3(IV)NC1 with time in both human B cells and THP-1 cells.
Figure 4.9 is representative of three experiments using this method. Interval times
between pulsing with intact antigen or peptide and fixation of APC prior to co-culture
varied slightly between experiments. Presentation of DR15/ISLWKGFSFI on both B cells
and THP-1 cells pulsed with ISLWKGFSFI-containing peptide occurred at all timepoints
providing a positive control. Presentation of DR15/ISLWKGFSFI was not detected until 12
hours in both B cell and THP-1 cells when pulsed with intact a3(IV)NC1. Presentation
increased with time thereafter for up to 29 hours.
The presentation of DR15/ISLWKGFSFI was up to 8 fold greater in B cells and up to 10
fold greater in THP-1 cells when pulsed with molar equivalent of ISLWKGFSFI-containing
peptide compared to intact a3(IV)NC1. This suggested that natural levels of protease
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activity accounted for some degree of generation of ISLWKGFSFI peptide from
a3(IV)NC1, but the process must be very inefficient.
Cells pulsed with 20 pg/ml
ISLWKGFSFI
peptide or 300 pg/ml intact
antigen for 4,
6, 8, 12, 18, 20 or 24 hours
At the end of each timepoint,
THP-1 cells fixed then washed x 3 in R10
before adding ISLWKGFSFI-specific
hybridoma, ha3p132.3 (0.5 x 105)
L Cells co-cultured for 24 hoursat 37°C 5% C02 and 24 hour supernatant analyzed
for IL-2 using ELISA
Figure 4.8 Schematic diagram demonstrating method used in the first 3 experiments

































Figure 4.9 Presentation of DR15/ISLWKGFSFI by human EBV transformed B cells (A) and
THP-1 cells (B) pulsed with intact antigen or ISLWKGFSFI peptide for intervals of 4-24
terminated by light fixation. In both graphs APC were pulsed with either 20pg/ml ISLWKGFSFI
peptide (denoted here as AS346) or 300pg/ml intact a3(IV)NC1. (Cells were pulsed with roughly
equimolar concentrations of peptide (7.5pM in 20pg/ml of ISLWKGFSFI-containing peptide and
9pM in 300pg/ml of intact a3(IV)NC1)). Cells were fixed at 4, 6, 8, 12, 18, 20 and 24 hours before
washing and co-culture with hybridoma ha3p132.3 as described in Figure 4.8 (Error bars represent
the SD from the mean of 2 ELISA plate test wells detecting IL-2 levels from the same 24 hour
supernatant sample). The presentation of DR15/ISLWKGFSFI on both B cells and TFIP-1 cells
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was determined by level of IL-2 in the 24 hour co-culture supernatant. Expression of HLA DR in
both B cells and IFNy/PMA-treated THP-1 cells was similar as determined by median fluorescence
of FITC-conjugated mouse anti-human HLA DP DQ DR mAb compared with isotype control.
4.2.6 In human APC, ISLWKGFSFI peptide is presented by 4 hours of
pulsing of intact antigen and presentation increases with time.
The results exhibited variability that possibly related to variation in viability and state of
activation of THP-1 cells as well as B cells and hybridomas, despite my considerable
efforts. To address this concern I undertook a further set of experiments. The new
method is outlined in Figure 4.10 and changes detailed in the legend below.
The most important change ensured that THP-1 cells were stimulated then eventually
aliquoted and pulsed with antigen or peptide at the same time. Both B cells and THP-1
cells were co-cultured with hybridoma ha3p132.3 simultaneously and the experiment
terminated at the same time. Results were considerably more consistent and are
summarised in Figure 4.11.
In contrast to observations in the first set of experiments, presentation of ISLWKGFSFI
peptide was observed as early as 4 hours and in some cases, 2 hours in THP-1 cells
pulsed with intact a3(IV)NC1. This was the first time expression of peptide had been
detected as early as 2 hours and given that is was observed in more than one
experiment, it would seem a true observation. Presentation of DR15/ISLWKGFSFI was
detected at 2 hours in 1 of the 3 experiments in a3(IV)NC1 pulsed EBV transformed B
cells.
Presentation of DR15/ISLWKGFSFI increased with time in both B cells and THP-1 cells
pulsed with either ISLWKGFSFI peptide or a3(IV)NC1. This would seem logical in the
case of intact antigen where protein takes time to unfold and digest before peptide is
available to bind to class II. In the case of peptide, observations are a little more difficult to
explain as it is well known that peptide can bind directly to class II on the surface of APC
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(Lindner, 1996, Aoi, 1997, Harris, 1996) and it would follow that peptide binding should
reach an equilibrium of on/off binding and presentation should no longer increase. One
possible explanation is the increased synthesis of class II within the cell with time
affording an increase in available class II molecules for binding to peptide. In the case of
APC pulsed with intact a3(IV)NC1, results clearly demonstrate, as in the first 3
experiments, that both EBV transformed B cells and THP-1 cells are capable of
processing and presenting ISLWKGFSFI peptide even in the presence of natural levels of
aspartate proteases. Although not shown here, processing was required in these
circumstances as APC fixed prior to pulsing with intact antigen were unable to present
DR15/ISLWKGFSFI (see figure 4.3).
A difference was demonstrated in the presentation of DR15/ISLWKGFSFI between THP-
1 cells and EBV transformed B cells where presentation of DR15/ISLWKGFSFI was
optimal at 12 hours in the case of THP-1 cells and 18 hours with EBV transformed B cell.
With respect to intact a3(IV)NC1, this may reflect differences in methods of antigen
uptake rather than processing. However a similar pattern was seen with peptide which is
capable of binding to the surface of APC.
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18 &24 hours
LAt the end of each timepointrelevant plates were fixed then washed
washed in R10 x2 and left at4°C
Figure 4.10 Schematic diagram demonstrating method used in experiments discussed in
Section 4.3.2 examining time points in processing of intact a3(IV)NC1 in EBV transformed B
cells and THP-1 cells. The main changes to method are outlined in red. Minor changes are as
follows; The concentration of ISLWKGFSFI peptide used was 10pg/ml (3.75pM) with 100gg/ml
(3pM) a3(IV)NC1 ensuring equimolar concentrations of peptide and peptide containing antigen were
pulsed into APC. A different B cell line, LCL061 (DR7.15 expressing) was used in these
experiments. A different preparation of recombinant ISLWKGFSFI peptide was used in these
experiments. Due to a lower protein yield (5mg/ml rather than 16mg/ml) a higher volume of 6M
urea/50mM Tris was required to dissolve a3(IV)NC1 (see chapter 2). This relative higher
concentration of urea may explain, when protein was tested prior to use, the observation that the
greatest response was seen with 100pg/ml rather than 300pg/ml. For this reason, 100pg/ml was
selected as the optimum concentration of a3(IV)NC1 to use. Of importance, this still contained a










6 8 10 12 14 16 18 20 22 24 26 28













6 8 10 12 14 16 18 20 22 24 26 28
incubation time prior to fixing (hours)
Figure 4.11 Presentation of DR15/ISLWKGFSFI in human EBV transformed B cells (A) and
THP-1 cells (B) pulsed with intact antigen or ISLWKGFSFI peptide. Each graph represents IL-
2 production at various time points in response to either ISLWKGFSFI-containing peptide (black)
or intact a3(IV)NC1 (red). The continuous line represents the mean of 3 separate experiments.
Bars represent the range in IL-2 levels in 24 hours supernatants at each time point. Expression of
122
HLA DR in both B cells and IFNy/PMA-treated THP-1 cells was similar as determined by median
fluorescence of FITC-conjugated mouse anti-human HLA DP DQ DR mAb compared with isotype
control.
4.3 Discussion
Experiments in the first section of this chapter confirmed that at least 2 of the 7
hybridomas generated against ISLWKGFSFI, were capable of responding to
DR15/ISLWKGFSFI on the surface of APC incubated with intact a3(IV)NC1 as
determined by production of IL-2. Both splenocytes from DR15 TG mice and human
DR15 expressing APC presented ISLWKGFSFI to hybridomas ha3p132.3 and
ha3p132.15. I confirmed that processing was required before ISLWKGFSFI was
presented, as APC that were lightly fixed prior to incubating with a3(IV)NC1, were unable
to stimulate ha3p132.3. Similarly, pre-treatment of human APC with chloroquine
abrogated ha3p132.3 response to a3(!V)NC1 pulsed DR15 expressing B cells. Response
was specific and not due to LPS contamination.
The second section examined the time taken from incubation with a3(IV)NC1 to
presentation of DR15/ISLWKGFSFI on the surface of APC. Although these experiments
could not differentiate time taken for antigen to be internalised from time required for
generation of ISLWKGFSFI and presentation with DR15 on APC surface, it generated
some interesting observations despite several initial difficulties in optimising the
experiment.
Most noticeable was the difference between B cells and stimulated THP-1 cells in the
time required before DR15/ISLWKGFSFI was presented where presentation of
DR15/ISLWKGFSFI was optimal at 12 hours in the case of THP-1 cells and 18 hours with
EBV transformed B cell. Although this may reflect differences in methods of antigen
uptake rather than processing, experiments later described in Chapter 6 suggest that
variation in processing and, in particular, the level of protease activity within the APC may
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account for differences. This is discussed further in Chapter 8. Presentation of
DR15/ISLWKGFSFI increased with time in both B cells and THP-1 cells pulsed with
a3(IV)NC1. This would appear logical given that recombinant antigen is a tightly folded




Processing of a3(IV)NC1 by Cathepsin D/E
5.1 Introduction
Results from Chapter 4 confirmed that ISLWKGFSFI-specific T cell hybridomas
ha3p132.3 and ha3p132.15 responded to APC pulsed with intact antigen. This enabled
me to start examining the factors that might influence presentation of ISLWKGFSFI
peptide from the Goodpasture autoantigen.
The evidence that processing factors are both critical and influential in the presentation of
ISLWKGFSFI has been introduced in Chapter 1. Previous work suggested processing
factors diminish presentation of several sites of a3(IV)NC1 peptides including
ISLWKGFSFI, but evidently presentation nevertheless occurs. Biochemical analysis of
the a3(IV)NC1 peptides bound to HLA-DR15 on the surface of a3(IV)NC1-pulsed APC
found that the most abundantly presented a3(IV)NC1 peptides were not those with
highest affinity for HLA-DR15 (Phelps 1996, 1998). The results could be interpreted as
evidence that processing factors prevent some peptides (including some with higher
affinity for DR15) from gaining access to MHC class II molecules within APC. Similar
conclusions have been reached in experiments with other antigens (Sercarz, 2002).
Therefore I resolved to examine the effects of the processing milieu within APC on
ISLWKGFSFI presentation.
Prior to starting my PhD, the group had used a biochemical approach to examine the
processing of a3(IV)NC1 by isolated lysozomes and lysosomal enzymes. The results of
these experiments generated crucial information relating to the initial unlocking and
sequential processing of a3(IV)NC1, the proteolytic enzymes responsible for this and
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their influence on processing of disease associated peptides known to stimulate patients'
T cells in Goodpasture's disease.
Goodpasture autoantigen (a3(IV)NC1, ~31kD) incubated with B cell lysosomes was
cleaved within a few minutes to form ~9 and ~22kD fragments, then increasing quantities
of smaller peptides (Zou, 2007). The processing was completely abrogated by Pepstatin
A, a specific inhibitor of Cathepsin D/E, even though lysosomal extracts contain a rich
array of proteases. Purified Cathepsin D generated the same major a3(IV)NC1 fragments
as entire lysosomes, suggesting Cathepsin D cleavages are required to initiate
a3(IV)NC1 processing. The initial unlocking cleavages destroyed 2 major self-epitopes,
including ISLWKGFSFI, and subsequent preferred cleavages destroyed all the other T
cell epitopes recognised by most patients' autoreactive T cells (Zou, 2007).
The objectives of this chapter were threefold.
1. To examine the effects of pre-digestion with cathepsin D on recombinant
a3(IV)NC1 by pulsing human DR15 expressing APC with digestion products and
comparing presentation of ISLWKGFSFI with APC pulsed with intact a3(IV)NC1,
using the ISLWKGFSFI specific T cell hybridoma, ha3p132.3.
2. To investigate whether aspartate proteases net reduced ISLWKGFSFI
presentation by intact B cells.
3. To determine if the balance is for or against the presentation of ISLWKGFSFI
peptide in human antigen presenting cells pulsed with intact a3(IV)NC1.
In this chapter I will demonstrate that pre-digestion of a3(IV)NC1 with cathepsin D leads
to a significant reduction in presentation of ISLWKGFSFI in B cells when compared to B
cell pulsed with intact a3(IV)NC1. Furthermore, in the presence of natural levels of
aspartate protease activity, ISLWKGFSFI-presentation by B cells was 2-3 fold greater for
B cells incubated with ISLWKGFSFI-containing peptide than molar equivalent quantities
of intact a3(IV)NC1. This supports the suggestion that aspartate protease activity in B
cells diminishes presentation of the ISLWKGFSFI epitope, as predicted from the earlier in
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vitro studies and suggests the balance is more against than for the presentation of
ISLWKGFSFI peptide in human antigen presenting cells pulsed with intact a3(IV)NC1
5.2 Results
To determine if cathepsin D influenced the generation of ISLWKGFSFI peptide from
intact a3(IV)NC1, I elected initially to adapt the in vitro approach utilised within our lab for
biochemical studies. This had the advantage of being an established technique with
already optimized methods that had demonstrated the efficient unlocking and subsequent
processing of a3(IV)NC1. I determined to pulse human DR15 expressing EBV
transformed B cells with these digestion products and compare the presentation of
DR15/ISLWKGFSFI with B cells pulsed with intact a3(IV)NC1 assessed by the production
of IL-2 by the ISLWKGFSFI-specific T cell hybridoma ha3p132.3.
The hybridoma ha3p132.3 was used in all subsequent experiments because it had the
properties of responding to intact a3(IV)NC1 and to overlapping a 3(IV)NC1 peptides with
fine specificity indistinguishable (with 15mer peptides overlapping by 10 from patients' T
cells (Chapter 3). It was also the healthiest of all the hybridomas. It remained clonal
throughout all experiments (determined by FACS as described in chapter 2 and 3) and
viability was consistently >95% unless the cell line was allowed to become over-
confluent. It responded to both the ISLWKGFSFI peptide and intact recombinant
a3(IV)NC1 in a consistent and replicable manner above all other hybridomas.
5.2.1 Does pre-digestion of a3(IV)NC1 with Cathepsin D prevent
presentation of ISLWKGFSFI peptide?
Figure 5.1 outlines the method employed in these experiments and Figure 5.2 is an
example of an SDS page gel comparing intact recombinant a3(IV)NC1 with cathepsin D
digested products. Preliminary experiments suggested that pre-digestion of recombinant
a3(IV)NC1 with cathepsin D (irrespective of time allowed for digestion) resulted in a
reduction in presentation of DR15/ISLWKGFSFI on B cells which had been pulsed with
cathepsin D-digested a3(IV)NC1 compared with B cells pulsed with intact a3(IV)NC1
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(Figure 5.3). Presentation was however not completely abrogated. Although less
profound, a reduction in IL-2 was also seen in the control sample where a3(IV)NC1 had
been incubated with DTT in the absence of cathepsin D.
Figure 5.4 summarises 3 separate experiments including the first experiment illustrated in
Figure 5.3. Method between these experiments varied only slightly in that later
experiments included results from B cells pulsed with cathepsin D pre-treated a3(IV)NC1
which had been digested for as little as 5 minutes only. Results were consistent at all time
points in all three experiments and demonstrated a significant reduction in the
presentation of DR15/ISLWKGFSFI in B cells pulsed with Cathepsin D digested
a3(IV)NC1 compared with untreated a3(IV)NC1. The differences were unlikely to be due
to chance (two way ANOVA p=0.01)
In the presence of DTT but no citrate buffer or cathepsin D, production of IL-2 by
ha3p132.3 was reduced by approximately 30-50% (not shown here). Thus it appears that
DTT does exert some influence on the digestion of a3(IV)NC1 and production of peptide,
ISLWKGFSFI. This was irrespective of concentration of DTT used. In these processing
experiments, DTT was added as a reducing agent to assist Cathepsin D digestion. Work
in other groups examining processing of different protein antigen, such has insulin, have
demonstrated that reduction of disulphide bonds alone may be sufficient to allow
presentation of antigen derived peptides to class II restricted T cells (Jensen, 1991 &
1993, Collins, 1991). It was in theory possible that DTT itself could be influencing the
digestion and processing of a3(IV)NC1 and potential generation of ISLWKGFSFI peptide,
however, the reduction in IL-2 production was considerably less than seen in cathepsin D
+ DTT treated a3(IV)NC1 pulsed B cells (70-80% reduction) suggesting that Cathepsin D
was still largely responsible for the reduced presentation of ISLWKGFSFI.
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Figure 5.1 Schematic diagram demonstrating method used in experiments examining the
influence of cathepsin D digestion of intact a3(IV)NC1 on expression of ISLWKGFSFI
presentation in EBV transformed B cells. Purified cathepsin D was reconstituted (in phosphate
buffer-reconstituted in water i.e. 25ug lyophilized from 27.3pl NaP042 pH 6.5 reconstituted in H20).
The digestion was carried out in acidic and reducing conditions. Recombinant a3(IV)NC1 was
dissolved in 6M urea & incubated with purified human liver Cathepsin D (Athens Research &
Technology) in the presence of DTT and citrate buffer at 37°C for 30, 60 and 120 minutes. The
activity of Cathepsin D and thus digestion was then stopped by raising the pH by removing 2pl
from the end volume and adding 2pl 0.5M TrisCI (pH 6.8). EBV transformed B cells were spun,
counted and aliquoted at 1x105 cells per well and left on ice before adding digested and un¬
digested samples directly to the wells. Pulsed B cells were incubated for 3 hours before co-
cultured with ha3p132.3. 24 hour co-culture supernatant analysed for the concentration of IL-2.
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Marker a3 a3 a3 a3 a3 a3 a3 a3 a3
Cath D . + .+ + - +
Time m 15 15 30 30 60 60 90 90
Figure 5.2 Time course of processing of a3(!V)NC1 with purified human cathespin D SDS
PAGE analysis of purified recombinant a3(IV)NC1 (denoted as a3) with (+) or without (-) prior
digestion with cathepsin D for different time intervals (15, 30, 60 & 90 minutes). Several darker




























































Figure 5.3 Pre-digestion of a3(IV)NC1 with cathepsin D and resultant influence on presentation
of DR15/ISLWKGFSFI after pulsing EBV transformed B cells with digestion products. CTRL:
control Cath D: cathepsin D CB: citrate buffer T: time (minutes) alpha3: a3(IV)NC1. Cathepsin D
digestion was carried out as detailed in Figure 5.1. Whole recombinant antigen or digestion products
were added to B cells as detailed. Resultant DR15/ISLWKGFSFI presentation was assessed by IL-2
levels in a 24 hour co-culture supernatant with DR15/ISLWKGFSFI-specific hybridoma, ha3p132.3.
This figure shows IL-2 levels in co-cultures from B cells pulsed with digestion products at 30, 60 and
120 minutes (T30, T60 T90). Results demonstrate a reduction of IL-2 levels in all samples pulsed with
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Figure 5.4 Summary of 3 experiments. Each dot represents presentation of DR15/ISLWKGFSFI
on the surface of DR15 expressing EBV transformed B cells as quantified by the level of IL-2
produced by DR15/ISLWKGFSFI-specific T cell hybridomas that had been co-cultured with pulsed
B cells. The first series of dots represents every result at different timepoints in all 3 experiments
in B cells that were pulsed with ct3(IV)NC1 and had been pre-digested with Cathepsin D. The
second series represents every result from B cells pulsed with untreated or intact a3(IV)NC. The
bar in each column represents the mean level of IL-2 in all experiments. Reduction in
DR15/ISLWKGFSFI expression in APC pulsed with a3(IV)NC1 digested with Cathepsin D was
consistent at all timepoints in 3 separate experiments and the difference was unlikely to be due to
chance ( 2 way ANOVA p= 0.01).
Experiments illustrated in Figure 5.4 provided supportive evidence that Cathepsin D
influenced the processing of a3(IV)NC1 and subsequent expression of ISLWKGFSFI
peptide on DR15. Conditions in these experiments were clearly non-physiologic however
and were established initially to ascertain what influence (if any) Cathepsin D had on the
processing of ISLWKGFSFI peptide from a3(IV)NC1. In the final section of this chapter I
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wanted to ask whether aspartate protease activity within living B cells and THP-1 cells
reduced presentation of ISLWKGFSFI as suggested by the initial studies.
5.2.2 Do natural levels of aspartate protease activity in EBV transformed B
cells and THP-1 cells influence the presentation of DR15/ISLWKGFSFI?
In Chapter 4, presentation of the ISLWKGFSFI epitope by EBV transformed B cells
incubated with intact a3(IV)NC1 was processing-dependent (inhibited by fixing the APC
or pre-treating with chloroquine) and of low efficiency compared to B cells incubated with
molar equivalent quantities of a3(IV)NC1 peptide. Although many factors may have
contributed to the differences in presentation, including efficiency of antigen uptake and of
processing, the observation that ISLWKGFSFI epitope was generated within APC from
intact a3(IV)NC1 would allow me to test whether aspartate proteases net reduced
ISLWKGFSFI presentation by intact B cells.
Figure 5.5 illustrates results from 3 separate experiments where human DR15 expressing
APC (EBV transformed B cells and THP-1 cells) were pulsed with either intact a3(IV)NC1
or equimolar concentration of ISLWKGFSFI-peptide. Thereafter cells were lightly fixed
and presentation of ISLWKGFSFI on the surface of APC determined by co-culture with
ha3p132.2 as previously described. In the presence of natural levels of aspartate
protease activity, ISLWKGFSFI presentation was 2-8 fold greater in EBV transformed B
cells and 0.8-10 fold greater in THP-1 cells when incubated with ISLWKGFSFI-containing
peptide compared to molar quantities of intact a3(IV)NC1.This would support the
hypothesis that aspartate protease activity in B cells diminishes presentation of the
ISLWKGFSFI epitope, as predicted from both in vitro studies and initial Cathepsin D




































WISL WISL a3 WISL a3
Figure 5.5 Presentation of DR15/ISLWKGFSFI on EBV transformed B cells (A) and THP-1
cells (B) pulsed with either ISLWKGFSFI peptide (light bars) or intact a3(IV)NC1 (dark bars).
Each graph demonstrates 3 separate experiments. EBV transformed B cells and THP-1 cells were
pulsed with equimolar concentrations of ISLWKGFSFI peptide (3.75pM) and a3(IV)NC1 (3pM) for
12 hours before fixing and washing cells then co-culturing with DR15/ISLWKGFSFI specific
hybridoma, ha3p132.3. Production of IL-2 is representative of presentation of DR15/ISLWKGFSFI
on the surface of APC after pulsing with either peptide or intact a3(IV)NC1.
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5.3 Discussion
Results presented in Chapter 4 demonstrated that DR15 expressing B cells incubated
with intact a3(IV)NC1 were able to present the ISLWKGFSFI epitope despite its
containing 2 peptide bonds known to be cut in early processing by B cell lysosomes in
vitro (Zou, 2007). B cells incubated with abundant (300pg/ml) a3(IV)NC1 were able to
present ISLWKGFSFI, as assessed by IL-2 production by ha3p132.3, and presentation
was processing-dependent because it was inhibited by fixation and chloroquine (Figures
4.3 & 4.4, Chapter 4) Therefore processing of a3(IV)NC1 within intact B cells does
generate some ISLWKGFSFI which is presented on DR15 in the conformation
recognised by ha3p132.3.
In vitro work by Zou et al had suggested that lysosomes and more specifically, aspartate
proteases, cathepsin D/E, were the proteolytic enzymes responsible for the unlocking of
a3(IV)NC1 and subsequent destruction of all disease associated peptides including
ISLWKGFSFI.
The initial experiments in this chapter were set up to re-examine whether the observation
that cathepsin D/E destroyed the T cell epitope, ISLWKGFSFI in vitro had similar
consequences in living EBV transformed B cells.
I initially elected to pre-digest recombinant a3(IV)NC1 with Cathepsin D prior to adding to
B cells. This approach had some limitations in that the concentration of cathepsin D and
subsequent digestion of a3(IV)NC1 was uncertainly physiological. Nonetheless these
preliminary experiments were instigated to observe if there was any discernable influence
on a3(IV)NC1 processing due to cathepsin D prior to more detailed and physiological
work. The concomitant pulsing of equimolar concentrations of a3(IV)NC1 that had not
been pre-treated with cathepsin D served as a control for any in vivo processing
influences on the presentation of ISLWKGFSFI. Preliminary results demonstrated a
reduction in presentation of ISLWKGFSFI in B cells pulsed with a3(IV)NC1 pre-digested
with cathepsin D. Results from 3 experiments confirmed this finding to be reproducible
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and statistically significant. Controls confirmed that these effects were largely due to
cathepsin D alone.
These initial results utilising an entirely different system, clearly supported the
biochemical data demonstrating that pre-digestion of a3(IV)NC1 with Cathepsin D
abrogated presentation of DR15/ISLWKGFSFI.
The influence of cathepsin D was consistent in a more physiologic setting, where in the
presence of natural levels of aspartate protease activity, ISLWKGFSFI-presentation by
living EBV transformed B cells, was 2-3 fold greater for B cells incubated with
ISLWKGFSFI-containing peptide than molar equivalent quantities of intact a3(IV)NC1.
This supports the suggestion that aspartate protease activity in B cells diminishes
presentation of the ISLWKGFSFI epitope, as predicted from the earlier biochemical
studies.
Experiments described in chapter 4 had flagged up the quandary that in vitro
observations suggested that cathepsin D was required to unlock and process intact
a3(IV)NC1, at the same time destroying self epitopes (including ISLWKGFSFI peptide).
This raised the question, how was it possible that ISLWKGFSFI peptide was presented in
a3(IV)NC1-pulsed DR15 expressing APC at all? Is the balance for or against the
presentation of ISLWKGFSFI peptide in human antigen presenting cells pulsed with intact
a3(IV)NC1?
The final section of this chapter focused on experiments examining the influence of
natural levels of aspartate protease activity on presentation of DR15/ISLWKGFSFI.
Results demonstrated that although rapid destruction by endosomal aspartate proteases
can account for a reduction in ISLWKGFSFI presentation in B cells pulsed with intact
a3(IV)NC1 compared with equimolar concentrations of ISLWKGFSFI, sufficient
ISLWKGFSFI to stimulate T cells can be presented by DR15-expressing B cells under
particular conditions, such as culture in high concentrations of a3(IV)NC1. Cells were
pulsed with up to 300pg/ml a3(IV)NC1 which is likely to reflect a much greater abundance
of a3(IV)NC1 than is naturally available for uptake and processing suggesting that
cathepsin D may be 'saturated' (if observations are not an effect of conformation). This
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may help explain how many of the stimuli reported to trigger Goodpasture's disease
would be expected to increase turnover of basement membrane a3(IV)NC1 (Phelps,
2000) thus flooding the system.
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Chapter 6
Inhibition of aspartate protease activity on processing of
a3(IV)NC1 in human antigen presenting cells
6.1 Introduction
Results from biochemical studies discussed in the introduction (Zou, 2007) and my own
observations in chapter 4, suggested that the aspartate protease, Cathepsin D could play
a key role in the unlocking of a3(IV)NC1 allowing further processing. Biochemical results
had also demonstrated that Cathepsin D (or an aspartate protease with identical
specificities) was crucial in the further processing and subsequent destruction of the
major epitopes recognised by patients' T cells with active Goodpasture's disease.
Chapter 5 showed reduced presentation for a3 peptides and confirmed that cathepsin D
could be a factor in diminished presentation because pre-incubation lead to reduced
presentation, albeit under non-physiologic conditions. In order to test the hypothesis that
the cathepsin D levels naturally occurring within human APC might influence presentation
of ISLWKGFSFI, I elected to compare presentation by APC either pre-treated with an
inhibitor of aspartate protease activity or left untreated.
There are a number of possible approaches available which could be applied to the
inhibition of cathepsin D/E activity in vivo. These included the use of specific cathepsin
D/E inhibitors such as pepstatin, genetic manipulation using antisense-cathepsin D
cDNA, siRNA, or the use of APC generated from cathepsin D-null mice.
I elected initially to use a specific inhibitor of cathepsin D/E, Pepstatin A, for a number of
reasons. Firstly, it is a widely used specific inhibitor of aspartate proteases. It can be used
without substantial toxic effect in cell culture and was the most straightforward initial
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approach available to inhibit Cathepsin D activity. The alternative approaches detailed
above are discussed further in the chapter.
The first part of this chapter focuses on the influence of cathepsin D inhibition on
a3(IV)NC1 processing in different antigen presenting cells at varying time points because
my earlier work showed the time points selected for analysis of processing had a
substantial impact on results (see Chapter 4). The second section addresses describes
experiments to determine whether cathepsin D activity within APC is in fact inhibited by
pepstatin A.
6.2 Results
6.2.1 Does pre-treatment of THP-1 cells and B cells with an aspartate
protease inhibitor influence presentation of DR15/ISLWKGFSFI?
In order to investigate the influence of the natural levels of aspartate protease within the
processing machinery of human APC, I first examined presentation of
DR15/ISLWKGFSFI by a3(IV)NC1-pulsed TFIP-1 cells that had been either pre-treated
by pepstatin A or left untreated. The experimental design is shown in Figure 6.1.
The first experiment compared two ways of limiting the interval during which processing
could occur because the duration of action of pepstatin was likely to be less than required
for presentation to T cell hybridomas to yield detectable IL-2. The results (Figure 6.2)
showed a greater diminuation in IL-2 production when processing was curtailed by light
fixation than by washing, compared to APC allowed to continue internalising and
processing a3(IV)NC1 throughout the 24 hours incubation with the T cell hybridomas.
Nevertheless it was discernable that pre-treatment with Pepstatin A did increase
presentation and that the increase was greater with higher concentrations of pepstatin A.
An essentially similar experiment in which EBV transformed B cells were used in place of
TFIP-1 cells (not shown here) gave inconclusive results with very low levels of IL-2. This
was not unexpected as my previous work had shown that presentation of a3(IV)NC1 by
cells was lower level, peaking neaier 12 hours.
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Therefore I elected to undertake a set of experiments allowing varying intervals for
antigen processing before fixing/washing as well as varying concentrations of pepstatin A
pre-treatment. The experimental design is shown in Figure 6.3 and cumulative results of 3
experiments are shown in Figures 6.4 and 6.5
Demonstrated in figure 6.4, at all four time points, pepstatin A had a significant and
consistent effect on presentation of ISLWKGFSFI by a3 pulsed B cells where
presentation increased with both 1pM and 10pM pepstatin A. Presentation was not
altered by pepstatin A in B cells pulsed with ISLWKGFSFI peptide. Similar experiments
employing THP-1 cells as APC shows that an increase in presentation of ISLWKGFSFI
only occurred at certain timepoints (4 and 18 hours in presence of 10pM pepstatin A) but
presentation of ISLWKGFSFI was either reduced or otherwise unaltered by pepstatin A at
other timepoints in THP-1 cells pulsed with recombinant a3(VI)NC1 (Figure 6.5).
The results demonstrated that both THP-1 and B cells presented DR15/ISLWKGFSFI
processed from intact a3(VI)NC1, and that the level of presentation increased with longer
periods of processing (4-12 hours) suggesting that epitope generation was limiting.
Moreover cathepsin D/E activity was shown to be a factor in limiting DR15/ISLWKGFSFI
presentation as its inhibition consistently enhanced presentation at least in B cells. (Zou,
2007)
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Figure 6.1 Method used in first 3 experiments examining influence of pepstatin A on processing of
a3(IV)NC1 Each sample was set up in duplicate and the supernatant from both test wells mixed and
aliquoted in duplicate for analysis using ELISA. Cell viability in the THP-1 line was 75%. A control plate of
THP-1 cells fixed with FACS fix and washed prior to adding peptide and ha3p132.3 was included to ensure
any effects of Pepstatin were due to the specific inhibition of Cathepsin D and its effects on antigen
processing.
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Figure 6.2 THP-1 cells washed (A), fixed (B), neither washed nor fixed (C) after 5 hours
pulsing with ISLWKGFSFI or a3(IV)NC1 in the presence of Pepstatin A THP-1 cells were pre-
treated with PMA and IFNy as described in Figure 6.1. The were pre-treated with 0-100pM pepstatin
A (indicated on x axis ) for 30 minutes before pulsing with either 10pg/ml (3.75pM) ISLWKGFSFI
peptide (denoted as WISL and indicated as black diamonds) or 300mg/ml (9pM) a3(IV)NC1
(indicated as black squares). Cells were incubated for 5 hours before lightly fixing then washing (A),
washing (B) or leaving without fixing or washing (C). A number if issues arose from this first
experiment which were addressed in future experiments demonstrated in Figure 6.4
1. Cell viability In previous experiments, viability of THP-1 cells was -70-80%. A new cell line was
thawed and split regularly so cells were not allowed to become over-confluent. Cell viability was
>95% for THP-1 cells in all subsequent experiments. I also elected to use a different EBV
transformed B cell line, LCL061( DR15.7). Cell viability was >95%.
2. Antigen and peptide A different preparation of recombinant a3(IV)NC1 was used in the next set of
experiments. Prior to use, the antigen had been tested against ha3p132.3 (see experimental
methods in chapter 2). Testing antigen demonstrated that in this case 100pg/ml gave the best
response compared to 200 & 300pg/ml. One possible explanation was that the protein yield from this
preparation was smaller (approximately 6mg/ml rather than the previous 16mg/ml). As samples were
dissolved in 6M urea, higher concentrations of a3(IV)NC1 such as 300pg/ml used in assays
contained relatively higher concentrations of urea which could in turn have a toxic effects on cells). In
subsequent experiments, I ensured that approximately equimolar concentrations of peptide were
pulsed into cells (3.75pM ISLWKGFSFI and 3pM a3(IV)NC1).
3. Method Experimental details are highlighted in figure 6.3. There were a number of key
differences: At the end of each time point, APC were fixed and washed as previously described.
Before the third wash, the plate was left at 4°C until all time points had been completed. It was at this
stage that all plates underwent a third and final wash before adding Ha3p132.3.
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Figure 6.4 Pepstatin A enhances presentation of ISLWKGFSFI by B cells. DR15 expressing B cells were
pulsed with equimolar concentrations of ISLWKGFSFI or a3(IV)NC1 with or without pepstatin A (1 or 10pM).
Cells were incubated for 4 (A), 6 (B), 12 (C), and 18 (D) hours before fixing then incubating with ha3p132.3.
Influence of pepstatin was assessed by comparing IL-2 concentration in co-cultures with or without pepstatin
and expressed as % change in IL-2 concentration (y axis). Each graph represents 3 experiments (denoted as • ♦
a). At all 4 time points, pepstatin A had a significant effect on presentation of DR15/ISLWKGFSFI in B cells
pulsed with a3 but no demonstrable influence on B cells pulsed with peptide. Mean of 3 experiments (bar)
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Figure 6.5 Pepstatin A and presentation of ISLWKGFSFl by THP-1 cells. Change in presentation of
ISLWKGFSFI to T cell hybridomas effected by 2 concentrations of pepstatin A, expressed as % change in IL-2
concentration measured by ELISA. DR15 expressing THP-1 cells were pulsed with equimolar concentrations
of ISLWKGFSFI peptide or whole recombinant antigen, a3(IV)NC1. Cells were incubated for 4 (A), 6 (B),12
(C), and 18 (D) hours before fixing, washing and incubating with DR15/ISLWKGFSFI the specific hybridoma,
ha3p132.3. Each graph represents 3 separate experiments (denoted as . ♦ a). The mean of all 3 experiments is
represented by a bar. Pepstatin A had no clear or consistent effect on presentation of ISLWKGFSFI by THP-1
cells pulsed with either peptide or antigen.
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6.2.2 Levels of constitutive aspartate protease activity in B cells & THP-1
cells.
One explanation for the much more variable but generally weaker effect of pepstatin A on
THP-1 cells as compared to B cells was the potential presence of higher concentrations
of cathepsin D within THP-1 cells. To examine this possibility, I measured cathepsin D
activity in both THP-1 cells and B cells.
There are now numerous assays available to examine the activity of cathepsin D. The
principle in the majority of these kits relies on the use of a substrate which contains a
specific cathepsin D (and or E) cleavage site. Substrates are either labelled in some way
such as biotinylation or contain a fluorescent moiety and a quenching group. When
cleaved the fluorescence increases and can be detected at specific wavelengths due to a
reduction in quenching following the separation of the fluorescent and quenching
moieties. Pepstatin A is in fact commonly used in these assays as a control in
determining cathepsin D activity.
I chose the Calbiochem InnoZyme™ Fluorogenic Cathepsin D Immunocapture Activity
Assay Kit (see chapter 2). This is a selective fluorogenic assay for the quantitative in vitro
determination of cathepsin D activity.
In preliminary cathepsin D assays, I detected cathepsin D activity in the lysates of as few
as 0.5 x105 APC, (not shown here), measuring cathepsin D concentrations of up to
1,56ng/ml (minimal detectable concentration of assay of 0.2ng/ml).
The assay clearly showed much higher aspartate protease activity (in the order of ten-fold
increase) in THP-1 lysates compared to B cell lysates (Figure 6.6) but further
interpretation was frustrating. Preliminary work demonstrated a trend where cell lysates
from APC pre-treated with pepstatin A demonstrated less cathepsin D activity than those
untreated, as would be expected, but subsequent experiments showed no effect of
pepstatin A. I experienced considerable difficulties in establishing this assay. This was
initially due to a faulty assay where the controls failed to develop. Time constraints also
limited my ability to pursue this further. It was relevant however that the assay
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recommended the use of 1x106-1x107 cells when analysing lysates. The majority of my
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Figure 6.6 Cathepsin D/E activity in lysates of THP-1 and B cells. Graph representative of 4
experiments where 1x10s B cells (LCL061) or PMA/IFNy treated THP-1 cells were pulsed with
100pg/ml a3(IV)NC1 and incubated with 0, 1 5, 10 and 50pM pepstatin A. Assays were set up as
in processing experiments in 96 well plates and incubated at 37°C 5% C02 for 24 hours. Cells
were then collected and lysed as described in methods (Chapter 2). Protein concentration was
determined using a BCA assay as described before adding samples and standards to the 96 well
assay plate, adding substrate solution and assay buffer as described and measuring fluorescence
of the unquenched peptide on a fluorescent plate reader
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6.2.3 Probing Cathepsin D activity by substrate modification.
As an independent further test of the influence of aspartate protease activity on
ISLWKGFSFI presentation, I utilised analogues of ISLWKGFSFI with reduced
susceptibility to cathepsin D.
ISLWKGFSFI is most scissile to cathepsin D at the LW peptide bond. Since cathepsin D
has a strong preference for L over its isomer, I, at the P position around substrate peptide
bonds, I reasoned an analogue peptide with substitution of leucine for isoleucine
(ISLWKGFSF ISIWKGFSF) should allow much more resistant cleavage by cathepsin D
but very likely to retain recognition by the T cell hybridomas I had made (given time
constraints and availability of suitable IA/E/a3KO mice, it was not possible to generate T
cell hybridomas specific for this mutated peptide). Figure 6.7 demonstrates that only 1
(ha3p132.6) of 8 DR15/ISLWKGFSFI specific T cell hybridomas was also responsive to
the altered peptide.
This allowed me to observe the influence of pepstatin A on the presentation of modified
peptide, which in theory if resistant to cleavage by cathepsin D, should not be influenced
by Pepstatin A. Contrary to prediction, pepstatin A enhanced presentation of both peptide
(Figure 6.8) as well as intact antigen suggesting that the modified peptide presentation
was enhanced by protection from aspartate protease despite its expected greater
resistance to at least cathepsin D.
To investigate the effect of the mutation on Cathepsin D susceptibility directly, I next
incubated modified and unmodified peptide with Cathepsin D in vitro and determined the
extent of digestion by MALDI-tof mass spectrometry. The results showed that whilst
resistant at the IW peptide bond, as predicted, the altered peptide was still very scissile to
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Figure 6.7 Response (IL-2 production) of T cell hybridoma to WISL & WISI peptide analogues
A. Only one hybridoma out of 7, ha3p132.6, was capable of recognising modified peptide WISI. B.
Response to ISLWKGFSFI (denoted as AS346), modified antigen, WISI and intact a3(IV)NC1 using
the T cell hybridoma, ha3p132.3. Response to ISLWKGFSFI peptide and a3(IV)NC1 was clearly
demonstrated but no response was seen to modified antigen, WISI. C. Response to ISLWKGFSFI,
modified antigen, WISI and a3(IV)NC1 in the T cell hybridoma, ha3p132.6. Response to modified
peptide, WISI was observed although response to ISLWKGFSFI and whole antigen was weaker in
this particular experiment compared with ha3p132.3 (note relative concentration of IL-2 was around
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Figure 6. 8 Influence of pepstatin A on presentation of WISL (denoted as AS346), modified
peptide, WISI or intact a3(IV)NC1.
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6.2.4 Susceptibility of modified peptide, WISI, to cathepsin D cleavage
As presentation of both ISLWKGFSFI and, unexpectedly, modified peptide were
increased in the presence of pepstatin A, it was postulated that modified peptide was
susceptible to cleavage by Cathepsin D. To address this, both modified peptide,
ISIWKGFSFI and control peptide, ISLWKGFSFI were digested with cathepsin D as
previously described (Zou, 2007) and the digested products analysed and identified using
MALDI-tof mass spectrometry. (For method detail, see Chapter 2)
Table 6.1 represents the digestion products of non-modified peptide (ISLWKGFSFI) and
modified peptide (ISIWKGFSFI) after treatment with cathepsin D as determined using
MALDI-tof mass spectrometry.
The known molecular weight of ISLWKGFSFI is 2599.29. The strongest peak was
identified at 2599.1 pre-digestion. On exposure to Cathepsin D for 30 minutes, a number
of new peaks were identified; 771 and 969 were the strongest (see below). Letters in red
represent the sequence of the identified digestion. These results confirmed previous
work, where digestion with cathepsin D cleaved between WISL/WKG FSF/IMF.
The digestion products from cathepsin D-treated modified peptide, ISIWKGFSFI (where
leucine has been replaced by isoleucine) demonstrates the strongest peak at 1856 pre-
digestion. The known molecular weight of ISIWKGFSFI is 1855.93. On exposure to
Cathepsin D for 30 minutes, a number of new peaks were identified. 1464.2 and 1855.93
were the strongest (see below). Letters in red represent the sequence of the identified
digestion. Therefore the modified peptide, ISIWKGFSFI, was not significantly cleaved at
WISI/WKG, compared to the natural peptide which was cleaved at WISL/WKG to release
fragments. This would suggest that, as predicted, ISIWKGFSFI in this critical area was
less susceptible to cleavage by cathepsin D. However, the modified peptide was
extensively cleaved at other sites. This could explain the results observed with modified
peptide in processing experiments where both ISLWKGFSFI and modified peptide were






















B Cathepsin D treated ISIWKGFSFI digestion products
Table 6.1 Cathepsin D digestion products
6.3 Discussion
The results presented in Chapter 4 showed that presentation of ISLWKGFSFI from intact
antigen was inefficient compared with peptide, and confirmed previous biochemical data
that aspartate proteases within the APC cleaved within ISLWKGFSFI, as might account
for less efficient processing.
Initial work discussed in this chapter demonstrated that the level of protease activity
within human EBV transformed B cells was sufficient to substantially diminish
presentation of ISLWKGFSFI. Pre-digestion of a3(IV)NC1 with cathepsin D prior to
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pulsing into APC suggested that it may be the enzyme responsible but this needed to be
demonstrated. The next step in identifying cathepsin D/E as the critical enzymes would
be to observe the differences in presentation of peptide under conditions of reduced
activity or concentration of the enzyme. In theory, a reduction in enzyme availability within
APC would conversely lead to an increase in peptide expression.
The methods by which cathepsin D activity can be reduced or effectively abolished are
numerous. Some microbial protease inhibitors are known to inhibit the intracellular
proteases of living cells. They also have the advantage of being site specific and have a
small molecular weight so that they can easily penetrate the cell membrane (Puri, 1988)
Cathepsin D is a representative of the acid or carboxyl-dependent classes of
endopeptidases which also include pepsin, chymosin and renin. The enzymes can be
inhibited by a variety of reagents which covalently react with carboxyl groups, e.g.
(lundblad and stein, 1969, Takahashi, 1972, Tang, 1971). However few effective
reversible inhibitors are known. Initial study of cathepsin D relied heavily on the use of
inhibitory antisera. This had certain important disadvantages including the high molecular
weight of the antibody molecules and the complex chemical nature of the inhibition. A
naturally occurring tight binding inhibitor of carboxyl-proteinases, pepstatin, was first
described by Morishima in 1970. Pepstatin is obtained from filtrates of cultures of
streptomyces (Morishima, 1972). It is a potent but reversible inhibitor of aspartic
proteases. It forms a 1:1 complex with proteases such as Cathepsin D, pepsin, renin,
bovine chymotrypsin (Umezawa, 1976, Marciniszyn, 1977) and protease B (Takahashi,
1976). As an inhibitor it is highly selective.
Initial interest in the inhibiting effects of pepstatin on cathesin D was as a means of
determining the concentration of cathepsin D and thus its activity in a variety of biological
and pathological processes. The nature of the interaction between cathepsin D and
pepstatin A have therefore been intensively studied. Cathepsin D has a tight binding to
pepstatin. Gel-chromatographic experiments have shown that binding of pepstatin and its
derivatives is strongly pH dependant.
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Results from preliminary experiments gave inconclusive results with respect to the
influence of pepstatin A on presentation of DR15/ISLWKGFSFI in EBV transformed B
cells. Results with THP-1 cells were more encouraging where pre-treatment with
Pepstatin A did increase presentation DR15/ISLWKGFSFI and that the increase was
greater with higher concentrations of pepstatin A.
Both B cells and THP-1 cells pulsed with ISLWKGFSFI-containing peptide then left
without washing or fixing demonstrated at least a 2-3 fold increase in presentation of
ISLWKGFSFI in the presence of natural levels of B cell and THP-1 cell aspartate
protease activity than in cells pulsed with molar equivalent quantities of intact a3(IV)NC1.
Partial inhibition of aspartate protease activity with pepstatin A increased ISLWKGFSFI-
presentation on intact a3(IV)NC1 in a dose dependant manner although this was mainly
observed in the THP-1 cells which had been neither fixed nor washed.
I therefore undertook a second set of experiments using a modified protocol that allowed
varying intervals for antigen processing before fixing/washing as well as varying
concentrations of pepstatin A pre-treatment. This set of 3 experiments generated several
observations:
• Both B cells and THP-1 cells when pulsed with intact a3(IV)NC1 presented
DR15/ISLWKGFSFI in the presence of natural levels of aspartate proteases and this
expression increased with time.
• Partial inhibition of the aspartate protease, Cathepsin D by the specific inhibitor,
Pepstatin A resulted in an increase in presentation of DR15/ISLWKGFSFI in B cells
pulsed with intact a3(IV)NC1 but no influence on expression was observed in APC pulsed
with ISLWKGFSFI-containing peptide. These findings were consistent in 3 experiments
and significant (unpaired t-test)
• Presentation of DR15/ISLWKGFSFI on THP-1 cells was extremely variable, where in
some cases expression of DR15/ISLWKGFSFI fell. For this reason it was not possible to
determine any clear influence of Pepstatin A on a3(IV)NC1 processing in THP-1 cells.
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One putative explanation for this last observation could be the increased presence of
cathepsin D in activated THP-1 cells in comparison with B cells. If enzyme levels were
significantly higher in THP-1 cells, it is possible that Pepstatin A was 'saturated' and of
insufficient concentration to abrogate the effects of Cathepsin D. It is difficult to quantify
'physiologic' levels of enzyme activity and in turn measure the extent of cathepsin D
inhibition, especially in THP-1 cells. My attempts to measure Cathepsin D activity and
inhibition were initially thwarted by a faulty assay where the controls consistently failed to
develop. Time constraints also limited my ability to optimise the assay. Nonetheless, one
interesting observation was apparent from later experiments. The assay clearly showed
much higher aspartate protease activity (in the order of ten-fold increase) in THP-1
lysates compared to B cell lysates (Figure 6.6) supporting the idea of increased aspartate
protease activity within THP-1 cells.
It is perhaps relevant to note that the assay recommended the use of 1x106 to 1x107 cells
when analysing lysates. The majority of my experiments were attempting to detect
cathepsin D activity from lysates of 0.5x105 to 1x105 cells. Attempts latterly to use cell
numbers closer to those recommended still failed to detect any significant change on
cathepsin D activity in the presence of increasing concentration of pepstatin in both B and
THP-1 cells.
Further attempts to confirm that cathepsin D was responsible for abrogating expression of
DR15/ISLWKGFSFI by modifying ISLWKGFSFI peptide such that leucine was
exchanged for the cathepsin D resistant, isoleucine, proved disappointing. Having
fortuitously demonstrated that one of the ISLWKGFSFI-specific T cell hybridomas was
also capable of recognising ISIWKGFSFI in addition to a3(IV)NC1, results demonstrated
that expression of either peptide increased in a dose responsive manner with pepstatin. If
the mutated peptide was indeed resistant to cathepsin D cleavage this would suggest that
either cathepsin D was not the proteolytic enzyme responsible for cleavage (as we would
have expected pepstatin A to have no effect on the mutated peptide). Alternatively the
single amino acid substitution may not have resulted in resistance to cathepsin D. This
second explanation was supported by data analysing digestion products of both original
and modified peptide. Although isoleucine did prevent cleavage at the crucial scissile
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bond, cleavage was demonstrated to occur at 2 different sites. Work with overlapping
peptides (15mers overlapping by 10) has identified the sequence most likely to be
recognised by patient's T cells as well as the hybridomas to be ISLWKGFSFI. As this
sequence also contains the two sites cleaved by cathepsin D in the digestion of modified
peptide this could explain where in the presence of pepstatin A, the presentation of
modified peptide is augmented.
Although time precluded further attempts to confirm Cathepsin D as the enzyme
responsible for reduced expression of DR15/ISLWKGFSFI, alternative approaches may
have included the use of a cathepsin D knock out mouse or the utilisation of a cathepsin
D specific probe to substantiate observations. An alternative approach could have
included the use of other inhibitors such as the AEP inhibitor, MV026630 (AEP is required
for the cleavage of pro-cathepsin D into the proteolytically active Cathepsin D and its
inhibition in turn would abrogate cathepsin D activity). Alternative approaches are





As detailed in Chapter 1, Goodpasture's disease has very striking associations with
alleles inherited at the MHC class II loci. A strong positive disease association is
described with greater than 80% of patients carrying DRB1*1501 (one of the alleles
contributing to DR specificity). An even more impressive but contrasting association is
that seen with DR7 alleles which appear to protect from disease even in the presence of
DRB1*1501 (Phelps, 1999). The phenomenon has been termed dominant protection and
similar HLA associations have been described in other autoimmune diseases and animal
models of autoimmunity (Phelps, 1999).
The exact mechanism accounting for the association of MHC with autoimmunity is not
known but it seems likely and indeed there is evidence to support that expression of class
II molecules themselves can account for the associations (Deng, 1993). We know that
MHC molecules can influence immune response by their peptide binding preferences and
subsequent display of peptide-MHC complexes to T cells. It seems likely that peptide
binding preferences would also influence immune response to self proteins.
Evidence supporting the direct influence of class II molecule expression and susceptibility
to autoimmune disease has been demonstrated in mice transgenic for HLA class II alleles
(Taneja, 1998). How MHC differences can in turn influence susceptibility is controversial.
The mechanisms involved are likely to vary in different autoimmune diseases and in turn
models of disease.
Postulated mechanisms by which HLA may protect from disease relates to influencing
presentation of self antigen which in turn can lead to a) deletion of auto reactive T cells or
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the inhibition of their selection b) induction of anergy of autoreactive T cells c) diversion of
the phenotype of autoreactive T cells to that of a regulatory phenotype d) "capture" of the
determinants recognised by autoreactive T cells and e) positive selection of regulatory T
cells.
Work by Phelps et al (Phelps, 2000) examining the peptide binding preferences of HLA-
DR molecules with divergent associations with susceptibility to Goodpasture's disease
demonstrated that DRB 1*0701 confers strong dominant protection from disease (OR 0.3)
such that those individuals inheriting B1*1501 with *0701 have no higher risk than the
general population. Using an inhibition assay they demonstrated that DR7 molecules
have greater affinity for a3(IV)NC1 peptides than DR15. They suspected dominant
protection could arise by DR7 capturing peptides in turn preventing their display bound to
DR15. Indeed their binding data suggested that the major a3(IV)NC1 peptides presented
bound to DR15 by DR15 homozygous APC would bind preferentially to DR7 in DR7,15
heterozygote APC.
T cell hybridomas specific for DR15/ISLWKGFSFI afforded an opportunity to examine this
hypothesis by comparing presentation of ISLWKGFSF by antigen presenting cells with
and without the co-expression of DR7.
7.2 Results
7.2.1. DR7,15 expressing APC demonstrate a trend for generating more
abundant DR15/ISLWKGFSFI complex than DR15/15 homozygous APC
Initial experiments compared ISLWKGFSFI presentation by four different EBV-
transformed B cells which were either DR15 homozygotes or DR15,7 heterozygotes
pulsed with ISLWKGFSFI peptide or intact a3(IV)NC1. Two lines were homozygous for
DR15 (LCL013 & LCL036) and the second two heterozygous for DR15 and DR7 (LCL039
& LCL041) (see table 7.1).
Surprisingly, when pulsed with intact a3 there was a trend for DR7-expressing APC to
generate more abundant DR15/ISLWKGFSFI complex than DR15/15 APC (Figure 7.1),
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contrary to what would be expected if DR7 was capturing ISLWKGFSFI peptide,
preventing presentation by DR15. Variability differed between cell lines and could
putatively account for by variation in DR15/ISLWKGFSFI between the B cell lines. To
address the issue of viability, a second experiment was performed (Figure 7.2) including
a third DR15,7 expressing B cell line, LCL047. As a control, a non-DR7 expressing
heterozygote was included, LCL106 (DR15, 11). Viability of B cell lines did not account
for differences observed in presentation of DR15/ISLWKGFSFI where the B cells
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Figure 7.1 DR15,7 heterozygous EBV transformed B cells demonstrate a trend for
presenting DR15/ISLWKGFSFI in greater abundance than DR15,15 homozygous cells. Each
graph is representative of 1 experiment. APC were pulsed as previously described (chapter 2) with
either 20pg/ml (7.5pM) ISLWKGFSFI-containing peptide or 300pg/ml (9pM) recombinant
a3(IV)NC1 except in the third experiment where concentration of peptide and a3(IV)NC1 was
3.75pM and 6pM respectively. APC were pulsed for 4 hours at 37°C 5% C02 before adding the
DR15/ISLWKGFSFI-specific T cell hybridoma ha3p132.3 in a ratio of 2:1. Co-cultures were
incubated for 24 hours and supernatant analysed for production of IL-2 as previously described.
Light bars represent IL-2 levels in a 24 hour co-culture in APC pulsed with ISLWKGFSFI-
containing peptide and dark bars with intact a3(IV)NC1. CRC013 and 036 are DR15 homozygous
and LCL039 and 041 DR15,7 heterozygous EBV transformed B cells. Standard error bars
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Figure 7.2 DR15.7 heterozygous EBV transformed B cells demonstrate a trend for
presenting DR15/ISLWKGFSFI in greater abundance than DR15.15 homozygous cells. B
cells were pulsed with either ISLWKGFSFI peptide (3.75pM) or a3(IV)NC1 (9pm). Experimental
set up was as described in Figure 7.1. There was a trend for increased presentation of
DR15/ISLWKGFSFI in the DR15.7 expressing heterozygotes when pulsed with intact a3(IV)NC1.
Non-DR7 expressing heterozygotes (LCL106) failed to stimulate ha3p132.3. The viability of APC
did not appear to influence DR15/ISLWKGFSFI expression as the 2 highest stimulators of
ha3p132.3 (LCL047 and LCL061) had a viability of around 50%. It was unusual however that the
DR15 homozygote, CRC013 failed to express DR15/ISLWKGFSFI when pulsed with either
ISLWKGFSFI-containing peptide or intact a3(IV)NC1 despite a viability of >95%.
7.2.2 The expression of HLA DR does not correlate with the increased
abundance of DR15/ISLWKGFSFI seen in DR15,7 heterozygous EBV
transformed B cells
To assess if expression of FILA DR as determined by flow cytometry corresponded with
any variation in presentation of DR15/ISLWKGFSFI in a3(IV)NC1-pulsed B cells, I
repeated the above experiments using a number of EBV transformed B cells from healthy
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volunteers with different HLA DR expression (a kind donation form Mrs Gwen Wilkie, Dick
Vet School, Edinburgh). These cells were homozygous for DR15,15 or heterozygous for
DR7,15 (see table 7.1). APC were pulsed with intact a3(IV)NC1 and the presentation of
DR15/ISLWKGFSFI complex determined as above. Cell lines were also stained for
expression of class II using a FITC-labelled monoclonal antibody to HLA DR,DP,DQ
(described in Chapter 2 ).
Results shown in Figure 7.3 demonstrate that there was no correlation between
expression of DR and presentation of DR15/ISLWKGFSFI on DR15,15 and DR15,7 B
cells and is unlikely to explain the trend for greater abundance of DR15/ISLWKGFSFI in
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Figure 7.3 Scatter plot comparing expression of HLA DR on EBV transformed B cells with
presentation of DR15/ISLWKGFSFI as determined by production of IL-2 assessed using
ELISA. In this experiment, the expression of HLA DR DP DQ on 4 different DR15 homozygous
and 4 different DR15,7 heterozygous EBV transformed B cells was determined using flow
cytometry (demonstrated on x axis as median fluorescence) and was compared with presentation
of DR15/ISLWKGFSFI as assessed by production of IL-2 in a 24 hour co-culture (demonstrated
on y axis as IL-2) when B cells were pulsed with intact a3(IV)NC1. DR15,7 heterozygous EBV
transformed B cells again presented DR15/ISLWKGFSFI as well as DR15.15 homozygotes. There
was a trend for presenting DR15/ISLWKGFSFI in greater abundance in the DR15.7 expressing B
cells pulsed with intact a3(IV)NC1. Expression of HLADR is expressed as the median fluorescence
using a mouse anti-human FITC labelled monoclonal antibody as described in chapter 2. All
samples were gated using a FITC conjugated mouse lgG2a to exclude any non-specific binding.
There was no clear correlation with the abundance of DR15/ISLWKGFSFI expressed on B cells as
determined by IL-2 production and level of expression of HLA DR using flow cytometry.
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7.2.3 The DR7-associated enhancement of DR15/ISLWKGFSFI presentation
is consistent and significant.
The experiments shown in Figures 7.2 and 7.3 demonstrated that viability and expression
of HLA DR did not appear to explain differences in presentation of DR15/ISLWKGFSFI
between DR15,15 and DR15,7 expressing B cells. The results of preliminary experiments
could, however, be accounted for by the variability between the B cell lines other than that
of their FILA expression. This was because they were derived at different times from
different individuals and inevitably exhibited somewhat different growth characteristics in
culture. To address these sources variability, a further experiment using larger numbers
of DR15,15 and DR15,7 expressing EBV transformed B cell lines among which one could
hope other sources of variability would average out. To ensure that any observed
increase in abundance of DR15/ISLWKGFSFI was specific to the DR7,15 and not a
feature of all DR15 heterozygotes, a number of non-DR7 heterozygotic DR15 expressing
EBV transformed B cells were included in the processing experiments.
Figure 7.4 demonstrates that the DR7-associated enhancement of DR15/ISLWKGFSFI
presentation observed in DR15/7 heterozygotes compared with DR15 homozygotes (and
DR15/non-DR7 heterozygotes) was consistent across 8 lines in 4 separate experiments.
The difference was unlikely to be due to chance (Mann-Whitney Rank Sum Test
P=0.005)
It was of interest that non-DR7 expressing DR15 heterozygotes were also capable of
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Figure 7.3 Scatter plot comparing expression of HLA DR on EBV transformed B cells with
presentation of DR15/ISLWKGFSFI as determined by production of IL-2 assessed using
ELISA. In this experiment, the expression of HLA DR DP DQ on 4 different DR15 homozygous
and 4 different DR15,7 heterozygous EBV transformed B cells was determined using flow
cytometry (demonstrated on x axis as median fluorescence) and was compared with presentation
of DR15/ISLWKGFSFI as assessed by production of IL-2 in a 24 hour co-culture (demonstrated
on y axis as IL-2) when B cells were pulsed with intact a3(IV)NC1. DR15,7 heterozygous EBV
transformed B cells again presented DR15/ISLWKGFSFI as well as DR15.15 homozygotes. There
was a trend for presenting DR15/ISLWKGFSFI in greater abundance in the DR15.7 expressing B
cells pulsed with intact a3(IV)NC1. Expression of HLADR is expressed as the median fluorescence
using a mouse anti-human FITC labelled monoclonal antibody as described in chapter 2. All
samples were gated using a FITC conjugated mouse lgG2a to exclude any non-specific binding.
There was no clear correlation with the abundance of DR15/ISLWKGFSFI expressed on B cells as
determined by IL-2 production and level of expression of HLA DR using flow cytometry.
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7.2.4 Can competitive inhibition with peptides of high affinity to DR7 help
confirm that co-expression of DR7 accounts for the increased abundance of
DR15/ISLWKGFSFI presentation on EBV transformed B cells?
One possible mechanism for the difference in DR15/ISLWKGFSFI expression was the
direct influence of DR7 on peptide binding to DR15. I determined to inhibit ISLWKGFSFI
uptake by DR7 and observe the effects (if any) on expression of DR15/ISLWKGFSFI. As
an initial approach I elected to inhibit ISLWKGFSFI binding to DR7 by pulsing B cells and
THP-1 cells with DR7-high affinity peptides. Both peptides P16 and P21 are reported to
bind to DR7 with much greater affinity than DR15 so might be expected to increase
presentation on DR15 by competitive displacement for DR7 if present on the peptide
binding compartment at a suitable concentration.
Figure 7.5 demonstrates that all 3 DR15,7 expressing cell lines both P16 and P21
reduced presentation of DR15/ISLWKGFSFI when APC were pulsed with ISLWKGFSFI
containing peptide and a3(IV)NC1. Reduction in presentation fell with increasing
concentration of inhibitory peptide.
As a similar reduction in DR15/ISLWKGFSFI presentation was observed in cells pulsed
with both peptide and antigen, this raised the possibility of a non-specific effect of the
inhibitor on DR15/ISLWKGFSFI presentation. As cell were not fixed at any time point it
was not possible to determine whether any effects observed were due to interference
with DR7 binding or a non-specific or even toxic effect of the inhibitory peptide.
One way to control for this was to examine the effects of inhibitory peptide on
DR15/ISLWKGFSFI presentation in DR15,15 homozygotes. P16 did not affect
presentation of DR15/ISLWKGFSFI in DR15 homozygotes pulsed with ISLWKGFSFI
peptide or antigen however the level of presentation of DR15/ISLWKGFSFI (including
controls without inhibitory peptide) on these APC was low compared with DR15,7
heterozygotes (shown in Figure 7.6 which represents one of two similar experiments). It
was not possible to conclude with certainty that there was a true difference in the effect of
P16 on DR15 homozygous or DR15.7 heterozygous cell lines. Observations remained
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consistent with DR15,7 heterozygous cell lines, however, where in the presence of P16,
presentation of DR15/ISLWKGFSFI was reduced when pulsed with intact a3(IV)NC1.
Levels of IL-2 were approximately 10 fold lower in comparison with B cells pulsed with
ISLWKGFSFI-containing peptide.
Due to time constraints, despite intriguing results, it was not possible to conclude with
certainty from these experiments with inhibitory peptide, whether any observed reduction
in presentation of DR15/ISLWKGFSFI in DR15,7 B cells when pulsed with a3(IV)NC1
had been as a result of blocking the DR7 peptide binding site or a non-specific and
potential toxic effect of inhibitory peptide on any cell line irrespective of DR7 expression.
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Figure 7.5 Competitive inhibition of DR7 binding by two peptides (P16 at top, P21 at bottom)
with high affinity for DR7 compared to DR15. Both inhibitory peptides were made up to a stock
concentration of 10mg/ml in DMSO and dissolved further to 0.5mg/ml in sterile PBS. Inhibitory
peptides, P16 or 21 were added at a concentration of 10, 20 or 40pg/ml. Cells were then left for 60
minutes on ice. ISLWKGFSFI peptide was then added to APC at a concentration of 20pg/ml
(7.5pM) and a3(IV)NC1 was pulsed at 200pg/ml (6pM). APC were incubated for a further 2.5
hours at 37°C before adding ha3p132.3 and incubating at 37°C for 24 hours. 3 different DR15,7
expressing B cell lines (LCL041, LCL047 & LCL061) were used. Graph demonstrates the
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presentation of DR15/ISLWKGFSFI on respective B cells pulsed with either ISLWKGFSFI
containing peptide (AS346) or a3(IV)NC1 (alpha3).
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Figure 7.6 Competitive inhibition of DR7 binding. Graph demonstrates the presentation of
DR15/ISLWKGFSFI on respective DR15,15 or DR15.7 expressing B cells pulsed with either (A)
ISLWKGFSFI containing peptide (AS346) or (B) a3(IV)NC1 (alpha3) in presence or absence of
inhibitory peptide P16 at concentrations of 5,10, 20 and 40pg/ml
7.3 Discussion
In this chapter I demonstrated that contrary to initial expectations, DR15/ISLWKGFSFI
presentation was enhanced in DR7,15 compared with DR15,15 expressing EBV
transformed B cells.
Despite the difficulties encountered confirming the influence of co-expression of DR7 on
expression of DR15/ISLWKGFSFI, this chapter produced some intriguing results.
Class II molecules are capable of binding unfolding proteins and peptides of long lengths
in addition to the previously acknowledged smaller peptide fragments. On unfolding, the
most available high affinity binding regions then bind preferentially to class II MHC. These
bound protein sequences would then be protected from proteolysis by MHC and go on to
become immunodominant T cell determinants (Deng, 1993). For self antigens, T cells
with specificity for those dominantly displayed determinants will be subject to strong
tolerance induction. This process whereby determinants within an unfolding protein
antigen compete for binding to the same class II molecule has been termed determinant
capture and has since been extended as a means by which protection could be provided
by the expression of specific class II molecules in autoimmune diseases such as DM and
MS.
Deng et al published seminal work in where they compared the immunogenicity of hen
egg lysozyme (HEL) in a NOD mouse (NOD x BALB/c) Ft and Eda transgenic NOD.
Response to the subdominant ANOD- restricted determinant epitope disappeared on
introduction of Ed molecule and was restored when scission of HEL separated this
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determinant from its adjoining competitively dominant Ed-restricted determinant. This
suggested that Ed bound and protected its dominant determinant if exposed on a long
peptide while neighbouring determinants were lost during proteolysis (Deng et al 1993).
There is a dominant negative association observed with DR7 and susceptibility to
Goodpasture's disease. With the knowledge that, ISLWKGFSFI, a key epitope
recognised by patients' T cells with disease has one of the strongest affinities for DR7
with only intermediate affinity for the disease associated DR15 (Phelps, 1996), the
generation of ISLWKGFSFI-specific T cell hybridomas provided an ideal opportunity to
examine whether determinant capture of ISLWKGFSFI peptide could account for the
dominant protective effect associated with co-expression of DR7 with DR15. In theory this
immunodominant peptide would bind preferentially to DR7 in turn preventing binding to
DR15 leading to a decrease in response by the DR15/ISLWKGFSFI specific T cell
hybridomas.
Results illustrated in this chapter suggested that DR7 did indeed influence expression of
DR15/ISLWKGFSFI on the surface of alpha3 pulsed APC. However observations were
contrary to expectations where I found that DR15/ISLWKGFSFI presentation was
considerably enhanced in DR15/7 compared to DR15/15 expressing EBV transformed B
cells. Therefore DR7 co-expression does not reduce ISLWKGFSFI presentation on
DR15, and determinant capture is unlikely to account for dominant protection.
One alternative hypothesis is that as a result of determinant capture, DR7 could afford
protection by enhancing presentation of DR15/ISLWKGFSFI in health leading to deletion
or regulation of DR15/ISLWKGFSFI specific T cells during establishment of central
tolerance. This in fact seems more logical given previous arguments that T cells
recognising self peptides escape tolerance as a result of reduced presentation of the
same self peptides during central tolerance.
There remains the question how does co-expression of DR7 with DR15 enhance binding
of ISLWKGFSFI to DR15 when binding data suggests it would bind preferentially to DR7?
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Competitive capture is one potential explanation where different determinants of an
unfolded antigen compete for binding to a class II molecule. This has been demonstrated
in an animal model of MS where the hierarchy of 3 overlapping determinants within a
region of the Golli-MBP complex was characterised. All were demonstrated to compete
for binding to l-Au but due to competitive capture by flanking determinants, one lower
affinity determinant was not expressed (Mavarakis et al 2008). If other DR7 high affinity
determinants were competing for DR7 binding, this could in turn "free" ISLWKGFSFI





In this study of a3(IV)NC1 processing and presentation I set out to examine whether the
destructive processing of the major disease associated peptides influenced presentation
by APC so as to potentially account for the existence of T cells in the peripheral repertoire
with reactivity towards these self peptides.
In the course of my research I successfully generated T cell hybridomas from a
humanised mouse transgenic for human HLA DR15 which were specific for one of the
major disease associated a3(IV)NC1 peptides, dap131-150. These T cell hybridomas
were used as peptide detectors to study the processing of a3(IV)NC1 by living human
and mouse APC. The peptide, dap131-150, was demonstrated to be susceptible to
destruction by a protease in the endosome of APC, cathepsin D. The response of the T
cell hybridomas specific for the same major disease associated peptide when incubated
with intact a3(IV)NC1-pulsed APC were significantly enhanced by the cathepsin D/E
inhibitor, Pepstatin A. Taken together this work shows that naturally occurring Cathepsin
D activity within human B cells or APC, significantly diminishes presentation of at least
one a3(IV)NC1-derived peptide known to be recognised by patients' T cells. The results
suggest that destructive processing could be a factor in the escape from central-tolerance
of major auto reactive T cells destroying them in the course of antigen processing
supporting the hypothesis suggested above.
In this chapter I hope to highlight a number of strengths and limitations of this work and
discuss some of the controversies raised before discussing the implications of my results
in the context of the immunopathogenesis of Goodpasture's disease and potentially to
autoimmunity in general.
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8.2 Generation and utility of T cell hybridomas
Since the early reports of hybridoma production, a number of technical advances have
been introduced to facilitate and improve the production of both B and T cell hybridoma
clones therefore maximising the chance of generating peptide specific hybridomas.
Wood et al were the first to describe a mouse T cell hybridoma capable of specifically
responding to human PBMC. The mouse used to generate the hybridomas was an HLA-
DR4 transgenic mouse (Woods, 1994) but since this time little further work has been
carried out to further characterise and utilise this technique. Indeed, until recently, few
groups had attempted to evaluate the use of HLA transgenic mice to construct HLA class
I and II restricted T cell hybridomas capable of recognising peptide MHC complexes on
human APC.
Canaday et al described methods for systematic production of T cell hybridomas related
to human HLA alleles and their application to study human APC function involving
processing of Influenza A, Mycobacterium TB and tetanus toxin (Canaday, 2003). More
recently Von Delwig et al and Boots et al have utilised T cell hybridomas generated from
mice TG for human HLA DR1 and DR4 respectively in the study of processing of different
epitopes in the study of collagen-induced arthritis (Von Delwig, 2006, Boots, 2007). Chou
et al have also generated a number of humanised myelin peptide specific T cell
hybridomas from mice TG for human DRB1*1501 (Chou, 2004). To our knowledge, this is
the first description of T cell hybridoma production restricted to human HLA and specific
for disease associated peptides to a known human renal auto antigen.
I generated 7 DR15 restricted hybridomas capable of recognising the a3(IV)NC1 derived
disease associated peptide, ISLWKGFSFI. The hybridomas were peptide specific, and
recognition was restricted to presentation of ISLWKGFSFI on DR15 expressing APC.
Canaday et al demonstrated hybridoma responses on exposure to 1x104 macrophages
and 2x103 dendrite cells. In my hands, the smallest number of EBV transformed B cells
and THP-1 cells used was 2.5x104. Hybridomas responded in a consistent manner
although it became clear at an early stage that 2 of the 7 hybridomas, ha3p132.3 and
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ha3p132.15 responded better in terms of IL-2 production. In addition, the viability of these
cells was good. They consistently expressed both TCR and CD4 and the T cell
populations remained clonal. For this reason these lines were selected for use in most of
the future experiments.
One of the biggest setbacks in the course of my research was the difficulty in generating
hybridomas that were specific to other disease associated peptides, in particular, the
other major disease associated peptide, dap71-90 The peptide, AS345
(SPFLFCNVNDVCNFASRND) was used to prime mice and again used with in vitro recall
responses. The difficulties encountered in generating AS345 specific hybridomas were
unfortunately numerous. Problems initially related to the use of transgenic mice which co-
expressed mouse class II with human HLA DR15. Although 4 T cell hybridomas were
generated that were specific for AS345, none of these were restricted to presentation by
DR15. Mouse class II KO/DR15+ transgenic mice were subsequently generated and
used for all further immunisations. However, difficulties were then encountered
maintaining healthy cell lines prior to fusion. Initial attempts resulted in the loss of T cell
lines after the fourth round of re-stimulation despite demonstrating in vitro recall response
on retrieval of splenocytes from immunised mice. Subsequent attempts adopted an
alternative approach where fusion was attempted after only 1 round of re-stimulation. This
carried the risk that peptide specific T cell clones would not be selected out and indeed,
despite the production of greater than 40 healthy T cell clones, none were specific for
AS345. A final attempt established T cell lines using lymph nodes from primed mice
(which contain around 80% T lymphocytes as opposed to 10% in splenocytes). Despite
once again demonstrating in vitro recall responses to AS345, none of the subsequent
hybridomas generated recognised this peptide.
Although the reasons for failure to generate DR15 restricted T cell hybridomas against
this particular peptide are not clear, it was apparent in later experiments that part of the
problem was an inability to maintain a sustained response to peptide prior to fusion. One
explanation is the presence of 2 cysteine amino acids in AS345 which form a disulphide
bond within the peptide. This in turn alters the conformation such that AS345 forms a
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loop-like structure. It was possible that peptide used to immunise mice may have been
reduced thus altering the conformation and immunogenicity of the peptide.
Although results with other disease associated peptides were perhaps disappointing, I
had generated a number of T cell hybridomas against the disease associated peptide,
ISLWKGFSFI. These hybridomas were a powerful tool with which to examine aspects of
a3(IV)NC1 processing. The particular advantage of T cell hybridomas over mass
spectrometry is their specificity. Although mass spectrometry has the advantage of
exquisite sensitivity, it generates a complex array of peptides in which the identification of
specific peptides of interest can be difficult (particularly if peptides are expressed at low
levels). Hybridomas, in contrast, can be used as "peptide detectors" to recognise specific
peptide/HLA complexes presented on the surface of antigen presenting cells with high
sensitivity. This targeting of specific disease associated peptides such as ISLWKGFSFI,
allows the influence of processing factors on individual peptides to be investigated.
8.3 Intracellular processing of intact a3(IV)NC1 is necessary
before T cell hybridomas respond to DR15/ISLWKGFSFI
complexes.
Most exogenous antigens require intracellular processing before presented by class II on
the surface of APC. There is evidence however demonstrating that cell surface MHC
class II can be directly loaded with native protein if epitopes are located in structurally
flexible and accessible regions (Sette, 1989). In addition, MHC class II molecules on the
surface of fixed APC have been shown to directly bind and present extra cellular epitopes
and fragmented proteins (Lindner, 1996, Aoi, 1997, Harris, 1996) and even denatured
intact protein (Jensen 1991 & 1993, Carrisco-Marin 1998). The data show that this is not
the case with a3(IV)NC1.
For the approach proposed to investigate the influences of endosomal proteolytic
enzymes within the MHC class II processing pathway, it was crucial to demonstrate
intracellular processing within APC was necessary before T cell hybridomas were
capable of recognising DR15/ISLWKGFSFI complexes on the surface of APC pulsed with
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intact a3(IV)NC1. Different DR15 expressing APC including the human monocytic cell
line THP-1 and several DR15 expressing EBV transformed B cell lines, were shown
capable of stimulating 5 of the 7 DR15/ISLWKGFSFI specific hybridomas in a dose
responsive manner when pulsed with intact a3(IV)NC1, but in every case processing was
confirmed necessary by the inability of pre-fixed DR15 expressing APC to stimulate
hybridomas. In contrast, pre-fixed APC pulsed with peptide did induce a response,
implying that ISLWKGFSFI is almost certainly capable of binding DR15 directly on the
surface of fixed APC. Response to antigen was specific and not due to LPS
contamination.
The demonstration that processing of a3(IV)NC1 was required before the peptide specific
T cell hybridomas could respond to DR15/P14 complexes on the surface of APC ensured
that I could study putative factors thought important in the generation or destruction of the
disease associated peptide, ISLWKGFSFI.
8.4 Influence of aspartate protease activity on processing of
a3(IV)NC1 in human antigen presenting cells
Biochemical studies had strongly implicated cathepsin D as the enzyme responsible for
initial unlocking and processing of a3(IV)NC1, it was logical that this should be the first
proteolytic enzyme on which to focus.
As a first attempt to examine the influences of cathepsin D specifically on processing of
a3(IV)NC1, I elected to use an in vitro approach by pre-incubating recombinant
a3(IV)NC1 with cathepsin D prior to pulsing the digested protein into APC. This had the
advantage of focusing on cathepsin D specifically which had been identified in
biochemical studies as a putative enzyme in the destructive processing of
ISLWKGFSFI/dap131 -150 (Zou, 2007).
Results from this set of experiments demonstrated that there was indeed a fall in IL-2
production by the T cell hybridoma, ha3p132.3 in cells were co-cultured with APC pulsed
with cathepsin D-digested a3(IV)NC1 compared with intact a3(IV)NC1. This approach
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had some limitations in that the concentration of cathepsin D and subsequent digestion of
a3(IV)NC1 was non-physiological. The results however confirmed biochemical data
showing a reduction in presentation of ISLWKGFSFI peptide following digestion of intact
a3(IV)NC1 with cathepsin D.
To examine the effect of natural levels of cathepsin D on presentation of ISLWKGFSFI
peptide, the presentation of DR15/ISLWKGFSFI in DR15 expressing APC pulsed with
abundant intact a3(IV)NC1 or ISLWKGFSFI peptide was compared using hybridoma,
ha3132.3. In the presence of natural levels of B cell aspartate protease activity
ISLWKGFSFI-presentation by B cells was greater for B cells incubated with
ISLWKGFSFI-containing peptide than molar equivalent quantities of intact a3(IV)NC1.
This supports the suggestion that aspartate protease activity in B cells diminishes
presentation of the ISLWKGFSFi epitope, as predicted from the earlier in vitro studies
and preliminary work with cathepsin D pre-digestion experiments. It was difficult to control
for these experiments, however, due to the uncertainty of knowing the exact
concentration of antigen compared to peptide used each the assay. This was due to
variation in quantifying stock concentration of protein antigen. Nevertheless, it was a
consistent finding in experiments that despite incubation with Cathepsin D for up to 120
minutes or comparing the presentation of peptide in B cells pulsed with either
ISLWKGFSFI-containing peptide or molar equivalent quantities of intact a3(IV)NC1 in the
presence of natural levels of aspartate proteases, B cells were still capable of presenting
ISLWKGFSFI albeit at a significantly reduced level in comparison with intact a3(IV)NC1.
The data suggested that although rapid destruction by endosomal aspartate proteases
can account for a reduction in ISLWKGFSFI presentation, sufficient ISLWKGFSFI to
stimulate T cells can be presented by DR15-expressing B cells under particular
conditions, such as culture in high concentrations of a3(IV)NC1. This may help explain
how many of the stimuli reported increase the turnover of basement membrane
a3(IV)NC1 (thus flooding the system) are associated with Goodpasture's disease
(Phelps, 2000).
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8.5 Inhibition of cathepsin D and influence on processing of
a3(IV)NC1
Crucial to further studies was the confirmation that cathepsin D was the responsible
proteolytic enzyme for the destruction and resultant reduction in surface presentation of
ISLWKGFSFI peptide.
There are now a number of methods by which cathepsin D activity can be reduced or
effectively abolished. Microbial protease inhibitors are known to inhibit the intracellular
proteases of living cells in a non-cytotoxic manner. They also have the advantage of
being site specific and have a small molecular weight so that they can easily penetrate
the cell membrane (Puri, 1988). For these reasons I elected to use the specific aspartate
protease inhibitor, Pepstatin A to inhibit Cathepsin D activity.
Experiments involving the aspartate protease inhibitor, pepstatin A, demonstrated partial
inhibition of aspartate protease activity where pepstatin A increased ISLWKGFSFI-
presentation on intact a3(IV)NC1 in a dose dependent manner. In cells pulsed with
a3(IV)NC1 that were neither fixed nor washed prior to co-culturing with ha3p132.3, a
tenfold increase in IL-2 production in the supernatant was observed. One explanation for
this could be increasing expression of surface DR15/P14 complexes with time.
Alternatively, the proteolysis of IL-2 has been attributed to a large extent Cathepsin D/E.
Ohnishi et al demonstrated a ten fold increase in the half life of IL-2 in mice injected with
the cathepsin D inhibitor, pepstatin A (Ohnishi, 1990). In vitro work has also supported a
role of aspartate proteases on IL-2 production where pepstatin A significantly inhibited IL-
2 production in ova specific T cell hybridomas (Mizuochi, 1994, Rodriguez, 1992). This
may well be of relevance in the experiments where cells were neither washed nor fixed
prior to co-culture with the T cell hybridoma ha3p132.3. To address this concern, cells
were lightly fixed then washed after incubation with peptide and antigen, ensuring no
pepstatin remained prior to co-culture. An increase in IL-2 in the 24 hour co-culture
supernatant was seen as before, suggesting this was a true observation and not a direct
effect of pepstatin on IL-2 production.
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DR15 expressing EBV transformed B cells, in the presence of pepstatin A demonstrated
a clear increase in expression of DR15/ISLWKGFSFI after pulsing with intact
recombinant a3(IV)NC1. Results were more difficult to interpret in the case of THP-1 cells
where it was not possible to identify even a trend in the level of expression of
DR15/ISLWKGFSFI in cells pulsed with either ISLWKGFSFI-containing peptide or intact
a3(IV)NC1 in the presence of pepstatin A.
8.6 Influence of different antigen presenting cells on processing
of intact a3(IV)NC1.
The role of different professional antigen presenting cells such as dendritic cells, B cells
and macrophages in the initiation and maintenance of autoimmune responses is well
documented. They have been demonstrated to play a pivotal role in the pathogenesis of
autoimmune diseases where they present self-epitopes to auto reactive T cells in animal
models of autoimmunity such as RA and MS (Bayry, 2004, Holmdahl, 1991, Panayi,
2005, Dittel, 1999) but the differences in processing and presentation of auto antigen are
less clear.
B cells are certainly effective APC and antigen-specific B cells may be important in the
initiation of autoimmunity (Roth, 1996, Panayi, 2005). Human EBV transformed B cells
from healthy volunteers were initially decided upon as APC as they provided a range of B
cells homozygous for DR15, the class II molecules strongly associated with disease
susceptibility. Previous work within the lab had utilised EBV transformed B cells in the
study of a3(IV)NC1 processing using biochemical approaches and methods had
therefore already been well established by which B cells could be effectively pulsed with
recombinant antigen resulting in efficient uptake and subsequent processing.
Both quantitative and qualitative differences have been documented between antigen-
specific and non-specific B cells. Clearly antigen-specific B cells would have been more
desirable (Simitsek, 1995, Watts, 1993) as would a3(IV)NC1-specific B cells from patients
with active and untreated Goodpasture's disease. It should also be borne in mind that
EBV transformation may alter aspects of the phenotype of B cells including the level of
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surface class II expression and possibly the efficiency of antigen presentation (De
Campos-Lima, 1993). It is not known however whether antigen processing is qualitatively
different in transformed B cells.
It was for this reason, as well as to investigate whether any differences in processing
could be observed between alternative DR15 expressing cell lines, that I elected to
include a different APC. THP-1 cells are a DR15,1 expressing monocytic cell line that can
be differentiated into a macrophage phenotype on exposure to PMA and induced to
express MHC class II by IFNy (Sakamoto, 1999). It is also interesting to note that IFNy
has been described as capable of inducing apoptosis in THP-1 cells (Inagaki, 2002)
which may explain the poorer cell viability at time points of 18-24 hours and reduced
response to both peptide ISLWKGFSFI and a3(IV)NC1 in general, (discussed later)
Marked variation in the uptake, processing, presentation and dissemination of antigen
between APC has been described. Differences in protease content is a clear example
where macrophages have been shown to contain high levels of lysosomal proteases
which rapidly degrade proteins whereas DC and B cells were protease poor, retaining
antigen for longer with a more limited capacity for degradation. This in turn however
favoured antigen presentation (Delamarre, 2005). Whether a similar explanation could
account for differences in the presentation of ISLWKGFSFI over time between EBV
transformed B cells and THP-1 cells would have been a further avenue of interest had
time allowed. Unfortunately, preliminary studies using the cathepsin D assay to determine
the level of aspartate protease activity within each cell line proved problematic as
discussed below.
8.7 Influence of antigen conformation on a3(IV)NC1 processing
The observation from processing experiments in both B cells and THP-1 cells
demonstrated that if APC were incubated with abundant a3(IV)NC1, ISLWKGFSFI was
still presented as assessed by IL-2 production by ISLWKGFSFI specific hybridoma,
ha3p132.3. If rapid destruction by the endosomal protease, cathepsin D, is postulated to
cleave and destroy ISLWKGFSFI, how can this peptide ever be presented to ha3p132.3?
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One explanation lies in the knowledge that APC were incubated with high concentrations
of a3(IV)NC1, suggesting that in the presence of abundant antigen, the system may be
'flooded' allowing sufficient ISLWKGFSFI to stimulate ha3p132.3. An alternative
explanation is variability in the conformation of recombinant antigen and its influence on
processing and presentation of ISLWKGFSFI peptide.
Although a3(IV)NC1 was made with the human sequence, it differed from native
a3(IV)NC1 in a number of structural respects. Quaternary structure is quite different
where most native a3(IV)NC1 is complexed with other type IV collagen chains into
hexamers that are stable to significant protease and denaturant attack. The structure of
recombinant protein is monomeric. Structure has been shown to influence the
presentation of other complex proteins such as hCG (Rouas, 1993) haemoglobin (Atassi,
1989) In addition, patients with Goodpasture's disease have antibodies to epitopes within
a3(IV)NC1 which may in turn protect or enhance presentation of certain peptides as
shown in other antigens such as tetanus toxin (Simitsek, 1995).
Recombinant protein was subjected to a refolding protocol that promoted disulfide bond
formation allowing some degree of folding and disulfide bond formation, but it is likely that
several conformations of recombinant a3(IV)NC1 may have resulted. This may account
for the incomplete effects of cathepsin D pre-digestion of a3(IV)NC1 on abrogating
ISLWKGFSFI presentation. This may also explain the presentation of ISLWKGFSFI
peptide on APC pulsed with recombinant a3(IV)NC1 in the presence of natural levels of
aspartate proteases.
Just as the conformation of protein antigen may influence the processing of antigen, there
is evidence to suggest that the processing of antigen by alternative pathways may
influence the T cell repertoire.
There is a substantial body of evidence supporting different populations of T cells (type A
and type B) that recognise alternative conformational isomers (conformers) of the same
MHC-peptide complexes (Viner, 1995, 1996, Peterson, 1999, Pu, 2002).
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Studies of HEL and its presentation by l-AkCD4+T cells primed by immunisation by the
dominant peptide processed from HEL segregate into two subsets; type A T cells which
recognise a MHC-peptide complex formed in the APC with exogenous peptide that
recapitulates that of complexes formed by intracellular processing of native protein. There
is a second subset (type B) that recognise the complex formed by peptide derived from
exogenous protein but not the complex from identical peptide derived from that of
intracellular native protein. (Viner, 1995 & 1996, Peterson, 1999, Pu, 2002). The
importance of this phenomenon was demonstrated with the observation that type B T
cells that escape thymic negative selection can peripheralise in conditions where type A T
cells to the same epitope undergo complete thymic central deletion. This was
demonstrated by Peterson et al with type B T cells reactive to the 48-62 HEL epitope in
mice transgenic for HEL expression (Peterson, 1999) and Lovitch et al with type B T cells
recognising an abundant autologous epitope in wild-type B10.BR mice (Lovitch 2003).
This latter finding suggested that self-reactive type B T cells are present in the naive
repertoire where their activation can result in autoimmune pathology.
Pu et al demonstrated that type A and type B conformers are generated in distinct
vesicles with type A conformers forming in late endosomes/lysosomes and type B
conformer restricted to early endosomes and the cell surface and in addition this
restriction is mediated through the action of DM (Pu, 2002).
As type B reactivity is not explained by failure of APC to generate peptide during
processing, post-translational modification of the peptide or peptide binding in an
alternative register, it has been hypothesized that formation of MHC-peptide complexes in
distinct intracellular compartments may underlie the generation of the two conformers.
8.8 Confirmation of Cathepsin D as the proteolytic enzyme
responsible for reduced expression of DR15/ISLWKGFSFI
Results from chapter 5 where pre-digestion of a3(IV)NC1 with purified human cathepsin
D reduced presentation of ISLWKGFSFI peptide and chapter 6 where inhibition of
cathepsin D increased presentation of DR15/ISLWKGFSFI strongly support a role for
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cathepsin D in a3(IV)NC1 processing. Proteolytic enzymes have been implicated in the
destruction of epitopes in other studies (Rodriguez, 1995) and interestingly, cathepsin D
has been implicated in the destructive processing of myoglobin (Watts, 2003, Moss,
2005). Redundancy amongst proteases is well documented and this could prevent
detection of important protease involvement in single-protease knockout experiments.
Phelps et al have demonstrated that Cathepsins D and E have similar activity in
processing of a3(IV)NC1 (Zou, 2008).
Difficulties with both the cathepsin D assay and the use of cathepsin D resistant modified
antigen (discussed in chapter 6) meant that it was not possible to identify cathepsin D
conclusively as the proteolytic enzyme responsible for the reduced surface expression of
DR15/ISLWKGFSFI.
However, biochemical data from our lab along with results from pre-digestion
experiments with cathepsin D and inhibition experiments using the cathepsin D/E specific
inhibitor provided strong evidence supporting the hypothesis that cathepsin D or a
proteolytic enzyme with similar substrate specificities was responsible for the destructive
processing of the disease associated peptide ISLWKGFSFI.
8.9 Alternative approaches to confirm the role of cathepsin D in
a3(IV)NC1 processing
Time constraints unfortunately prevented me from selecting an alternative approach to
confirm of refute the role of cathepsin D in the processing of a3(IV)NC1. Discussed below
are a number of possible approaches used to abrogate the effect of cathepsin D that
have been employed in other areas of research.
1. Site directed mutagenesis
The use of site directed mutagenesis to alter or delete an amino acid thought critical in
the cleavage and subsequent processing of a protein or peptide has been used for some
years now to confirm the identify of putative enzymes in processing (Abboud-Jarrous,
2005, Dunn, 2000). The alternative approach of mutagenesis ot cathepsin D itself has
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also been used. Glondu et al used this approach to assess the mitogenic role of
cathepsin D in the proliferation of cancer cells. Mutagenesis in this respect abrogated the
proteolytic activity of cathepsin D although it maintained its ability to stimulate cells
(Glondu, 2001).
2. siRNA
RNA interference has become in recent years a powerful tool for understanding gene
function. The use of siRNA has been applied to investigate the role of cathepsin D in
programmed cell death (Gui, 2006) as well as antigen processing. Singh et al used
siRNA to knock out cathepsin D in macrophages thus demonstrating a crucial role in the
processing and presentation of an immunodominant epitope Ag85B from mycobacterium
tuberculosis. (Singh, 2006). This technique would be an attractive alternative approach to
the use of aspartate protease inhibitors. This could be of particular importance in
delineating the specificity of cathepsin D in processing of a3(IV)NC1 as available
inhibitors such as pepstatin A are still capable of inhibiting other aspartate proteases such
as renin and pepsin and cathepsin E.
3. Cathepsin D Knockout
As the study of lysosomal proteases got underway in the 70s and 80s it was noted that
genetic defects in lysosomal proteases had not as yet been described. This suggested
that the defect of one protease may be compensated for by another i.e. a degree of
redundancy was present or that a deficiency may in fact be lethal early on in embryonic
life (Dean,1975).
Saftig et al described a cathepsin D -I- mouse generated by gene targeting. These mice
were found to develop normally in the first 2 weeks but stopped thriving in the third week
due to mucosal atrophy and subsequent necrosis resulting in death by day 26+/- 1. There
was also loss of lymphoid populations with the destruction of the thymus and spleen
where the ratio of cell proliferation to elimination was altered to favour elimination with T
and B cell populations particularly affected (Saftig, 1995).
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Obtaining APC from cathepsin D -/- mice would have been an attractive alternative
approach to examine the influence of cathepsin D on a3(IV)NC1 processing. However in
practice, this would not have been possible due to the restricted lifespan of cathepsin D -
/- mice and the resultant inability to cross breed with mouse class II KO DR15 mice.
8.10 Cathepsin D and apoptosis
In the last few years several reports have implicated Cathepsin D in apoptosis (Turk,
2000, 2001, 2002). The role of cathepsin B in apoptosis was described recently by
Guicciardi (2000) and Stoka (2001). Schestkowa et at induced apoptosis in Hela cells and
human fibroblasts by microinjecting either mature cathepsin D or its inactive precursor pro
cathepsin D into the cytosol. The results confirmed that its effects were independent of its
catalytic activity (Schestkowa, 2007). The molecular mechanisms of cell death promotion
from lysosomal proteases is not yet clearly understood. A pro-apoptotic member of the
Bcl-2 family, Bid appears to be central in cathepsin (including cathepsin D) -mediated
apoptosis however. Bid is a linker between extrinsic (via death receptors) and intrinsic
(mitochondrial) pathways (Li, 1998, Luo, 1998). How Bid is activated by proteases is not
clear but Cathepsin D is linked to the Bid signaling pathway and may act as a
downstream target (Heinrich, 2004). The role of cathepsins in mediating apoptosis is
likely to be complicated and involving many mechanisms. Understanding of these
mechanisms is however improving and we know that different cell types can favour
different routes and/or mechanisms of cell death. Whether the role of cathepsin D in
mediating apoptosis in either the EBV transformed B cells or THP-1 cells has any
influence of the results from the processing experiments detailed above is still purely
speculative.
8.11 Implications of observations and immunopathogenesis of
disease
Although a considerable amount of work has been published examining the influence of
proteases including aspartate proteases on the processing of protein antigens, little has
been published examining the processing of autoantigen.
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This work has demonstrated that presentation of a key epitope in Goodpasture's disease
is susceptible to destruction by the aspartate protease, cathepsin D. In EBV transformed
B cells the level of aspartate protease activity was sufficient to diminish presentation of
peptide despite this peptide having high affinity for HLA DR15 molecules. In addition,
presentation was significantly enhanced in the presence of the protease inhibitor,
Pepstatin A.
The potential importance of destructive processing in autoimmunity was first
demonstrated by Manoury et al where they demonstrated the influence of AEP on the
presentation of a key epitope from myelin basic protein, the target of autoimmunity in
multiple sclerosis (Manoury, 2002)
This work supports the hypothesis that destructive processing can prevent or reduce
presentation of self peptides to potentially auto reactive T cells and in doing so, shape
autoimmunity to a3(IV)NC1 and establish self-tolerance. As suggested in animal models
of autoimmunity (Moudgil, 2000), cathepsin D cleavage of a3(IV)NC1 and AEP cleavage
of MBP may be human examples of antigen processing that generates "cryptic epitopes"
that is to say epitopes with high class II binding affinity but low constitutive presentation.
Self-proteins as they are constitutively presented such that T cells that recognise epitopes
from self-proteins that are not usually presented or cryptic epitopes may be less subject
to control (Elson,1995, Gammon,1989). This has implications in turn for their ability to
develop a pathogenic autoimmune response in certain conditions.
Recent work published by Zou et al has demonstrated that healthy individuals as well as
patients have auto reactive T cells specific for epitopes in the Goodpasture autoantigen
(Zou, 2008). Of interest, the 6 peptides which evoked a response in >50% of the healthy
individuals was not caused by selectivity of HLA class II but rather was a result of
susceptibility to Cathepsin D digestion where there was a high correlation between
susceptibility to cathepsin D digestion and the capacity to stimulate primary T cell
responses.
There remains the key question however, that if destructive processing does account for
the presence of auto reactive T cells in the peripheral repertoire by suppressing
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constitutive presentation of self-epitopes, how are these epitopes presented in the
disease state to drive the autoimmune response?
A number of possible explanations exist. Antigen processing may be modulated by for
example bound antibodies (Antoniou, 2002, Simitsek, 1995) or by the actions of aberrant
APC (Hall, 2005). Non-autoimmune inflammation may alter accessibility extra cellular
modifications of APC or indeed their handling by APC or responsive T cells. Of note in
Goodpasture's disease there are associations with disease onset and certain
inflammatory events such as renal vasculitis, renal trauma and membranous nephropathy
(Phelps, 1996). In addition to creating an inflammatory response, many of these
conditions may result in an increase turnover of glomerular basement membrane and in
theory an increase in production of a3(IV)NC1. The data from my own work demonstrate
that destruction by aspartate proteases can account for a deficit if ISLWKGFSFI but
importantly it also demonstrated that sufficient ISLWKGFSFI to stimulate T cells can be
presented by both DR15-bearing B cells and macrophages under certain circumstances
such as culture high concentrations of a3(IV)NC1 and that partial inhibition of aspartate
protease activity is sufficient to substantially increased its presentation.
Therefore the expression of ISLWKGFSFI is likely to be low level rather than absent and
the level of presentation a balance which may be influenced by positive factors such as
abundance of a3(IV)NC1 (perhaps determined by basement membrane turnover) and
negative factors such as activity of endosomal proteases.
Although the transformation of this work into a therapeutic approach is clearly still some
years away, this work adds to that of others demonstrating that individual enzymes do
make clear and non-redundant contributions to the processing of key epitopes in certain
autoimmune diseases. I hope this in turn would help encourage efforts to manipulate
potential vaccine candidates in order that processing is re-tuned to processing machinery.
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8.12 Future work
The work generated from this thesis has firstly provided a powerful tool in which to dissect
the influences of processing on the generation or destruction of a3(IV)NC1 peptides
recognised by patients' T cells. It was perhaps a disappointment that I managed to
generate hybridomas that were specific and HLA DR15-restricted for only one of a
number of a3(IV)NC1 potential peptides of interest. This particular disease associated
peptide was however one of two major self-epitopes recognised by patients' T cells and
therefore of key interest in this work. The demonstration that cathepsin D activity could
significantly diminish presentation of this a3(IV)NC1 peptide has helped to provide strong
evidence supporting the hypothesis that destructive processing may account for the
survival of self reactive T cells in the mature peripheral repertoire.
This work has also resulted in an opportunity to go on to study many other aspects of the
processing in autoimmune disease.
Firstly, are other disease associated peptides in Goodpasture's disease and other
autoimmune diseases influenced similarly by aspartate proteases? Biochemical
approaches in our lab have shown this to be the case. Generation of T cell hybridomas
specific for other disease associated peptides as well as naturally processed a3(IV)NC1
peptides would help elucidate if the destructive propensity of aspartate proteases on
these peptides also occurred in live DR15 expressing human APC.
Secondly, for epitopes such as ISLWKGFSFI whose processing influences presentation,
it is likely that disease initiation depends on a change in presentation. These methods
described may enable the study of other factors postulated to influence aspects of uptake
and processing of a3(IV)NC1. Of particular interest would be the influence of
conformation and steric effects on a3(IV)NC1 and subsequent processing. Although
bacterial recombinant techniques have advanced considerably since their first
description, the protein yielded is unfolded and its conformation less accurate. The
generation of native a3(IV)NC1 would be the ideal although yield can often be low.
Alternative production techniques such as the use of insect cell lines to generate
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a3(IV)NC1 could also be considered. Other conformational influences would also be of
interest such as the importance of disulphide linkages and the degree of unfolding of
a3(IV)NC1. The steric effects of a3(IV)NC1 bound to patients' antibodies or in complex
with other chains have been shown in other studies to influence the processing and
resultant expression of disease associated peptides.
Finally, preliminary work examining the influence of DR7 co-expression on the processing
and expression of DA peptides such as ISLWKGFSFI generated intriguing results. Future
work determining if DR7 was responsible for increased presentation of ISLWKGFSFI
peptide involving either more specific DR7-blocking peptides or further attempts at DR7
transfection into DR7- cell lines would be desirable. If this was demonstrated clearly,
study of the influences of DR7,15 co-expression on other disease associated peptides
would be fascinating. In a similar vein, given the association of other HLA class II
molecules with disease susceptibility and protection, it would be relatively easy to perform
similar processing experiments with a wide range of DR15/non-DR7 heterozygous human
APC. Examination of the co-expression of a different class II molecule and potential
influence on presentation of various DA peptides would be fascinating-particularly if level
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